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ABSTRACT
Clostridium difficile is recognised to be the most common cause of infective
diarrhoea in hospital patients. In addition, the incidence of this disease has been increasing
throughout the 1990's, which is ofparticular concern amongst elderly patients. In this
climate, it is of great importance to determine what are the most significant factors that
predispose to this infection. This knowledge can then be used to prevent cases of the disease
arising, by reducing the risk to the individual or to the hospital community as a whole.
Whilst knowledge about the aetiology of C. difficile infection (CDI) is very
important, it is also valuable to study its epidemiology. This can help with our
understanding regarding transmission of the disease, and help to identify epidemic clones.
Such strains can then be further examined to try to determine the reasons for them being
more frequently associated with disease. It is possible to check whether current diagnostic
tests are adequate by monitoring for aberrant strains such as C. difficile toxin A negative /
toxin B positive isolates. Constant, independent review ofnewly developed diagnostic tests
is essential to ensure that they offer a sufficiently high level of sensitivity and specificity to
be clinically useful.
New rapid methods for the diagnosis of CDI are constantly being developed. One of
these, the Oxoid toxin A test (Unipath, Basingstoke, Hampshire, UK), was evaluated by
comparison with a cytopathic effect (CPE) method, using 100 strains of C. difficile. The
performance of the Oxoid toxin A test was only as good as the CPE method read at 6 hours,
with a sensitivity of 72% and a specificity of 94%. This is not likely to be sufficiently
accurate to be relied on as a single test for CDI. Furthermore, with the advent of disease
caused by toxin A negative / toxin B positive strains, toxin A tests are no longer to be
recommended for CDI diagnosis.
The epidemiology of CDI was studied in two ways. 1) The prevalence of C. difficile
toxin A negative / toxin B positive strains was measured in 269 isolates from symptomatic
hospital patients in Leeds and Bradford, using toxin gene PCR detection. 2) A comparison
of C. difficile strain types was made between isolates from symptomatic community patients
in Leeds and Truro, using ribo-spacer (RS) PCR. There were 15 isolates from Leeds and 39
from Truro. The epidemiological investigations indicated that there were no toxin A
negative / toxin B positive strains apparent in Leeds or Bradford, although these strains have
been reported from other areas of the country. The comparison of community strains
revealed significant differences between Leeds and Truro. Amongst Leeds community
patients, 60% of strains isolated were identical to the 'endemic' hospital strain (which
accounts for over 80% of sporadic CDI cases in Leeds hospital patients). By contrast, this
strain was not present in the Truro population (p= <0.0001).
In order to examine the likelihood of CDI following treatment with either
cefotaxime (CTX) or piperacillin-tazobactam (PT), a prospective, ward based, crossover
study was carried out. This was performed on two well matched care of the elderly wards,
with patients who required empirical broad-spectrum antibiotic treatment. Although only 48
patients were enrolled in this study, a highly significant difference was noted in the incidence
ofCDI and C. difficile colonisation between the two groups. The odds ratio (OR) for CDI in
CTX treated patients compared with those who received PT was 14.6 (CI= 1.7-124.7). The





There have been several stages in the development of our knowledge regarding the
aetiology ofpseudomembranous colitis (PMC) and its relationship to Clostridium difficile.
First, came the description by Finney in 1893, of a 'diphtheritic colitis' where membranous
plaques were found in the distal small bowel, as well as membranes in the large bowel
(Finney, 1893). At the time, the cause of the syndrome was not known. Subsequently, Hall
and O'Toole (1935) discovered a bacterium in the stools ofhealthy newborn children, which
they named Bacillus difficilis because of their difficulty in isolating it. They also observed it
to produce a toxin which was lethal when injected into rabbits and guinea pigs (Hall and
O'Toole, 1935); (Snyder, 1937). However, as it seemed to cause no harm to colonised
infants, a pathogenic role in humans was not considered until much later.
Over the next few decades, several hypotheses were advanced as to the aetiology of
PMC. One of the earliest was a suggestion that intestinal hypoxia, occurring secondary to
hypotension could be the cause (Penner and Bernheim, 1939). Later, as antibiotic use
became more widespread throughout the 1950's, Staphylococcus aureus was implicated
because it had been isolated from some patients with diarrhoea (Altermeier et al. 1963);
(Hummel et al. 1964); (Wakefield and Somers, 1953), and vancomycin appeared to have a
beneficial effect on the condition (Khan and Hall, 1966). After it was realised that many
cases of colitis seemed to have no link with S. aureus, (Dearing et al. 1960) and it had
proved difficult to induce colitic changes in animal models using this organism (Kay et al.
1958); (Prohaska et al. 1956), the enthusiasm behind the theory waned.
Although some investigation of patients in whom C. difficile had been isolated from
clinical samples was performed by Smith and King (1962), their conclusion was that the
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toxin effects seen in animal studies were not relevant to human disease. Throughout the
1960's the incidence of PMC increased (Hummel et al. 1964), and studies in the 1970's
indicated that lincomycin and clindamycin use was often associated with subsequent
diarrhoea or colitis (LeFrock et al 1975). Small, (1968) observed that hamsters given
lincomycin developed fatal enterocolitis, but the cause of this was not known. In 1973,
Tedesco carried out a prospective study in 200 patients where the rate of diarrhoea following
clindamycin therapy was 21% and the rate of PMC 10% (Tedesco et al. 1974). Other reports,
however, showed lower incidence rates (Gurwith et al. 1977); (Ramirez-Ronda, 1974);
(Swartzberg et al. 1977). At this time the condition was known as 'clindamycin colitis'
(Kabins and Spira, 1975). In 1974, Green reported the detection of a cytotoxin in the faeces
of guinea pigs following their treatment with penicillin (Green, 1974) (this was the first
report of the action of toxin B, although at the time the effect was thought to be due to a
virus). Also in this year, a PhD thesis was published by Hafiz (Hafiz, 1974), which was the
most comprehensive piece ofwork on C. difficile at the time. It indicated that the organism
was widespread in the environment and usually produced a toxin. At the time that these
three simultaneous pieces ofwork were published, it was not appreciated that the organism,
the toxin and PMC were related.
A few years later, in 1977, Larson described the first case of a cytopathic toxin in
faeces (Larson et al. 1977), from a patient who developed colitis following a course of
penicillin. Rifkin, in the same year, reported toxic stool filtrates from two patients, and went
on to demonstrate that sterile filtrates from these patients produced a fatal enterocolitis when
instilled into the peritoneum ofhamsters (Rifkin et al. 1977). The effect was found to be
neutralised by Clostridium sordellii antitoxin (Alio et al. 1979); (Chang et al. 1978a);
(Larson and Price, 1977); (Rehg, 1980); (Rifkin et al. 1977) and so at the time, C. sordellii
was felt to be the cause of PMC (Anonymous, 1977). However, in 1978 the true identity of
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the aetiological agent in PMC was revealed to be C. difficile (Bartlett et al. 1978a); (George
RH etal. 1978); (George et al. 1978a); (Larson et al. 1978).
1.2 CHARACTERISTICS OF CLOSTRIDIUM DIFFICILE
1.2.1 Morphology and cultural characteristics
C. difficile is a Gram-positive to Gram-variable bacillus of 0.3-0.8pm in diameter
and 2-9pm in length and is not acid-fast. It has parallel sides, produces large, oval,
subterminal spores that swell the cell slightly and is motile in early broth culture by means of
peritrichate flagella. C. difficile grows optimally at 30-37°C, but can also survive at 25°C or
45°C. Being an obligate anaerobe, it will not grow in the presence of oxygen. Culture is
usually performed in a nitrogen/hydrogen atmosphere, using either an anaerobic cabinet or
an anaerobic jar. It does not require blood to grow and colonies on most media become
apparent, although small, at 24 h of incubation, with typical morphology being achieved by
48 h.
Colonial morphology may be quite variable, especially on blood agar, but the
organism does produce a very characteristic smell, variously described as similar to that of
horse or elephant manure. After 48 h incubation on selective media, most colonies appear
2-4 mm in diameter, circular, flat and spreading with irregular edges. They are usually a
greyish colour with a granular, ground-glass appearance. If scraped from the agar plate onto
a swab, the colony appears slightly yellowish in colour and is of a butyrous nature. On blood
agar the colonies are non-haemolytic and may appear more smooth and shiny in nature with
a whitish colour, whilst retaining irregular edges, although some colonies do still show the
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granular, ground-glass appearance. The typical odour is less noticeable when the organism
is cultured on blood agar as opposed to a selective medium. Particularly when grown on
blood agar, a single strain may exhibit more than one type of colonial morphology
simultaneously. Colonies have also been noted to fluoresce a yellow-green colour on
exposure to long-wave (360nm) ultraviolet (UV) radiation (George et al. 1979). However,
this feature is rather medium dependent and some selective media used for C. difficile
isolation, e. g. cycloserine-cefoxitin fructose agar (CCFA), autofluoresce due to the neutral
red indicator (Kaufffnan and Weaver, 1960). When inhospitable conditions are encountered
by C. difficile, then spores are produced as a means of survival. Spore production on
selective media is not as pronounced as on blood agar, but recovery can be enhanced by the
addition of 0.1% sodium taurocholate to solid growth media (Wilson et al. 1982).
C. difficile is catalase, oxidase, indole, nitrate, DNAse and urease negative but
hydrolyses aesculin and liquefies 2% gelatin. It is lipase and lecithinase negative. Other
useful tests include prolyl aminopeptidase (+ve), leucine aminopeptidase (+ve),
13-galactosidase (-ve), and acid phosphatase (-ve) (Aspinall and Deader, 1992).
1.2.2 Structure
The cellular fatty acids (CFA) of C. difficile have been studied (Moss and Lewis,
1967) and more recently CFA profiles have been shown to vary with nutritional conditions
(Hopkins and MacFarlane, 2000). Drucker et al (1996) reported the phospholipid profiles of
32 outbreak strains and cell-surface carbohydrate antigens have also been investigated
(Poxton and Cartmill, 1982). C. difficile is known to produce capsular material (Davies and
Borriello, 1990) and to possess several peritrichous flagella for movement. The flagellin
gene has been sequenced and the flagellin characterised, having a molecular mass of
approximately 39kDa (Tasteyre et al. 1997); (Tasteyre et al. 2000a). Polar fimbriae are also
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present on the cell, which are 4-9 nm in diameter and 6 pm in length (Borriello et al. 1988a).
Several C. difficile surface proteins have been proposed as playing a possible role in
adhesion. Eveillard et al. (1993) and Kaijalainen et al. (1994) have described 27 kDa and 40
kDa proteins, whilst Waligora et al. (1999) described 40 kDa, 50 kDa And 70 kDa proteins
which could bind to Vero cells.
1.2.3 Metabolism
C. difficile has a fermentative, proteolytic metabolism, producing acid and gas from
glucose, aesculin, fructose, mannitol and mannose. Its major metabolic products are acetate
and butyrate, although isobutyrate, isocaproate and isovalerate are produced in lesser
amounts. One particular property of C. difficile is its deamination ofphenylalanine to
parahydroxyphenylacetic acid and further decarboxylation of p-hydroxyphenylacetic acid to
produce p-cresol (Phillips and Rogers, 1981), which gives rise to a characteristic odour.
1.2.4 Virulence factors
There have been quite a number of established and proposed virulence factors
previously described for C. difficile (Borriello, 1990); (Borriello, 1998); (Larson et al.
1978). The main virulence factors are two toxins, designated toxin A and toxin B.
However, other factors are also important, especially in allowing the organism to establish
itself in the gut. These include adherence to the intestinal mucosa, chemotaxis and motility,
capsule production and hydrolytic and proteolytic enzyme production. Work in the hamster
model has demonstrated that not all strains of toxin producing C. difficile are equally
virulent (Borriello et al. 1987); (Delmee and Avesani, 1990). Furthermore, non-toxigenic
strains are felt to have little if any pathogenic potential (Lyerly et al. 1988). Although
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patients with diarrhoea have had such strains detected in their stools, it is not known
whether they were involved in the aetiology of the diarrhoea.
1.2.4.1 Toxins A and B
1.2.4.1.1 Physical properties of the toxins
C. difficile manufactures several toxic products. The two most widely known, and
generally thought to be the organism's main virulence factors, are toxin A and toxin B
(Borriello et al. 1990); (Sullivan et al. 1982); (Taylor et al. 1980); (Taylor et al. 1981).
Although these have also been described as enterotoxin and cytotoxin respectively, this
nomenclature is slightly misleading. Both toxins are able to cause a cytopathic effect, with
toxin B being far more potent in this respect (Lyerly et al. 1988); (Sullivan et al. 1982).
However, toxin B does not possess any enterotoxin like properties. Levels of toxin produced
can differ between strains by more than 6 logs (a million times) although equal amounts of
each toxin are thought to be generated (Lyerly et al. 1988). In addition, three other factors
have been described.
One appears to be a poorly stable enterotoxin (Banno et al. 1984); (Giuliano et al.
1988); (Mitchell et al. 1987), another has been shown to produce changes in electrical
potential in isolated segments of rabbit intestine (Justus et al. 1982), whilst the third is
described as an actin-specific ADP-ribosyl-transferase (Popoff et al. 1988). Torres et al.
(1990) also described three enterotoxic factors, termed CI, C2, and C3. The precise function
of these latter three factors, along with their role in the pathogenesis of C. difficile disease, if
any, is uncertain.
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In contrast, there have been numerous reports characterising both the nature and
properties of toxins A and B (Gianfrilli et al. 1984a); (Lyerly et al. 1982); (Lyerly et al.
1986a); (Lyerly et al. 1986b); (Meador and Tweten, 1988); (Pothoulakis et al. 1986); (Rihn
et al. 1984); (Rolfe and Finegold, 1979); (Taylor and Bartlett, 1979); (Thelestam and
Bronnegard, 1979); (von Eichel-Streiber et al. 1990), as well as their effect on gut mucosa in
the animal model (Libby et al. 1982). Both toxins are found to have a cytotoxic effect, with
toxin B being considerably more potent (Knoop et al. 1993); (Lyerly et al. 1985). They also
both result in increased vascular permeability and haemorrhage. In addition, toxin A causes
marked fluid accumulation in various animal models (Ketley et al. 1987); (Lima et al. 1988);
(Mitchell et al. 1986), resulting in it being called enterotoxin. However, toxin A does not act
as a secretogogue, but results indirectly in fluid accumulation, secondary to mucosal damage
and release of cytokines from leucocytes (see section 1.2.4.1.6). Kamiya and Borriello,
(1992) report detection of a form oftoxin A without haemagglutinating capability but which
retains cytotoxicity and suggest that it might be a pro-toxin. The toxin genes for C. difficile
have been sequenced (Barroso et al. 1990); (Dove et al. 1990) and the toxins characterised,
with molecular masses of 308 kDa for toxin A and 269 kDa for toxin B (Johnson JL et al.
1990); (Sauerbom and von Eichel-Streiber, 1990). The two toxins are heat labile and are
susceptible to proteolytic breakdown, with toxin B being the less stable of the two (Banno et
al. 1984); (Sullivan et al. 1982); (Taylor et al. 1981). They have been shown by von
Eichel-Streiber et al. (1992) to have 63% amino acid homology and both are thought to have
receptor binding domains in the carboxy terminal repeat region (von Eichel-Streiber and
Sauerbom, 1990); (Pothoulakis, 1996a), with enzymatic domains localised to the amino
terminus (Faust et al. 1998); (Hofmann et al. 1997); (von Eichel-Streiber et al. 1995). The
carboxy terminal peptide repeat sequence oftoxin A (Dove et al. 1990) has been shown to be
homologous to the carbohydrate binding region of streptococcal glucosyltransferases (von
Eichel-Streiber and Sauerbom, 1990).
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1.2.4.1.2 Animal model experiments
As discussed in section 1.1, early work indicated that C. difficile was associated with
PMC and that the organism produced toxic factors. Chang et al. (1978b) described the
colitis, which develops in hamsters following clindamycin administration, as a model for C.
difficile colitis in humans. Animal experiments have been conducted using other species but
none are as susceptible as hamsters to C. difficile disease (Fekety, 1974). Another early
observation was that faecal filtrates from patients with PMC, or caecal contents ofhamsters
injected with clindamycin, caused death in normal hamsters when injected intracaecally
(Bartlett et al. 1977a); (Bartlett et al. 1978b); (Bartlett etal. 1980). Following these
discoveries, many investigators continued their research by trying to characterise the nature
and function of these toxins using both in vitro, as well as in vivo (animal model) methods.
Initial attempts at purification and characterisation focussed upon the cytotoxin (Humphrey
et al. 1979); (Rolfe and Finegold, 1979); (Taylor and Bartlett, 1979). Then came evidence of
another distinct toxin with enterotoxin like properties (Banno et al. 1981); (Taylor et al.
1981). Taylor et al. (1981) demonstrated that this enterotoxin was distinct from the
previously known cytotoxin, and was capable of inducing haemorrhagic fluid accumulation
in ligated rabbit ileal loops. These loops also showed histological changes of haemorrhage
and mucosal destruction. Similar effects were seen when the enterotoxin was injected into
ligated hamster ileal and large bowel loops. When the enterotoxin was injected into the
unligated caeca of hamsters, it was lethal, whereas cytotoxin only caused small areas of focal
haemorrhage. This enterotoxin was designated as toxin A, and felt to be the most significant
toxin in the pathogenesis of C. difficile disease.
Sullivan et al. (1982) purified both toxins and demonstrated their cytotoxic effects
on Chinese hamster ovary (CHO-K1) cells. They also demonstrated that both toxins were
lethal to mice when injected intraperitoneally. The lethality of both toxins has been
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demonstrated by a number of investigators, using several animal models, either by
intravenous, intraperitoneal or subcutaneous injection (Arnon et al. 1984); (Banno et al.
1981); (Banno etal. 1984); (Lyerly et al. 1986b); (Sullivan et al. 1982); (Taylor et al. 1981).
Although both toxins appeared equally potent in animal lethality tests by Sullivan et al. and
Lyerly et al., other investigators found toxin A to be far more potent than toxin B. The
possible explanation for this discrepancy is that the toxin preparations may not have been
equally pure, or that because toxin B is less stable (Banno et al. 1984); (Sullivan et al. 1982);
(Taylor et al. 1981), storage conditions may have allowed it to deteriorate faster than
toxin A.
Lyerly et al. (1985) investigated the effects of toxins A and B given intragastrically
to rats, mice and hamsters. They demonstrated that hamsters were far more susceptible to C.
difficile toxins than either mice or rats. Culture filtrates, as well as toxin A given alone,
resulted in intestinal pathology and death, whereas neither feature was observed after toxin B
administration alone. However, if small quantities of toxin A (too low to cause pathological
changes alone) were given with toxin B, hamsters became ill and died. Similarly, if toxin B
was administered to animals with bruised caeca, pathological changes and death were
observed. This suggests that toxin B is only able to manifest its toxic properties if it has
access to deeper tissues via a damaged or disrupted mucosal surface. Furthermore, it is
likely that in the presence of significant amounts oftoxin A, it can contribute significantly to
the development of C. difficile colitis. Therefore previous observations that toxin B alone
was lethal after intracaecal injection (Libby et al. 1982) may have resulted from the fact that
associated damage to the mucosa allowed the toxin deeper access than if it had been
administered orally. Another observation from this study was that repeated small doses of
toxin A appeared to have a cumulative effect, suggesting that the effects of the toxin on the
mucosa are not transient. Mitchell et al. (1986) and Lima et al. (1988) demonstrated that the
effects of toxin A were more pronounced on rabbit ileum than on the colon, and their
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findings concurred with those ofTriadafilopoulos et al. (1987) that toxin B alone does not
have an enterotoxic effect.
Kim et al. (1987) investigated the effect of immunising hamsters against toxin A or
toxin B to try and help elucidate the relative contribution of each toxin to disease. They
found that immunisation against toxin A alone, but not against toxin B alone was sufficient
to protect against clindamycin induced colitis. If lethal doses of either toxin were
administered orogastrically however, then only immunisation against the challenging toxin
protected against death. The conclusion was that toxin A is the more important toxin in
hamsters and that in the course of enterocolitis, levels of toxin B alone do not get high
enough to cause death. This allows immunisation against toxin A alone to protect against
death because the synergistic interaction between the two toxins is abolished. Further
evidence for the hypothesis that both toxins play a part in disease comes from the
observation that a greater percentage of infant hamsters suckling from mothers immunised
against only toxin A became ill, compared with a group suckling from mothers immunised
against both toxins.
1.2.4.1.3 In vitro experiments using human cell lines and tissues
There is evidence that different strains of C. difficile produce differing quantities of
toxin (Wren et al. 1987), and a suggestion that this may affect their pathogenic potential.
Other evidence supports the theory that the amount oftoxin produced by a strain of C.
difficile may relate to its virulence. Viscidi et al. (1981) measured the toxin concentrations
in vitro of C. difficile isolates which were obtained from healthy neonates, adults with toxin
associated diarrhoea, adults on antibiotics without diarrhoea and adults on antibiotics with
toxin negative diarrhoea. They found that the in vitro toxin titres of the strains from
neonates and from adults with toxin positive diarrhoea were much higher than those
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produced by strains from the asymptomatic adults on antibiotics or individuals with toxin
negative diarrhoea. It is possibly because some strains produced lower quantities of toxin
that they were less pathogenic. Discussion ofwhy neonates remain healthy despite the
presence of C. difficile toxins at high titres will take place in section 1.5.2.2.1.1.
Because of the suggestion of a synergistic interaction between the two toxins, and
although some evidence in the hamster model indicated that the degree of toxin A production
was better correlated with severity of disease than that of toxin B (Borriello el al. 1987),
further work was carried out using a human in vitro model. This was in order to try to
ascertain whether the effects of toxin A and B were different on the human bowel mucosa,
compared with the animal models. A study using human colonic mucosal sheets in Ussing
chambers demonstrated that toxins A and B cause dose-dependent, electrophysiological
changes as well as morphological damage (Riegler et al. 1995). Previous work with
polarised human intestinal T84 cells indicated that in apical (lumenal) exposure tests, toxin
A was the more potent of the two (Hecht et al. 1988); (Hecht et al. 1992), but this study
showed toxin B to be ten times more potent than toxin A. Another finding was that the
degree of mucosal damage was correlated with the toxin concentration, suggesting that
higher concentrations of toxin may give rise to more serious colitic changes in patients.
Work using cultured nonpolarised Don cells indicated that toxin B was 1000 times more
potent at intoxicating the cell than toxin A (Chaves-Olarte et al. 1997).
Recently, a very elegant study by Stubbe et al. (2000) demonstrated the effects of
toxins A and B on human colonic carcinoma-derived T84 cell monolayers. Using a system
whereby either the lumenal (apical) or serosal (basolateral) surface of the cell layer could be
exposed to toxin, they measured transepithelial resistance (TER) (as the most sensitive
measure of barrier function) as well as tight junction integrity and monolayer morphology.
Toxin A added apically resulted in a substantial reduction in TER, whereas toxin B added
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apically showed no effect. When added basolaterally, both toxins exerted a substantial
reduction in TER, with toxin B showing the greater fall. The effect of toxin A on tight
junctions after 6 h was minimal, but complete disorganisation had occurred by 24 h when
added apically. Toxin B added apically had no effect on tight junctions. When added
basolaterally, however, both toxins completely disrupted the tight junction network after 6 h.
Morphological changes with apical toxins only occurred with toxin A which demonstrated a
slight enlargement of the space between cells at 6 h, but complete disorganisation by 24 h.
Both toxins added basolaterally caused changes similar to apical toxin A, with a more rapid
effect of toxin B. Addition of a very small quantity of toxin A (with scarcely any change in
TER) plus toxin B apically resulted in a greater TER drop than with toxin A alone. Finally,
using monoclonal antibodies to toxin A Stubbe et cil. showed that it was possible to protect
against the effects of a toxin A plus B mixture added apically but not when added
basolaterally. These findings indicate that toxin B cannot penetrate normal tight junctions in
the bowel mucosa, but if these are damaged by toxin A, then toxin B will cause severe
cytotoxic effects on the lamina propria and lower layers. This work also suggests that there
are unlikely to be receptors for toxin B on the apical surface of intestinal mucosal cells, but
that they may well exist on the basolateral surface. The apparent lack of a functional site for
toxin B on the apical surface of intestinal mucosal cells could be the explanation for the
discrepancy between mucosal binding activities of toxins A and B previously noted (Rolfe,
1991).
1.2.4.1.4 Toxin receptors
A proposed receptor for toxin A has been described on rabbit erythrocytes as well as
on hamster brush border membranes (BBM) (Krivan et al. 1986). This receptor is a
glycoprotein which contains the trisaccharide Galal-3Galp l-4GlcNAc. The same receptor
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has also been identified in the rat ileal BBM (Pothoulakis et al. 1991), and a slightly
different one in the rabbit ileal BBM (Clark et al. 1987); (Pothoulakis et al. 1996b). This
trisaccharide is not expressed on human cells, so the human toxin A receptor must be
different but does appear to be a glycoprotein (Pothoulakis et al. 1992). Lewis I, X and Y
antigens can bind toxin A (Tucker and Wilkins, 1991) and may act as functional receptors
but they are not universally expressed by intestinal epithelial cells. The relative distribution
of toxin A receptors in the gut epithelium may be one of the factors which determines the
severity of disease in an individual. Toxin A binding activity in the newborn rabbit BBM is
absent, with a diminished biological response to toxin. Biological response and binding
activity then rise together to reach adult levels by 30-40 days of age (Eglow et al. 1992).
This finding may result from the absence of receptors at the time of birth, which then
develop by the age of 30-40 days. A similar observation has been made with infant
hamsters, which can be harmlessly colonised by C. difficile between the ages of 4-13 days,
despite high toxin titres. Outside this window, they do not become colonised with C.
difficile unless treated with antibiotics, which results in the development of colitis and death.
As proposed by Chang et al. (1986), such a deficiency of receptors may also be the reason
why neonates and infants are so often asymptomatically colonised by C. difficile, even in the
presence ofhigh toxin titres. Very little is currently known about toxin B receptors, although
from the work by Stubbe et al. (2000), it would be reasonable to expect them to be present
on the basolateral, rather than the apical surface of the intestinal mucosal cells.
1.2.4.1.5 The cellular mechanism of C. difficile toxins
After binding to their respective receptors, toxins A and B enter the cell and result in
alterations of actin containing filaments which causes cell rounding. The alterations consist
of a decrease in filamentous (F) actin with a reciprocal increase in globular (G) actin
(Pothoulakis et al. 1986). Calcium is known to be important if these changes are to occur, as
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depletion of intracellular calcium abolishes the effect of toxin B on actin microfilaments
(Gilbert et al. 1995). These changes are now known to be mediated by the effect of toxins A
and B on Rho proteins, which are low molecular weight GTP-binding proteins of the ras
superfamily (Dillon et al. 1995); (Just et al. 1994); (Just et al. 1995a). RhoA, one of the Rho
family proteins, is involved in actin assembly regulation (Hall, 1998) and is now known to
be glycosylated at threonine37 (located in its effector domain) by both toxins A and B (Just et
al. 1995b); (Just et al. 1995c). Two other proteins of the Rho family, Rac and Cdc42 are
also glucosylated by C. difficile toxins. Such a modification of the Rho family proteins
renders them inactive and prevents polymerisation of actin filaments, resulting in cell
retraction and rounding.
1.2.4.1.6 Mechanism of C. difficile toxin mediated inflammation
The precise way in which C. difficile toxins cause colitic changes in the colon is not
fully understood, but the process appears to be a complicated one. In addition to the direct
affects on actin microfilaments described above, which disrupt the intestinal epithelium,
subsequent actions on lamina propria neuroimmune cells, T cells, macrophages and
eosinophils may be significant. Toxin A is known to be able to stimulate a chemotactic
response in human granulocytes (Pothoulakis et al. 1988). Branka et al. (1997) found that
IL-8 production in a polarised homogenous goblet cell line (HT29-CI.16E) was up-regulated
in only 2-3 hours following exposure to low quantities of toxin A. This was associated with
down-regulation of mucin exocytosis in the cell line. IL-8 is known to be an important
factor in neutrophil chemotaxis and activation (Baggiolini et al. 1989). Neutrophil
infiltration has also been noted to be a feature following exposure of rabbit distal colon to
toxin A (Burakoff et al. 1995); (Kelly et al. 1994). Several other factors have been shown to
be important in C. difficile induced enteritis, by experiments where specific inhibitors were
used to abolish the effects of C. difficile toxins on the bowel mucosa in animal models or in
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vitro. Both neurokinin-1 (NK-1) receptors (also known as substance P receptors) and mast
cell degranulation have been shown to be involved in C. difficile disease in this way
(Castagliuolo et al. 1998); (Wershil et al. 1998). Individuals with C. difficile induced PMC
have been shown to have higher levels ofNK-1 receptors in the small blood vessels and
lymphoid aggregates of the bowel than control patients with ulcerative colitis (Mantyh et al.
1996). More recently, Castagliuolo et al. (1999) have reported that a bioactive peptide,
neurotensin (NT) is involved in the early stages of C. difficile toxin effects on gut mucosa.
Administration ofNT to rats has been found to result in mast cell degranulation (Carraway et
al. 1982) and increases in vascular permeability, histamine and leukotriene C4 levels
(Carraway et al. 1991). Castagliuolo et al. (1999) demonstrated that NT and NT receptors
are found at elevated levels in rat colonic mucosa early in the course of C. difficile colitis.
NT receptor antagonists were found to prevent toxic effects of toxin A on the bowel.
Reduced mast cell degranulation was noted and consequently reduced neutrophil infiltration,
as mast cell mediators can initiate neutrophil chemotaxis (Wershil et al. 1996). NT has also
been shown to stimulate the release ofNK-1 (Carraway and Mitra, 1994); (Stapelfeldt and
Szurszewski, 1989). Additionally, Castagliuolo et al. (1999) demonstrated that rat colonic
explants did not manifest mast cell degranulation after NT stimulation ifNK-1 receptors
were blocked. This suggests that NT is causing mast cell degranulation via an NK-1
mediated route. As well as mast cell degranulation, NK-1 is stimulatory to monocytes,
resulting in the release of the proinflammatory cytokines interleukin-1 (IL-1), tumour
necrosis factor-a (TNF-a) and interleukin-6 (IL-6) (Lotz et al. 1988) and increases
neutrophil cytotoxicity (Wozniak et al. 1989). Castagliuolo et al. (1999) conclude that
neuroendocrine N cells in the intestinal mucosa, which are contiguous with the bowel lumen
can be stimulated by toxin A to release NT. In turn, this results in the stimulation of cells in
the lamina propria to secrete NK, and mast cell degranulation is increased. NK also
stimulates other immune cells to release proinflammatory cytokines and neutrophils are
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chemotactically attracted to the area. Another effect of these inflammatory mediators may
be to up-regulate NT receptors.
Toxin B has also been shown to have some direct effects on lamina propria white
cells including macrophages (Sousa et al. 1997) and mast cells (Wex et al. 1997), resulting
in the further release of inflammatory cytokines. Access of toxin B to the lamina propria is
achieved after the destruction of tight junctions by toxin A, as earlier discussed in section
1.2.4.1.3.
Apart from the local inflammation which results from macrophage and neutrophil
release ofproinflammatory mediators, both toxins A and B are able to induce apoptosis in
intestinal epithelial cells (Fiorentini et al. 1998); (Mahida et al. 1998). When due to toxin A,
the release of interleukin-8 (IL-8) is another feature. Apoptosis secondary to toxin B may
also result in the increased release of cytokines that can increase local tissue damage
(Castagliuolo etal. 1999).
1.2.4.1.7 Importance of both toxins
For a long time toxin A was felt to be the most important factor in the development
of symptomatic C. difficile disease, primarily because of evidence from the hamster model
mentioned above. More recent evidence has shown toxin B to play a significant part in
damaging the intestinal mucosa (Riegler et al. 1995). In addition, strains of C. difficile
which do not produce normal toxin A have been associated with disease in children (Depitre
et al. 1993); (Kato et al. 1998) and adults (al-Barrak et al. 1999); (Brazier et al. 1999a);
(Kato et al. 1997); (Limaye et al. 2000); (Sambol et al. 2000). This further reinforces the
importance oftoxin B. Both toxins are felt to act in a synergistic fashion to cause the
pathological changes that result from C. difficile infection.
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It was generally thought that C. difficile strains were either toxigenic, with both
toxins produced, or non-toxigenic with neither (Lyerly et al. 1988). However, Gianfrilli et al.
(1984a) did report that 30% of strains of C. difficile from patients with diarrhoeal symptoms
or PMC appeared to have detectable levels of toxin B only. Haslam et al. (1986) described a
cytotoxigenic strain that did not produce toxin A when grown in media lacking in some
amino acids. Fluit et al. (1991), investigated 59 strains of C. difficile and demonstrated that
toxigenic strains had both toxin genes whilst non-toxigenic strains had neither. In 1991,
McMillin et al. described a strain which, whilst possessing the genetic material for toxin A
and B production, was not found to be toxigenic under the conditions tested (McMillin et al.
1991). This suggests that the organism can possess both toxin genes without necessarily
expressing them. Subsequent work has demonstrated that some strains have a deletion in the
toxin A gene and produce a modified toxin A, which is lacking in its carboxy terminal repeat
sequences (Torres, 1991); (Borriello et al. 1992a); (Depitre et al. 1993); (Lyerly et al. 1992);
(Sambol et al. 2000). Such a deletion renders it undetectable by traditional ELISA methods,
which rely on this region for toxin detection, but still capable of causing C. difficile disease
(Kato et al. 1997); (Limaye et al. 2000); (Sambol et al. 2000). In addition, one such strain
(8864) has been noted to produce slightly different toxin B to normal strains (Borriello et al.
1992a); (Lyerly et al. 1992); (Torres, 1991) and this toxin B has been found to be more
cytotoxic than normal by 5-10 fold (Lyerly et al. 1992). Conversely, a similar toxin A
negative strain, known as 1470 has been shown to have a toxin B which is less potent than
that from type strains of C. difficile (von Eichel-Streiber et al. 1995). One report of a strain
producing toxin A but lacking toxin B production has been made (Smith et al. 1992),
however this has not subsequently been confirmed by other groups. Cohen et al. (1998)
report a case of recurrent CDI where the strain causing disease for the third time was lacking
at least part of the toxin B gene.
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1.2.4.2 Adherence to intestinal mucosa
Adherence to the intestinal mucosa is thought to be an important step in the
progression towards disease caused by C. difficile. It was first noted to occur when C.
difficile was isolated from a washed biopsy sample, taken from a patient with PMC
(Borriello, 1979). Later work by Borriello et al. (1988b) in a hamster model, indicated that a
virulent strain was more adherent to the bowel mucosa than a poorly virulent strain or an
avirulent strain. C. difficile is known to possess fimbriae although their possible role in
adhesion remains unclear at present (Borriello, 1998a). Several workers have described cell
surface proteins, which could be involved with attachment to the gut mucosa (Eveillard et al.
1993); (Karjalainen et al. 1994); (Waligora et al. 1999). Environmental factors such as
sodium, calcium or iron concentration, as well as pH appear to affect the adherence of C.
difficile to vero cells in anaerobic conditions (Waligora et al. 1999). Other physical
properties have also been proposed as being contributory towards mucosal attachment. C.
difficile cells are found to be moderately hydrophobic (Wood-Helie et al. 1986) and have an
evenly distributed, net positive charge (Krishna et al. 1996). This may facilitate interaction
with negatively charged cells in the gut mucosa as well as with gut mucus, and contribute
towards the known phagocytosis resistance of C. difficile (Dailey et al. 1987). Adherence of
an avirulent strain to large and small bowel mucosa in a hamster model was increased to the
level seen in a virulent strain when co-administration of toxic culture filtrate was performed
(Borriello et al. 1988b). Heat inactivated toxin had no effect on adherence. This suggests
that adherence may be facilitated by toxins or some other secreted factor, and not that
avirulent strains lack some important cell surface structure or attachment protein.
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1.2.4.3 Chemotaxis and motility
Gut mucus has been demonstrated to be a chemoattractant for C. difficile in humans
as well as in animal models (Borriello and Bhatt, 1995). In a hamster model, the degree of
attraction correlated positively with the virulence of the strain used (Borriello and Bhatt,
1995). The flagella of C. difficile may play a part in adherence, as without these, directed
movement towards the mucosa would not be possible. However, Tasteyre et al. (2000b)
found that an antiserum raised against purified flagellin did not inhibit adherence to cultured
cells. This cannot be taken as proof that flagella do not aid adherence as even without
flagella, bacteria may sediment down to the cell monolayer spontaneously and then become
attached.
1.2.4.4 Capsule production
C. difficile is known to be resistant to phagocytosis (Dailey et al. 1987), and one of
the mechanisms by which this is achieved may be its production of a polysaccharide capsule
(Davies and Borriello, 1990). Davies and Borriello noted the capsular material to be either
loose-knit and branching, extending 350 nm from the cell wall, or dense and compact
extending only 100 nm. Growth on agar appeared to demonstrate microcolonies covered by
glycocalyx. Polymorphonuclear leucocytes, attracted to the mucosal surface but unable to
ingest C. difficile, may contribute to local tissue damage by release of digestive enzymes.
1.2.4.5 Proteolytic and hydrolytic enzyme production
Enzyme production has been known to be a feature of C. difficile since as long ago
as 1975, when Hafiz and Oakley (1976) described the production ofhyaluronidase and
gelatinase in 100% of 30 strains tested. Subsequent investigators have described the
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production of other hydrolytic enzymes, including chondroitin-4-sulphatase and collagenase
(Steffen and Hentges, 1981). Further detailed study of the breakdown of connective tissue
(Seddon et al. 1990) confirmed that most strains produce hyaluronidase, chondroitin-4-
sulphatase and heparinase, although the activity of the latter is generally weak. C. difficile
has also been demonstrated to produce proteases (Seddon and Borriello, 1992), and along
with the previously described hydrolytic enzymes, these may play a significant part in
causing mucosal damage. It is also suggested that such proteases might be involved in the
activation ofpro-toxin A (Seddon and Borriello, 1992). Enzymes such as hyaluronidase may
play an important part in the production ofnutritional factors, such as N-acetylglucosamine
from the breakdown ofhyaluronic acid.
1.2.5 Genetic structure
Most of the work on the genetic structure of C. difficile has centred around the genes
for its two main toxins. The toxin A (tcdA) and toxin B (tcdB) genes have both been
identified and sequenced (Barroso et al. 1990); (Dove et al. 1990); (von Eichel-Streiber et al.
1992), the former being 8.1-kb, whilst the latter is 7.1-kb in length. It has now been
determined (Braun et al. 1996); (Hammond and Johnson, 1995) that they are both in the
same vicinity on the bacterial chromosome, as part of a 19.6-kb pathogenicity locus (PaLoc).
Some of the other genes in the PaLoc (tcdC-E) are thought to be involved in the regulation
of the toxin genes tcdA-B (Moncrief et al. 1997). Moncrief et al. (1997) suggest that tcdC
may have a negative regulatory effect on toxin production and that tcdD seems to have a
positive regulatory role (see also Hundsberger et al. 1997). Initial studies suggested that the
PaLoc was present in toxigenic strains and lacking in non-toxigenic strains. It has since been
discovered that some strains, which produce abnormal toxins, have alterations in the PaLoc.
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Analysis of a recently identified strain (8864) which produces toxin B but not toxin
A (Borriello etal. 1992a); (Lyerly et al. 1992); (Torres, 1991) has demonstrated a 5.9-kb
deletion and a 1.1-kb insertion in the PaLoc. This corresponds to the production of a
truncated form oftoxin A and possible production of another protein of up to 22 kDa (Song
et al. 1999), coded for by a new gene named tcdF. Furthermore, tcclB in this strain is not
identical to that of the type strain simultaneously tested. Analysis of strain 1470 (serotype
F), another toxin A-negative, toxin B-positive strain described by Depitre et al. (1993), has
indicated that it has a 1.8-kb deletion in the PaLoc affecting tedA. This appears to result in a
complete lack of toxin A production (von Eichel-Streiber et al. 1999). Interestingly, this
strain does not cause disease in hamsters whereas strain 8864 remains active in that model.
Investigation of 48 toxin A negative, toxin B positive strains from around the world,
demonstrated them all to have a deletion in the toxin A gene of~1.7 kb, similar to strain
1470. Differences in the toxin B gene between different strains have also been noted by von
Eichel-Streiber et al. (1995). Cohen et al. (2000) describe a strain of C. difficile (P-829)
isolated from a symptomatic patient, which had no detectable production of either toxin A or
B. However, on analysing the PaLoc, they discovered deletions in tcdB, tcdC, tcdD and tcdE
whilst tcdA was detectable. Therefore, strain P-829 may produce a truncated toxin A, which
lacks part of its terminal repeat region and be is therefore undetectable by current ELISA
testing. Their work does confirm the hypothesis that most toxigenic strains have a highly
conserved PaLoc, whilst non-toxigenic strains are lacking this region entirely. The only
strains that appear to have an altered PaLoc, are those which produce modified toxins.
The flagellin gene (fliC) has been described, producing a protein of 290 amino acids
with an estimated molecular mass of 31 kDa. Flagellin extracted using SDS-PAGE has an
apparent molecular mass of 39 kDa (Tasteyre et al. 2000a). Both non-flagellated and
flagellated strains have been shown to possess the fliC gene. Analysis of fliC genes from
different C. difficile strains demonstrates conservation ofN- and C-terminal domains with a
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variable central region (Tasteyre et al. 2000b). Plasmids have also been described in C.
difficile, although their presence or absence does not appear to be associated with toxin
production or virulence (Hayter and Dale, 1984); (Lyerly et al. 1988).
1.3 AETIOLOGY AND CLINICAL MANIFESTATIONS OF
CLOSTRIDIUM DIFFICILE DISEASE
1.3.1 Acquisition of the organism
The first stage in the process leading towards disease due to C. difficile is acquisition
of the pathogen. Despite the organism having been isolated from many different places (see
table 1), it appears much more likely to be encountered in hospital than anywhere else (see
section 1.5.2.2.2). Acquisition is thought to be mainly via the hand to mouth route, with the
spores often being found to contaminate the environment. This is especially noticeable in
the vicinity of patients with CDI (Chang and Nelson, 2000); (Fekety et al. 1980); (Kim et al.
1981); (Mulligan et al. 1979); (Mulligan et al. 1980). Spores are particularly likely to build
up in poorly or infrequently cleaned sluice areas. Due to the persistent nature of spores once
in the environment, careful attention to frequent cleaning is important in order to prevent
their accumulation and minimise the risk of dissemination throughout the ward environment.
Once the environment is contaminated, it is relatively easy for health care professionals to
spread C. difficile to patients, or other ward areas, if they do not pay careful attention to
handwashing between patient interactions (Fekety et al. 1980); (McFarland et al. 1989). The
isolation of symptomatic patients also seems to represent a reasonable approach, although
some authorities challenge its utility (Sanderson and Richardson, 1997). Cases of C. difficile
infection due to nosocomial transmission are well documented (Heard et al. 1986); (Johnson
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et al. 1990a); (McFarland et al. 1989), (Testore et al. 1988) and this is thought to be the main
method ofacquisition for patients in hospital.
Table 1: Environmental sources from which C. difficile has been isolated
Camel dung River water
Donkey dung Sand
Horse dung Sea water
Lake water Soil
Mud Swimming pools
Raw vegetables Tap water
This table is adapted from Al Saif and Brazier, (1996) and Levett, (1986).
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1.3.2 Proliferation of the organism
Our main defence against C. difficile is the normal bowel flora of the gut. This has
been demonstrated in experiments which have indicated the phenomenon of 'colonisation
resistance', and its disturbance by antibiotics (see section 1.3.2.1). The role of the immune
system and antibody responses to toxin in the bowel is yet to be fully understood, but it
seems likely that it does contribute to protection from disease (see section 1.3.2.2).
Antibiotics are, without doubt, the one factor that is most likely to influence the ability of
normal gut flora to resist colonisation by C. difficile (see section 1.3.2.3). This is because
they disturb the natural balance ofprotective organisms. Other modalities such as
chemotherapeutic agents have also been shown to predispose towards development of C.
difficile disease, presumably by compromising the normal bowel flora (see section 1.3.2.4).
1.3.2.1 Colonisation resistance
Work using a hamster model showed that animals given antibiotics, or exposed to
toxigenic C. difficile alone, did not develop disease. However, those given antibiotics and
then exposed to toxigenic C. difficile almost always died (Larson and Borriello, 1990)
(Larson el al. 1980). Wilson et al. (1981) demonstrated that C. difficile counts were reduced
in hamsters that were given normal hamster caecal homogenates, and that animals given
such homogenates after exposure to antibiotics did not develop caecitis. Other authors have
also observed the inhibitory effect of some components of faecal flora on the establishment
of C. difficile (Borriello and Barclay, 1985); (Malamou-Ladas and Tabaqchali, 1982); (Rolfe
et al. 1981). Suppression of C. difficile by isolates of indigenous hamster flora was
demonstrated by Wilson et al. (1986). Borriello and Barclay, (1986) devised an in-vitro
model of colonisation resistance to C. difficile infection, where the organism was seeded into
faecal emulsions. Using this model, they determined that bacteria played an important role
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in 'colonisation resistance'. They found that Gram-negative facultative organisms appeared
to have no protective role, whereas anaerobes seemed very important. If all organisms were
removed and only the spores of endogenous Clostridia left, there was also no protective
effect. By using this model it was also possible to confirm that faecal emulsions from young
adults were inhibitory to C. difficile colonisation, those from elderly patients were less so,
and those from neonates were usually not inhibitory at all. These observations would seem
to fit with the hypothesis that neonates have a very rudimentary alimentary tract flora which
may allow easy colonisation with C. difficile (Larson et al. 1982). Wilson et al. (1986) also
demonstrated the effect of colonisation resistance, using gnotobiotic mice. Once these mice
were colonised by C. difficile, inoculation with caecal flora from 'normal' mice resulted in
loss of C. difficile within 2 weeks. The interaction of both Escherichia coli and non-
toxigenic C. difficile with toxigenic C. difficile has been investigated using a continuous flow
(CF) culture or an animal model in both hamsters and gnotobiotic mice (Borriello and
Barclay, 1985); (Borriello and Barclay, 1986); (Wilson and Freter, 1986); (Wilson and
Perini, 1988); (Wilson and Sheagren, 1983). Many other workers have also carried out
animal experiments which have demonstrated the ability of C. difficile to induce a colitic
illness in the absence of adequate protective flora, or have reported C. difficile disease in
other species (Abrams et al. 1980); (Chang et al. 1978b); (Corthier et al. 1985); (Czuprynski
etal. 1983); (Fekety et al. 1979); (Humphrey et al. 1979); (Jones et al. 1987); (Knoop,
1979); (Lusk et al. 1978); (Onderdonk et al. 1980); (Orchard et al. 1983); (Price et al. 1979);
(Rehg, 1980); (Rehg and Pakes, 1982); (Sugiyama et al. 1985); (Wilson et al. 1986).
In vivo evidence in humans for the beneficial effect ofprotective bowel flora is
available in the form of the reported beneficial effect of reintroduction of faecal flora or use
ofprobiotic agents in the treatment of C. difficile disease. Several authors have reported the
beneficial effect of using rectal infusions of faeces from normal hosts in the treatment of
recurrent C. difficile infection (Bowden et al. 1982); (Schwan et al. 1983); (Schwan et al.
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1984); (Tvede and Rask-Madsen, 1989), although Tjellstrom et al. (1993) document the
unsuccessful use of such therapy in one case of relapsing C. difficile diarrhoea. The use of
Lactobacillus casei GG has also been attempted for the treatment of relapsing CDI with
some success in two small, open trials (Biller et al. 1995); (Gorbach et al. 1987). The yeast
Saccharomyces boulardii has also been used, in conjunction with vancomycin, for the
treatment of relapsing C. difficile infections (McFarland et al. 1994); (Surawicz et al. 1989).
In the first study, a small open trial, 11 out of 13 patients had no further disease following
treatment with vancomycin for 10 days and S. boulardii for 28 days. In the second study, a
placebo controlled trial with 124 patients, a benefit was only seen in patients who were
suffering from relapsing disease. The recurrence rate in those who were being treated for
their first episode of CDI was the same in both test and control groups. Seal et al. (1987)
report the use of a non-toxigenic strain of C. difficile to treat relapsing diarrhoeal disease.
Several explanations have been proposed as to the reason why C. difficile
colonisation and proliferation is reduced in the presence of normal colonic flora. A
reduction in pH has been cited by Borriello and Barclay, (1986) as the possible mechanism,
but this was not confirmed by a more recent study using continuous flow (CF) culture by
Yamamoto-Osaki et al. (1994). In this study, the pH of the CF culture system was not seen
to alter despite C. difficile growth being inhibited. Interestingly, when a C. difficile positive
stool sample was used to start the CF culture system, viable numbers of C. difficile fell to
zero in around 4 days as the other organisms proliferated. Upon re-introduction, once a
steady state had been reached (after 10 days), counts of C. difficile were seen to increase. In
contrast, when a C. difficile negative stool sample was used as the starter, viable numbers of
C. difficile were seen to fall when introduced after a steady state was reached (10 days). The
flora of the C. difficile positive stool was noted to be less complex than the C. difficile
negative one but nevertheless, whilst actively proliferating, it was still able to inhibit C.
difficile growth. This ability was lost once the steady state was reached. When C. difficile
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negative faeces was used as a starter culture, the more complex flora was able to inhibit C.
difficile growth even once a steady state was reached. This phenomenon may be a
demonstration that competition for nutrients can suppress growth and prevent the
establishment of C. difficile. However, to achieve this requires either complex flora at a
steady state, or more rudimentary flora that is rapidly proliferating.
Wilson and Perini, (1988) investigated the way in which competition for nutrients in
mouse colonic flora may suppress the growth of C. difficile, and found that an unidentified
component of faecal flora was able to out compete C. difficile for nutrients. Haslam el al.
(1986) demonstrated that for growth in vitro, C. difficile required proline, valine, leucine,
/.vo-leucine and tryptophan. Using a CF culture system with infant faeces, they demonstrated
that a significant, almost complete reduction of some amino acids occurred, and this could be
related to the inhibition of C. difficile seen. In addition, C. difficile was inoculated into a
dialysed culture filtrate (harvested after incubation for 7 days with intestinal bacteria). Five
different amino acids were added singly to this filtrate, as well as none or all five at once.
Standard anaerobic broth was used for a growth control. The pH of the dialysed filtrates
with or without amino acids was lower than in the control broth. No proliferation of C.
difficile was observed in any of the filtrates where a single amino acid had been added.
When all five were added then C. difficile was able to proliferate and the pH was found to
rise. This suggests that lack of amino acids can play a significant role in the inhibition of C.
difficile growth although reduced pH may also be a factor.
Another factor, which has been mooted to give rise to inhibition of C. difficile
proliferation, is volatile fatty (VFA) acid concentrations in the gut. Rolfe, (1984) suggested
that VFAs played a significant part in colonisation resistance, however, other investigators
have demonstrated no such link when using an in-vitro model, gnotobiotic mice or a CF
culture system (Borriello and Barclay, 1985); (Su et al. 1987); (Yamamoto-Osaki et al.
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1994). It has also been suggested that lack of a carbon source may result in limited growth
of organisms in the colonic ecosystem (Freter et al. 1983), or that an individual's diet may
influence C. difficile toxin production (Mahe et al. 1987). Presence of non-toxigenic or
intermediate level toxin producing strains in the bowel of gnotobiotic mice has been shown
to protect against C. difficile disease (Corthier and Muller, 1988).
1.3.2.2 Immune response
The immune response, and in particular antibody production, appears likely to play a
significant part in protection from CDI. Lishman et al. (1981) was one of the first groups to
describe an antitoxin response to C. difficile disease. Later, in a study of 340 patients, serum
antibodies to toxin A and toxin B were shown to be present in more than 60% of those aged
over 2 years (Viscidi et al. 1983). Aronsson et al. (1983) also described an antibody
response to these two toxins, which appeared to be reduced in those with the most severe
colitis. In another study, antibody responses were more marked in patients with mild disease
than in those who were severely affected, and those with relapsing disease had the lowest
antibody levels (Aronsson et al. 1985a). Kelly et al. (1992) showed that IgA with activity
against toxin A was detectable in colonic aspirates of patients, although levels did not appear
to correlate with serum concentrations. However, it is thought that intestinal IgA responses
may parallel serum IgG responses (Johnson et al. 1992a). Serum antibodies of the IgG class
with activity against a C. difficile surface protein of 36 kD have also been reported in
patients with PMC (Pantosti et al. 1989). This surface protein has been purified and partially
characterised but its function remains uncertain (Cerquetti et al. 1992); (Cerquetti et al.
2000).
Increased serum levels of antitoxin A antibodies have been described by several
investigators after episodes of CDI (Aronsson et al. 1983); (Aronsson et al. 1985a); (Johnson
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et al. 1992a); (Viscidi et al. 1983). Johnson et al. (1992a) described increased antibody
levels even in patients with relapsing disease and suggested that high antibody levels
correlate with severity of illness rather than with protection from it. Mulligan et al. (1993)
demonstrated detectable levels of both IgA and IgM in serum, which were reactive against
somatic cell antigens of C. difficile. Furthermore, they noted that these levels were
significantly higher in asymptomatically colonised patients than in symptomatic patients or
controls, which suggests a possible protective role for an adequate immune response.
Similarly, Kyne et al. (2001) found that serum levels of IgM and IgG antibodies to toxin A
were higher in individuals who experienced a single episode of CDI compared with those
suffering multiple episodes. When Nakamura et al. (1981) investigated the toxin
neutralising activity of serum, they found that in young adults, neutralising ability was often
present, whereas it was almost always absent in samples from elderly patients. The utility of
an adequate immune response is indicated by the observation that hypogammaglobulinemia
may predispose children to C. difficile disease (Gryboski et al. 1991) and that relapsing C.
difficile colitis may respond to intravenously administered gamma globulin (Leung et al.
1991); (Salcedo et al. 1997); (Warny et al. 1995). A study by Wamy et al. (1994) suggested
that an adequate immune response does play a significant protective role against CDI. They
found that serum IgG and faecal IgA levels in patients with prolonged, relapsing CDI were
lower than those in patients with a short duration of symptoms. Serum IgA, rather than IgG
has been reported to be responsible for toxin neutralising ability (Johnson, 1997). Oral IgA
has been reported to be of some use, in conjunction with standard antibiotic therapy, for the
treatment ofpersistently relapsing CDI (Tjellstrom et al. 1993).
The importance of the immune response in minimising symptoms from CDI is
further reinforced by animal work which has demonstrated the efficacy of both active and
passive immunisation against C. difficile toxins. Early work using hamsters showed that
active immunisation against toxins A and B could protect against C. difficile colitis (Libby et
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al. 1982). The effectiveness of active (and passive) immunisation in hamsters, for the
prevention of antibiotic associated caecitis, was also demonstrated by Femie et al. (1983).
Kim et al. (1987) immunised hamsters against toxins A and B, and discovered that toxoid A
alone was protective whilst toxoid B alone was not. In addition, they demonstrated effective
passive immunisation, in that mothers with protective antibody levels were able to pass this
resistance to disease on to their offspring via breast milk. Passive immunisation in
gnotobiotic mice given monoclonal antibodies against toxin A has also been found to be
effective (Corthier et al. 1991). In the animal model it is thought that toxin A is the main
determinant of progression to disease. More recently, animal experiments using both rats
and hamsters have suggested that bovine immunoglobulin containing antibodies against
toxins A and B can be used to protect against C. difficile disease (Kelly et al. 1996); (Lyerly
et al. 1991). In-vitro experiments on both human fibroblasts and rat ileal loops have
demonstrated that antibodies to toxins A and B in bovine colostrum can effectively neutralise
their toxic effects (Kelly et al. 1996). Bovine anti C. difficile toxin antibodies from
colostrum have also been given to human volunteers to see whether they can survive passage
through the stomach and small bowel. The results indicate that significant amounts of
immunoglobulin survive transit through the stomach and small bowel, with residual
concentrations still capable of neutralising the cytotoxicity of toxins A and B (Kelly et al.
1997); (Warny et al. 1999). Stubbe et al. (2000) discovered that human colonic carcinoma
derived T84 monolayers were protected against cytopathic effects of toxins A and B by
monoclonal antibodies of the IgA and IgG classes. They also found that polymeric IgA was
more effective, and its effect more prolonged than that of monomeric IgA or IgG.
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1.3.2.3 The effect of antibiotics on bowel flora and C. difficile
Administration of antibiotics is thought to be the most significant predisposing factor
for CDI and this has been demonstrated when risk factors for it have been studied (Brown et
al. 1990); (Gerding et al. 1986); (Hutin et al. 1997); (Lai et al. 1997); (Schwaber et al.
2000); (Thibault et al. 1991); (Zimmerman, 1991). Katz et al. (1997) suggest that a lack of
antibiotic exposure in patients with no other clinical predictor could be used as a criterion for
not testing stool samples for C. difficile toxin. Most antibiotics have been associated with C.
difficile disease to some extent, with some agents being more often implicated than others
(see table 2). The frequency of association of disease with one agent rather than another may
be misleading as to its likelihood of inducing symptoms, because the relative frequencies of
use must be taken into account. In some instances patients have received antibiotics as long
as four weeks prior to symptoms, whilst some authorities recognise that antibiotics up to ten
weeks prior to illness may be a significant factor (Tedesco, 1982). Apart from the direct
effects of antibiotics on 'colonisation resistance', there may be other ways in which
antibiotics could influence the likelihood of developing CDI. It is possible that antibiotics
could affect the virulence of C. difficile directly. Addition of sub MIC concentrations of
antibiotics to cultures of C. difficile in brain heart infusion broth, have been shown to
increase toxin production. Vancomycin and penicillin are described as inducing this
phenomenon by Onderdonk et al. (1979). Clindamycin and cephaloridine were found to
augment toxin A and B production, whilst tetracycline had no effect (Honda et al. 1983).
Other investigators have also reported an increase in the cytotoxic activity of C. difficile
cultures when clindamycin is added (George et al. 1980); (Nakamura et al. 1982). Contrary
to this finding, Bare et al. (1992) investigated toxin A and B production in the presence of
clindamycin, both in vitro and in vivo but were unable to find any increase in production.
Onderdonk et al. (1979) did not find any increase in toxin production with subinhibitory
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concentrations of clindamycin. This suggests that not all C. difficile strains respond to the
same stimuli with an increase in toxin production.
Table 2: Risk of C. difficile infection associated with various antibiotics
Risk of Antibiotics
association
High clindamycin, 'second' and 'third generation' cephalosporins
Moderate 'first generation' cephalosporins, amoxycillin, ampicillin,
macrolides, tetracyclines, co-trimoxazole
Low quinolones, rifampicin, ureidopenicillins, trimethoprim,
aminoglycosides, metronidazole, vancomycin
This table is adapted from Wilcox, (2000)
When the effects of PT, CTX and ciprofloxacin on toxin production were studied
in-vitro (Freeman and Wilcox, 2000), no increase in toxin B production was found. As
discussed in section 1.2.4.2, adherence plays an important part in the ability of C. difficile to
colonise the gut. This ability may also be affected by antibiotics, as some are known to be
able to affect bacterial surface components (Schifferli and Beachey, 1988). Little work in
this area has been performed, but Krishna et al. (1996) carried out an experiment on hamster
caecal flora from animals either administered or not administered clindamycin. They found
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no subsequent difference in cell surface hydrophobicity of C. difficile cultured in either type
of caecal flora.
1.3.2.3.1 Clindamycin
As previously mentioned in section 1.1, Tedesco (1974) first brought the link
between clindamycin and pseudomebranous colitis to public attention. In 1978 several
investigators made the link between 'clindamicin colitis', as PMC was previously known,
and its causative agent C. difficile (Bartlett et al. 1978a); (George et al. 1978a); (George RH
et al. 1978); (Larson et al. 1978). At this time it was also observed that if hamsters were
given clindamycin, they suffered from a fatal enterocolitis also found to be due to C. difficile
(Chang et al. 1978b); (Lusk et al. 1978). Not only were caecal filtrates from such animals
cytotoxic to cells in tissue culture, but if filtered and injected into the caeca ofhealthy
hamsters, these animals would go on to develop pseudomembranous lesions (Bartlett et al.
1977a). The duration ofperturbation of faecal flora in hamsters following clindamycin
administration is extremely prolonged and was found to be between 1-2 months by Fekety et
al. (1980). Further work with the hamster model (Larson and Borriello, 1990) has confirmed
that when compared to ampicillin, flucloxacillin or cefuroxime, treatment with clindamycin
results in a much more prolonged period of subsequent susceptibility to CDI. The use of
clindamycin in hospitals today has declined markedly since the early reports of its
association with PMC (Aronsson et al. 1985b); (Bartlett, 1981); (Golledge et al. 1989); (Le
Frock et al. 1975), but there have been recent publications which have suggested that some
outbreaks of CDI may still be related to its use (Brown et al. 1990); (Johnson et al. 1999).
Pear et al. (1994) describe the control of an outbreak of CDI by restriction of clindamycin
use, after this was noted to be correlated with patients developing C. difficile diarrhoea.
Similarly, another outbreak ofCDI was noted to be associated with increased clindamycin
use, and the causative strain to be clindamycin resistant. Hospital wide reduction in the use
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of clindamycin reduced the incidence of CD1 from 11.5 cases/month to 3.33 cases/month.
Clindamycin susceptibility of C. difficile isolates was then seen to increase from 9% to 61%
(Climo et al. 1998). Local use of clindamycin has also been linked to CDI, with reports
following treatment with a vaginal cream preparation (Meadowcroft et al. 1998); (Trexler et
al. 1997); (Vikenes et al. 1999). Although it appears to be one of the most potent
predisposing factors to CDI (Gerding et al. 1995), currently, clindamycin is not frequently
the cause due to its reduced frequency of use.
1.3.2.3.2 Cephalosporins
There is widespread use of cephalosporins in hospitals today and they often provide
the mainstay of antimicrobial therapy, both for prophylaxis as well as for treatment of
infections. As with most classes of antibiotics, their use has been associated with the
development ofCDI. This was noted as long ago as 1981, when Bartlett reviewed 329
patient records to determine what predisposing antibiotics they had taken. He noticed that
over time clindamycin became less frequently implicated, but that the frequency of
association with cephalosporins increased. This probably related to the changing patterns of
antibiotic usage (Bartlett, 1981). Since then, a great number of reports on the associations of
cephalosporins with subsequent C. difficile disease have been published. Ebright et al.
(1981) showed that eight commonly used cephalosporins were capable of inducing colitis in
hamsters, which was indistinguishable from that caused by clindamycin. Bodey et al.
(1983), found that the bowel flora in recipients of ceftazidime and particularly ceftriaxone
was significantly disturbed, with reductions in both anaerobic and aerobic flora. This was
particularly marked with ceftriaxone, where all Gram-negative bacilli, 90% of anaerobes and
76% of aerobic gram-positive organisms were eradicated. The increased deleterious effects
of ceftriaxone on bowel flora may be due to its greater degree of biliary excretion. Another
investigator who evaluated the effect of antibiotics on human faecal flora was Mulligan, who
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found that five out of six patients who were monitored before, during and after therapy with
cefoxitin developed ingrowth of C. difficile. Marked reductions in components of normal
flora were also noted (Mulligan et al. 1984). Nord, (1987), whilst investigating the effects of
prophylactic antibiotics on 'colonisation resistance', discovered that cephalosporins were
more likely than penicillins to have a significant deleterious effect. Silva et al. (1984)
examined the records of 130 patients with presumed or proven C. difficile colitis and
determined that in 55% of cases, cephalosporins were associated with the onset of
symptoms. They also carried out experiments using the hamster model and demonstrated
that disease could be induced by administration of a cephalosporin. Similarly, Aronsson et
al. (1985b) reported data from Sweden between 1980-1982 indicating that cephalosporins
were implicated in cases of C. difficile colitis 40 times more often than narrow-spectrum
penicillins. A small study on the association of extended spectrum cephalosporins with C.
difficile diarrhoea, by Golledge et al. (1989), found that the relative risk of disease was
highest after taking clindamycin. The relative risk for cefotaxime, cefamandole and
ceftriaxone were not significantly different from each other and were only just lower than
that of clindamycin. When de Lalla et al. (1989) looked at 40 patients who had developed
CDI or PMC, they found that consumption of 'third generation' cephalosporins amongst this
group was significantly greater than consumption of ureidopenicillins. Similar findings were
also made in a case control study by Nelson et al., who found that the greatest risk factor for
the development of CDI was 'second' or 'third generation'cephalosporin exposure (Nelson
et al. 1994). Cartmill et al. (1994) showed that exposure to cephalosporins played a major
role in the development of a C. difficile outbreak, with 76.3% of 169 patients having
received antibiotics including a cephalosporin prior to developing symptoms of CDI.
Cephalosporin use was again significantly associated with CDI in a study on elderly patients
with community-acquired lower respiratory tract infection by MacGowan et al. (1997).
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The development of susceptibility to CDI does not necessarily require a long course
of antibiotics. One investigator, who looked at the effect ofjust a single dose of antibiotic on
the faecal flora of volunteers, showed that whilst cephalosporins were associated with the
emergence of C. difficile in the stools, penicillins were not (Ambrose et al. 1985). A control
group who did not receive antibiotics also showed no emergence of C. difficile.
Cephalosporins are often used as prophylactic agents and reports of subsequent CDI or
colitis have been made by several investigators (Arsura et al. 1985); (Block et al. 1985);
(Crabtree et al. 1999); (Keighley et al. 1983); (Roberts and Hughes, 1985); (Tan et al. 1979).
When single dose prophylactic antibiotics were investigated by Privitera et al. (1991), they
discovered that C. difficile was detectable in the stools of 23% ofpatients where a
cephalosporin was used, only 3.3% of samples from patients who had been given
mezlocillin, and in none of those given no antibiotic. Although all cephalosporins have been
implicated as incitory agents for CDI, most recent concerns have centred on the effects of the
'third generation' cephalosporins. This is partly because of the recent increase in use, and
partly because it is now felt that these agents in particular are especially likely to render an
individual susceptible to CDI. Anand et al. (1994), performed a large study evaluating CDI
over a two year period and found that ceftriaxone or ceftazidime use was highly correlated
with its development, whilst ticarcillin-clavulanate was not. In addition, they found many
more actual versus expected cases of CDI (based on usage) following 'third generation'
cephalosporins, slightly more actual versus expected cases for 'second generation'
cephalosporins and fewer actual versus expected cases for 'first generation' cephalosporins.
However, in their study, there was no data on C. difficile exposure for each patient group, no
information regarding duration of treatment with particular agents and no adjustment made
for age of recipient or cases where multiple antibiotics were received.
Cefotaxime has also been seriously linked with the subsequent development of CDI,
particularly in elderly patients (Impallomeni et al. 1995); (Lesna and Parham, 1996); (Starr
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and Impallomeni, 1997). A letter to the BMJ from the Corporate Drug Safety and
Development Department of Roussel (who manufacture cefotaxime) cast doubt over the
validity of the study by Impallomeni et al., although their evidence in favour of cefotaxime
appears scant (Rothschild et al. 1996). The figures that they quote for diarrhoea and PMC
developing in healthy volunteers given cefotaxime would be hard to apply to an ill, elderly,
more vulnerable population. When an outbreak of C. difficile diarrhoea in Sheffield was
investigated, cephalosporins were again implicated (Zadik and Moore, 1998). Rates of CDI
were calculated for each antibiotic divided by the quantity used, and corrections were made
to account for combinations. The rate ofCDI for ampicillin/amoxycillin was used as the
baseline and rates for other antibiotics were divided by this to obtain a 'rate ratio' (RR). The
greatest association with CDI was for cefotaxime where the RR was 27.5, ceftriaxone RR,
15.1, cefuroxime RR, 8.6 and ceftazidime RR, 6.4. When adjustments for combinations
were made the ratios were 16.9, 8 .6, 5.3 and 4.8 respectively. The increased risk ofCDI
following cefotaxime when compared with the risk after ampicillin/amoxycillin was
significant at the p=<0.000001 level. Further evidence for the association between
cephalosporins and CDI comes from a recent study by Schwaber et al. (2000), in which
receipt of a cephalosporin (particularly of the 'third generation') was significantly associated
with CDI but not with nosocomial diarrhoea of other aetiologies.
In addition to the numerous publications citing cephalosporins, particularly those of
the 'third generation', as potent inducers of CDI, there is also work describing the reduction
of the incidence of such disease by reducing prescriptions of these drugs (Brown et al.
1990); (Jones et al. 1997); (Ludlam et al. 1999); (McNulty et al. 1997); (Quale et al. 1996).
Other reports indicate that increased rates of C. difficile disease were noted following
relaxation of antibiotic policy, or change of policy resulting in greater cephalosporin use (Ho
et al. 1996); (Impallomeni et al. 1995). Increases in the use of cephalosporins such as
cefuroxime and cefotaxime were quite noticeable following the revised British Thoracic
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Society guidelines (1993) for the treatment of severe community-acquired pneumonia.
Cephalosporins are now probably the most significant risk factor for patients in hospital
today, with 'third generation' drugs being the highest risk group. This is because oftheir
extremely frequent use for many infections, and the fact that 'third generation'
cephalosporins appear to be second only to clindamycin in their ability to predispose patients
to the development of CDI. The future impact of 'fourth generation' drugs such as cefixime,
which is administered orally, is still yet to be folly investigated. However, oral cefixime is
known to have significant effects on bowel flora, reducing the amount ofmany organisms
including anaerobes (Finegold et al. 1987); (Nord et al. 1988). An association with
increased colonisation by C. difficile has also been described by several groups (Chachaty et
al. 1993); (Finegold et al. 1987); (Nord et al. 1988). In a group of 51 healthy volunteers,
Chachaty et al. (1993) found that colonisation with C. difficile rose from 6% before cefixime
to 57% after. It can therefore be seen that such drugs have the potential to cause serious
problems when administered to a more susceptible population, such as ill elderly patients.
Levy et al. (2000), investigated the use of antibiotics in an ambulatory care setting. Despite
CDI having a low incidence in this group, a significantly increased association with such
illness was only found with two drugs, both cephalosporins, cephalexin and cefixime. Due
to the lower frequency of testing for the possibility of CDI in patients outside hospital, the
number of cases could be underestimated and more care may be needed to diagnose such
individuals with diarrhoea in future. Currently cephalosporins, and especially 'third
generation' drugs, are probably the most significant contributor towards CDI in hospitals
today.
1.3.2.3.3 Penicillins
Commonly used antibiotics such as amoxycillin and ampicillin (aminopenicillins)
have often been associated with subsequent CDI, but this must be qualified by the number of
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doses of such treatments given to patients in comparison to other drugs. Whilst Bartlett
(1981) found that 80% of cases of CDI occurred in patients following therapy with either
ampicillin, clindamycin or cephalosporins, to accurately estimate the risk for each agent we
must divide the number of cases by the total amount or number of doses of each antibiotic
given. This would result in a rate per dose, or per gram of antibiotic. If the rate, so
calculated, for ampicillin is then standardised to 1, the other antibiotics can have a relative
risk (compared with ampicillin) calculated. The true accuracy of these figures does depend
upon all patients so considered having been at similar risk of developing CDI (susceptibility)
with regard to factors other than antibiotics, as well as having been equally exposed to the
organism. Other investigators have described aminopenicillins as often being implicated as
incitory agents for CDI, but without taking account of their frequency ofprescription. Silva
et al. (1984) carried out a study on 130 patients with CDI, as mentioned in section 1.3.2.3.2,
and discovered that 29% of cases were associated with prior ampicillin. When account is
taken of frequency of use of individual antibiotics, such as in the work by Zadik and Moore
(1998), a different picture emerges, with cephalosporins being far more likely than
amoxycillin or ampicillin to induce CDI (see section 1.3.2.3.2).
Ureidopenicillins, such as piperacillin or mezlocillin appear to have an even lower
risk than ampicillin of inciting C. difficile related diarrhoea. Several studies have shown
marked differences between the likelihood of developing CDI after ureidopenicillins versus
after cephalosporins (Ambrose et al. 1985); (Anand et al. 1994); (de Lalla et al. 1989);
(Golledge et al. 1989); (Keighley et al. 1983); (Privitera et al. 1991). The most interesting
of these studies is by Anand and colleagues. They carried out a retrospective study of
patients with toxin A positive stools over a 2 year period. Antibiotic usage, expressed as
doses administered was also recorded. They found that 'third generation' cephalosporins
were significantly associated with subsequent CDI, leading to many more cases than would
be expected based on quantity used alone (if all antibiotics are equally likely to render
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patients susceptible to CDI). Fewer cases than expected were associated with amoxycillin
and, significantly, no cases of CDI were noted following treatment with
ticarcillin/clavulanate, which was the most frequently used antibiotic by a factor of 1.5
(p=0.00001). Unfortunately, there is no information as to whether patients who were given
different antibiotics had similar illnesses, or were equally debilitated. Nor is there any
indication ofwhether courses of the different agents were for similar periods of time or if
patients had similar degrees of exposure to C. difficile. Another penicillin/beta-lactamase
inhibitor combination therapy, amoxycillin/clavulanic acid (co-amoxyclav), has also seldom
been associated with CDI. Mitchell et cil. (1996) studied a group of children being treated
with co-amoxyclav for otitis media. They found that no-one had toxin A or B in their stools
at enrolment, or when diarrhoea commenced. Whilst on therapy, 30% ofpatients studied
developed diarrhoea and 13% were found to have toxins present on exit testing (between 8-
34 days, mean 13 days). It is not clear whether the cause of diarrhoea in any of the 13% was
C. difficile. Hirschom et al. (1994) describe CDI in association with co-amoxyclav, but only
when it was given with either cefaclor or cefuroxime. One of the possible explanations for
ureidopenicillins having a lesser likelihood of leading to C. difficile disease is that they are
more active than cephalosporins against C. difficile (Chow et al. 1985).
1.3.2.3.4 4-Fluoroquinolones
Quinolones, such as ciprofloxacin and norfloxacin have only been introduced
relatively recently as antibiotic therapies. Nevertheless, they have undergone some scrutiny
to try to ascertain the likelihood of their use resulting in CDI. This investigation has
generally led to the conclusion that they do not often lead to CDI (Golledge et al. 1992);
(Schacht et al. 1988). Several reports even suggest that ciprofloxacin may be used in the
successful treatment of CDI (Daniels and Pristas, 1992); (Lettau, 1988). Some investigators
have reported an association between ciprofloxacin and CDI (Bates et al. 1990);
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(Bauwens et al. 1997); (Cain and O'Connor, 1990); (Crabtree et al. 1999); (Hillman et al.
1990); (Jones et al. 1997); (Loge, 1989); (Low and Harries, 1990); (McFarland et al. 1995),
but in several of these reports there may be other explanations as to the predisposing factor.
Salmonella enteritis predated the cases of CDI in three reports (Bates et al. 1990; Hillman et
al. 1990; Low and Harries, 1990) and enteric infection has been cited as a possible factor
leading to C. difficile disease (Falsen et al. 1980); (Riley et al. 1986). In the other report
(Cain and O'Connor, 1990), the patient had also been given a course of co-trimoxazole five
weeks before developing CDI which may have been more likely to have provoked the
illness. In work by Golledge et al. (1992), 213 patients receiving monotherapy with
ciprofloxacin were investigated and although 44 did have diarrhoea, none was found to have
C. difficile. A further 73 of the patients without diarrhoea were also screened for C. difficile
and found to be negative. Golledge and colleagues continued their investigations by
carrying out tests on human faecal samples in vitro, to see whether faecal emulsions 'treated'
with antibiotics would support the growth of C. difficile. They found that whilst clindamycin
used in this way rendered the faecal emulsions permissive to C. difficile growth, non-treated
samples or those treated with ciprofloxacin remained inhibitory to the organism. These
findings led them to the conclusion that ciprofloxacin is unlikely to render individuals
susceptible to CDI. On a theoretical basis, this finding may not be too surprising as
ciprofloxacin may not be bactericidal in anaerobic environments (Smith and Lewin, 1988),
however nor is it particularly active against C. difficile (Delmee and Avesani, 1986); (Edlund
and Nord, 1986).
1.3.2.3.5 Other antimicrobial agents
Although the antibiotics most commonly associated with CDI have been discussed
above, almost all antibiotics have been implicated at one time or another. Antibiotics that
are in common use, such as erythromycin, tetracycline and trimethoprim-sulphamethoxazole
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(co-trimoxazole) have been associated more frequently than agents such as chloramphenicol
and rifampicin. Gantz et al. (1979) report the association of erythromycin therapy with CDI.
Riley et al. (1991a) describe the implication oftetracyclines and co-trimoxazole in the
development of CDI in patients from a community setting. Silva et al. (1984) report the
association of chloramphenicol, erythromycin and co-trimoxazole with CDI. Another report
of co-trimoxazole associated with CDI is in HIV positive patients on prophylactic therapy
against Pneumocystis carina (Gordin et al. 1994) and malaria prophylaxis with doxycycline
has also lead to CDI (Golledge and Riley, 1995). Colardyn et al. (1984) report a case CDI
associated with imipenem therapy. Infrequently, there have been occasions where
antimicrobials usually used for the treatment of CDI have been said to induce disease. Both
metronidazole (Saginur et al. 1980); (Thomson et al. 1981) and vancomycin (Hecht and
Olinger, 1989); (Miller and Ringler, 1987); (Schenfeld and Pote, 1995) have been
implicated. Antituberculous drugs have also been noted to be associated with CDI on
occasion (Bartlett et al. 1981), particularly rifampicin (Byrd et al. 1997); (Fekety et al.
1983); (Foumier et al. 1980); (Prigogine et al. 1981). Newer antibiotics have been linked to
cases ofCDI, including clarithromycin (Braegger and Nadal, 1994); (Guyot et al. 2000) and
pristinamycin (Talon et al. 1995). One of the few classes of antibiotic to be very seldom
associated with C. difficile diarrhoea is the aminoglycosides (George, 1988). Silva et al.
(1984) report that aminoglycosides were implicated in quite a large number of cases, but
they were usually administered with other antibiotics, often cephalosporins. Several other
antimicrobial agents have been mentioned in association with CDI, including oxacillin and
dicloxacillin (Brook, 1980), spiramycin (Decaux and Devroede, 1978), miconazole (Bartlett,
1981), and albendazole (Shah et al. 1996).
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1.3.2.3.6 Prophylactic antibiotic use in surgery
As discussed in section 1.3.2.3.2, antibiotics that are only given for short durations,
such as for surgical prophylaxis have still been associated with CDI. In two studies
(Ambrose et al. 1985); (Privitera et al. 1991), cephalosporins were demonstrated to result in
more cases of CDI than ureidopenicillins. In one of these, development ofCDI was noted in
situations where only one dose of antibiotic had been given (Privitera et al. 1991). However,
Kreisel et al. (1995) investigated the development of CDI after prophylactic antibiotics and
found that patients who developed disease had received significantly longer courses of
treatment than those who did not. They also noted that the inapropriate use of prolonged
prophylaxis significantly predisposed towards CDI, and that affected patients stayed in
hospital for significantly longer periods. It should be appreciated that prophylactic
antibiotics can predispose to CDI, sometimes after only one dose, but that prolonged courses
are even more likely to result in such iatrogenic illness.
1.3.2.4 The effect of other agents on bowel flora and C. difficile
Apart from the well-known association between administration of antibiotics,
reduction of colonisation resistance and subsequent CDI, other agents have also been
reported to occasionally contribute towards such illness. Most common amongst such
reports are those linking antineoplastic agents to CDI (Anand and Glatt, 1993). Amongst
such drugs, methotrexate (Miller and Koomhof, 1984) and 5-fluorouracil (Sriuranpong and
Voravud, 1995) appear to be most often implicated. Silva et al. (1984) identified 4 cases out
of a total of 130 where antineoplastic drugs alone were implicated in C. difficile colitis.
These were cyclophosphamide, doxorubicin (adriamycin), 5-fluorouracil and methotrexate.
Roda, (1987) describes a case of PMC following treatment with cytarabine. More recently,
cisplatin has been associated with CDI (Emoto et al. 1996); (Park et al. 1999).
63
Jarvis et al. (1997) describe the association between mitoxantrone and etoposide with CDI,
but the patient concerned had also received antibiotics six weeks earlier. Paclitaxel, used for
both breast and ovarian cancer treatment has been linked to some cases of CDI (Ang et al.
2000); (Chi et al. 1999); (Husain et al. 1998). Other authors report CDI following
chemotherapy for various tumours (Cudmore et al. 1982); (Fainstein et al. 1981); (Kamthan
et al. 1992); (Paterson, 1997); (Satin et al. 1989). Ramos et al. (1997), report a case of CDI
in a patient having chlorambucil therapy for rheumatoid arthritis. Other medications which
have been cited as giving rise to CDI include: diclofenac (Gentric and Pennec, 1992),
sulphasalazine (Bartlett et al. 1981), silver sulphadiazine (Jennings and Hanumadass, 1998),
tacrolimus (Sharma and Holder, 1998) and tyrothricin (Demols et al. 1996). There have
been cases of CDI described where no prior antibiotic has been given (Moscovitz and
Bartlett, 1981). Contributory factors in such cases may include diabetes mellitus, hepatic
and renal failure, malnutrition and cystic fibrosis (Silva, 1989).
1.3.3 Clinical features of C. difficile infection
In common with disease due to other intestinal pathogens, C. difficile is associated
with a continuous spectrum of symptoms, ranging from asymptomatic colonisation to
fulminant PMC with toxic megacolon, possibly resulting in bowel perforation and even
death. As previously discussed, CDI most commonly ensues after antimicrobial or
antineoplastic therapy, although a very small number of cases are not associated with such
predisposing factors (Bartlett, 1992). Symptoms classically develop 5-10 days after
antibiotic therapy, but may not occur until 10 weeks have elapsed (Tedesco, 1982).
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1.3.3.1 Intestinal infection
The most prominent symptom associated with CDI is diarrhoea, which may be
present in varying degrees, from a couple of loose motions a day, to 20 or more profuse
watery stools per day. Mucus is often present but blood is found in only 5 to 10% of cases.
In cases that progress beyond mild diarrhoeal symptoms, other systemic features become
apparent. These include fever, leucocytosis and cramping abdominal pain. Patients with
colitis will often have a fever ofmore than 100°F and peripheral white cell count of 12,000
to 20,000/mm3. Abdominal distension, nausea, vomiting and dehydration are not uncommon
when disease persists. In very severe cases, diarrhoea may cease and abdominal distention
with tenderness become more prominent as the continuing inflammation of the colon results
in a paralytic ileus and development of a toxic megacolon. This is a very serious
complication and may presage bowel perforation and death. When colitis develops,
endoscopic investigation at the outset of disease usually reveals whitish/yellow mucosal
plaques 1-2 mm in size. As the disease progresses, these enlarge in size, coalescing to form
larger lesions whilst mucosal appearance between lesions may be normal or slightly
erythematous. Pseudomembranes, which are composed of fibrin, white cells, mucus and
cellular debris may be seen adhering to the mucosa. The pathological changes in the bowel
mucosa are usually limited to the colon in C. difficile disease, although rarely the terminal
ileum may be affected (Bartlett et al. 1979).
Presence of cytotoxin in the stools has been documented to occur in 10-25% of
antibiotic associated diarrhoea, 50-70% of antibiotic associated colitis and 90-100% of
antibiotic associated PMC (Bartlett, 1990) (see table 3). In cases of severe PMC, cytotoxin
may gain access to the circulation and was detected in the blood of two children who
suffered fatal C. difficile associated PMC (Qualman et al. 1990). Recurrence of symptoms
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following treatment is also a common feature ofCDI, occurring on up to 24% of occasions
(Wilcox and Spencer, 1992).
Table 3: Rates of C. difficile isolation and toxin detection from stool
samples of various populations




Patients with antibiotc-associated PMC 95-100 95-100
Patients with antibiotic-associated colitis 50-70 50-70




Hospitalised patients 10-25 2-8
Patients with gastrointestinal disease
unrelated to antibiotic exposure
2-3 0.5
Healthy adults 2-3 0
Healthy neonates 5-70 5-63
Table adapted from (Bartlett, 1994), Table 2
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1.3.3.2 Extra-intestinal disease
Other manifestations have been reported in association with C. difficile apart from
diarrhoeal illness or colitis. These include septicaemia, osteomyelitis, peritonitis, urogenital
infections, wound infections and splenic abscess (Levett, 1986) (see table 4). Protein-losing
enteropathy has also been reported (Rybolt et al. 1989) as well as production of ascites (Jafri
and Marshall, 1996). One case has been described where C. difficile was the cause of septic
arthritis in the prosthetic hip joint of a woman who 12 months earlier had suffered an episode
of CDI whilst in hospital having her hip replacement (McCarthy and Stingemore, 1999).
Another case was reported in a prosthetic knee joint (Pron et al. 1995). C. difficile has also
been associated with reactive arthritis (Bolton et al. 1981); (Lofgren et al. 1984).
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Table 4: Sites of extra-intestinal C. difficile disease
EXTRA-INTESTINAL MANIFESTATION REFERENCE
Abscess (soft tissue) (Beerens and Tahon-Castel, 1965)
(Danielsson et al. 1972)
(Eastwood, 1980)
Bacteraemia (Alpern and Dowell, 1971)
(Gorbach and Thadepalli, 1975)
(Rampling et al. 1982)
(Saginur et al. 1983)
(Smith and King, 1962)
Empyema (Simpson et al. 1996)
(Smith and King, 1962)
Gangrene (Chmelar and Tulachova, 1984)
Intra-abdominal infection after
penetrating trauma
(Thadepalli et al. 1972)
Osteomyelitis (Riley and Karthigasu, 1982)
(Towns et al. 1984)
Peritonitis / ascitic infection (Genta et al. 1984)
(Klinger et al. 1984)
(Saginur et al. 1983)
(Smith and King, 1962)
Reactive arthritis (Bolton etal. 1981)
(Hannonen et al. 1989)
(Lofgren et al. 1984)
Septic arthritis (McCarthy and Stingemore, 1999)
(Pron et al. 1995)
Splenic abscess (Saginur et al. 1983)
Urogenital infection (Smith and King, 1962)
(Thadepalli etal. 1973)
Wound infection (Smith and King, 1962)
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1.4 DIAGNOSIS OF CLOSTRIDIUM DIFFICILE DISEASE
The diagnosis of C. difficile disease generally requires the combination of an
appropriate clinical picture coupled with detection of C. difficile, its metabolites or toxins.
Alternatively, a typical appearance upon endoscopic investigation of the bowel, coupled with
biopsy and histological examination may be used. The detection of C. difficile, its
metabolites or toxins in the faeces of a patient with no clinical evidence of disease is usually
felt to represent C. difficile colonisation.
1.4.1 Specimen transport and characteristics
C. difficile is readily recoverable from most faecal samples due to its ability to
produce spores. However, when attempts are being made to detect C. difficile toxins, it is
preferable to use as fresh a sample as possible, and to avoid storage at room temperature.
This is because of the documented deterioration of C. difficile toxins which occurs at
ambient temperatures in stool samples (Bowman and Riley, 1986); (Brazier, 1993); (Chang
et al. 1979) and even at 4°C (Borriello et al. 1992b). It is not advisable to process solid
samples as toxin is seldom found, and its presence would be of uncertain significance in the
absence of symptoms (Department of Health and Public Health Laboratory Service Joint
Working Group, 1994).
1.4.2 Methods for detection of C. difficile or its metabolic products
1.4.2.1 Microscopy
Although microscopy for leucocytes has been recommended by some as being of
help in diagnosing CD1 (Bowman and Riley, 1988), its sensitivity and specificity are
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extremely poor (Shanholtzer et al. 1983). This is due to the many other possible causes of
faecal leucocytes. In addition, Gram staining is unable to distinguish one type of
Clostridium sp. from another. Other techniques, such as using fluorescence microscopy to
detect labelled C. difficile cell wall antibodies adhering to C. difficile in faecal smears
(Wilson et al. 1982b) are too non-specific to be used as sole diagnostic tests.
1.4.2.2 Gas-liquid chromatography
High-pressure gas liquid chromatography (GLC) has been studied as a means of
detecting C. difficile in stool samples (Levett, 1984a); (Pepersack et al. 1983), whilst others
used frequency pulsed electron capture GLC (Brooks et al. 1984). Metabolic products which
most reliably indicated C. difficile, when detected, were isocaproic acid and /;-cresol (Levett
and Phillips, 1985); (Phillips and Rogers, 1981). However, results from GLC testing have
proved too variable to be relied on diagnostically, some investigators reporting encouraging
findmgs, (Pepersack et al. 1983); (Potvliege et al. 1981), whilst others found poor results
(Levett, 1984a). A low positive predictive value makes the test unsuitable as a diagnostic
tool.
1.4.2.3 Culture
Early attempts at producing a medium on which to select C. difficile from other
faecal flora included the use of/>-cresol (Hafiz and Oakley, 1976), neomycin and sodium
azide (Bartlett et al. 1977b), kanamycin (Bartlett et al. 1978a), and clindamycin (Larson et
al. 1978). These all proved suboptimal, but a satisfactory medium containing cycloserine,
cefoxitin and fructose (CCFA) was developed by George et al. (1979). Further
modifications to this medium have since occurred, with the cycloserine and cefoxitin
concentrations being reduced by half to 250 mg/L and 8 mg/L respectively to reduce
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inhibition of C. difficile (Clabots et al. 1991); (Levett, 1985); (Willey and Bartlett, 1979).
Contrary to this, Peterson et al. (1996) found that if pre-reduced for 4 hours prior to
inoculation, CCFA with the original 500 mg/L and 16 mg/L performed better than CCFA
with the modified concentrations. Other selective media have been tried such as cycloserine-
mannitol agar (CMA) and cycloserine-mannitol blood agar, but whether these are better than
CCFA or not is uncertain. Some research suggests better isolation rates (Bartley et al. 1991);
(Marler et al. 1992), whilst others found worse rates (Iwen et al. 1989); (Mundy et al. 1995).
Egg yolk containing media has an advantage over that using blood, in that it can help
distinguish lipase/lecithinase producing species such as Clostridium sordellii from C.
difficile. In order to enhance recovery of C. difficile from spores, taurocholate addition has
been found to increase spore germination (Buggy et al. 1985); (Wilson et al. 1982a);
(Wilson, 1983). Another more recent finding is that addition of lysozyme 5 mg/L to bile salt
containing selective media further enhances recovery of C. difficile, presumably by
enhancing spore germination (Wilcox et al. 2000).
Enrichment broths for C. difficile isolation have also been described, with
cycloserine, cefoxitin and fructose (Buchanan et al. 1984); (Riley et al. 1987), cycloserine,
cefoxitin and gentamicin (Carroll et al. 1983), or cycloserine, cefoxitin and sodium
taurocholate (O'Farrell et al. 1984). They appear to offer a slight advantage over standard
Robertson's cooked meat broth.
1.4.2.4 Enrichment methods
Apart from enrichment broths, two other methods for improving C. difficile recovery
from stool samples are alcohol and heat shock techniques. These are designed to kill all
vegetative cells, leaving only spores, and thus reduce competing flora, making C. difficile
recognition easier. Alcohol shock involves mixing the stool specimen with an equal volume
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of 80% alcohol and leaving to stand for 1 h before subculture onto non-selective media.
Heat shock involves heating the sample to 70°C, in a water bath, for 20 min prior to culture.
Although not entirely clearcut, heat shock, and probably alcohol shock also, appear better
than culture onto solid media alone. Some studies indicate that alcohol shock (Clabots et al.
1989); (Riley et al. 1987) and heat shock (Hanff et al. 1993) improve sensitivity, whilst one
showed alcohol shock to be worse than direct plating onto selective agar (Borriello and
Honour, 1981), and another that heat shock was worse than such direct culture (Marler et al.
1992).
Culture methods have a very high sensitivity, approaching 100% in samples
containing cytotoxin (DeMaio and Bartlett, 1995); (Wilson et al. 1982a), but suffer from a
much lower specificity. Culture does not distinguish toxigenic from non-toxigenic strains,
so further work is then needed to determine toxin status. Consequently, culture of C. difficile
alone does not equate to CDI. Culture of the organism is of potential use when
epidemiological studies are being carried out, or information about epidemic strains is
required. It also allows sensitivity testing, although this is not really of importance in C.
difficile disease as drug resistance is not thought to account for treatment failure or relapses
(DeMaio and Bartlett, 1995).
1.4.2.5 Identification
Once an organism with the cultural characteristics of C. difficile has been isolated,
confirmatory evidence is required to ensure correct identification. Most authorities would
not consider the distinctive smell alone to be sufficient, although with experience this can be
very accurate. Similarly, fluorescence under UV light is not a reliable enough feature to be
depended on. There are several possibilities short of full biochemical testing which may be
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considered adequate. A latex agglutination kit (Microgen Ltd, Guildford, UK) which detects
somatic antigens may be considered useful, but cross-reacts with three other Clostridial
species (Bowman et al. 1986); (Brazier, 1990). Nevertheless, in conjunction with specific
cultural characteristics (see table 5), this may form a useful confirmatory test (Brazier,
1998). Production of L-proline-aminopeptidase is another characteristic feature of C.
difficile, and has been used by some as a useful confirmatory test on isolates with typical
growth features (Fedorko and Williams, 1997). Another rapid kit test for C. difficile
incorporating five tests, including L-proline-aminopeptidase, has been designed but is not
commercially available at present (Aspinall and Dealler, 1992).
Table 5: Differential tests for Clostridial species commonly mistaken for
C. difficile
SPECIES UV FLUORESCENCE LATEX* LECITHINASE ODOUR
C. difficile + + - +
C. innocuum + - - -




*Slide agglutination for somatic antigen (Microscreen, Microgen Ltd, Guildford, UK)
This table is adapted from (Brazier, 1995), Table 1
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One alternative identification method, which may be considered by institutions with
cell culture facilities, is to test for cytopathic effect, neutralisable by C. difficile or C.
sordellii antitoxin (see section 1.4.3.1). This can be performed on broth supematants, with
high level toxin producing strains giving positive results in 4-6 h. Alternatively, the
technique can be attempted directly from colonies, by first suspending 1-2 colonies in 0.5 ml
ofphosphate buffered saline (PBS) and then using this for the cytopathic effect test after
filtering. Centrifugation of the suspension can also be used to minimise any non-specific
toxic effects that may occur when a bacterial suspension is added to a cell culture line.
Positive results with this method can often be achieved in less than 4 hours (Settle,
unpublished observations). Screening of isolates in this way, from either broths or colonies,
can significantly reduce the number of expensive confirmatory kit tests required when large
numbers of isolates are being cultured for studies where confirmation of identity is
mandatory. Further tests need only then be performed on non-toxigenic strains.
1.4.2.6 Other methods
An assay of faecal lactoferrin levels has been considered as a possible aid to the
diagnosis of C. difficile disease (Yong et al. 1994). However, owing to its poor levels of
sensitivity and specificity is not appropriate as a diagnostic test in this milieu. Most
polymerase chain reaction methods have been aimed at toxin gene detection, but one early
method was designed to detect part of the 16s RNA gene of C. difficile (Gumerlock et al.
1991). This method was claimed to have a detection threshold often C. difficile organisms
amongst 106 E. coli. It could also distinguish between C. difficile and other species such as
C. sordellii or C. bifermentans. Asymptomatic patients were found to be negative by this
assay, whilst 23 patients with antibiotic-associated colitis were positive, as well as 4 patients
with diarrhoea who were C. difficile culture negative. The method is unable to distinguish
toxigenic from non-toxigenic strains.
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1.4.3 Toxin detection methods
1.4.3.1 Cvtotoxin assay by cytopathic effect (CPE)
Cytotoxin detection, using a mammalian cell line in tissue culture, is generally
accepted to be the gold standard single diagnostic test for C. difficile disease (Bond et al.
1995); (Fekety and Shah, 1993); (Brazier, 1998a). Its combination with culture for the
organism probably represents the optimal combination of methods for investigation of this
illness (Fang and Madinger, 1994); (Peterson and Kelly, 1993). The principle of the test is
that toxin B, and to a much lesser extent toxin A, produce an actinomorphic-like cytopathic
effect (CPE) in tissue culture monolayers exposed to them. This usually manifests as a
'rounding up' of the cells (see section 1.2.4.1.5). A number of different cell lines have been
investigated to try to determine which is most sensitive, with varying results (Chang et al.
1979); (Donta et al. 1982); (Murray and Weber, 1983); (Thelestam and Bronnegard, 1980).
Currently, fibroblast cell lines (America) or Vero cell lines (Europe) are preferred for CPE
testing (Brazier, 1998a). It is estimated that the tissue culture assay can detect lpg of toxin B
(Lyerly etal. 1988).
The test itself involves initial suspension of 1-2 g of faeces, in an equal volume of
PBS. This is centrifuged to remove large debris and then filtered through a 0.2 or 0.45pm
membrane filter. The sterile faecal supernatant thus produced is then added to the cell
monolayer culture (20pl of supernatant with 180pl ofgrowth medium) and incubated at
37°C. To ensure specificity, each specimen is tested in parallel with and without C. difficile
or C. sordellii antitoxin. A known weak positive extract is used as a positive control and
PBS only added to one well as a negative control. Examination for CPE is traditionally
performed at 24 and 48 h, although if high titres of toxin are present an effect can be
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observed at 6 h. Systems for CPE testing when laboratories do not have cell culture facilities
also exist, such as the Tox-Titer microtitre plate system (Bartels Immunodiagnostic Supplies
Inc., Bellevue, WA, USA) which uses human foreskin cells (Nachamkin et al. 1986); (Wu
and Gersch, 1986). Cytotoxin detection has become even more important now that strains
without detectable toxin A have been found to be associated with disease (Depitre et al.
1993); (Kato etal. 1997); (Kato etal. 1998); (Sambol etal. 2000).
1.4.3.2 Counterimmunoelectrophoresis (CIE)
As CPE testing in most institutions was found to require 24-48 h to obtain a result,
efforts were made to try to develop faster toxin detection methods. CIE was one such
approach, and was designed to detect toxin in the stool (Ryan et al. 1980). Initial reports
were encouraging (Welch et al. 1980), but later work reported poor sensitivity and
specificity for the method (Kurzynski et al. 1983); (Wu and Fung, 1983). This may have
been due to a possible cross-reaction with C. sordellii (Poxton and Byrne, 198 la), or
detection ofnon-toxigenic C. difficile strains (West and Wilkins, 1982). Attempts were
made to reduce false positivity rates by absorbtion of unwanted antibodies to whole C.
difficile cells (Ryan et al. 1983), but the method has still not become widely used. Several
reports indicate that the method has poor sensitivity and specificity as a diagnostic test
(Jarvis et al. 1983); (Levine et al. 1982); (Tilton et al. 1982).
1.4.3.3 Enzyme-linked immunosorbent assay (ELISA)
Another method that was developed to provide faster detection of C. difficile
toxin(s), was the ELISA. In this test, antibodies bind to toxin A or B in the first stage, and
then a second antibody with some means of spectrophotometry detection (for example
conjugated with horseradish peroxidase) binds to the first antibody. Then a substrate is
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added which will change colour in the presence of the second antibody, the intensity of the
colour indicating the quantity of toxin present. This allows automated reading of the result,
which can improve turnaround time and reduce test to test variability. Numerous different
manufacturers developed ELISA kits for toxin(s) A or A+B, and a comparison of these is
summarised below (table 6). It should be remembered that the figures for sensitivity and
specificity were usually generated in comparison to a CPE test. Consequently, if the CPE
method used in the comparison did not use the most sensitive cell line, the sensitivity and
specificity figures of the kit compared to it would be improved. This may in part explain the
enormous range of results for ELISAs, even when the same kit was being tested. It is
unlikely that ELISA methods can achieve the same sensitivity as CPE testing techniques
because their limit of toxin detection is in the nanogram range compared to the picogram
range for CPE methods (Lyerly, 1988). Nevertheless, ELISAs do provide a same day result
and can be particularly useful in situations where cell culture facilities are not available.
Because it is known that C. difficile strains without detectable toxin A can cause disease
(section 1.2.4.1.7), it is important to use an ELISA which can detect both toxins.
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Table 6: Published specificities and sensitivities for commercial C.
difficile toxin detection ELISA kits (compared with cytotoxin
detection)
KIT TOXIN SAMPLE SIZE SPECIFICITY SENSITIVITY
DETECTED (%) (%)
















Bartels A 329 92 94
463 95.5 95.1
700 96 87





CD-TOX A 160 88 92.3




This table is adapted from (Brazier, 1998a)
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1.4.3.4 Dot-immunobindinq assay
This method involves initial binding of toxin A to a membrane. Mouse monoclonal
antibody to toxin A is then added. Then, anti-mouse antibodies conjugated to horseradish
peroxidase are added. Finally, a chromogenic substrate is added which develops a blue-
green colour if horseradish peroxidase is present. One such assay, C. diff-CUBE (Difco
Laboratories, Detroit, MI, USA) was shown to have poor sensitivity and specificity by one
study (Kurzynski et al. 1992), but better results were demonstrated by Woods and Iwen,
(1990). Another method based on the same principle is the Immunocard (Meridian
Diagnostics Inc., Cincinnati, OH, USA). However, this test detects C. difficile glutamate
dehydrogenase and so is not specific for toxigenic strains. Reports of its performance vary,
with some being reasonable (Staneck et al. 1996), and some poor (Jacobs et al. 1996). More
recently, another similar toxin A test has become available. The Oxoid C. difficile toxin A
test kit (Unipath, Basingstoke, UK) demonstrates toxin A bound to a membrane by
complexing blue latex-coated antibody with the immobilised toxin. Sensitivity and
specificity figures claimed by the manufacturer are based on a multicenter evaluation of the
test (Bentley et al. 1998). The results showed a sensitivity and specificity of 83.1% and
96.9%, rising to 91% and 98% when discrepant results were resolved by culture.
Independent assessment of this kit demonstrated a sensitivity of 72% and specificity of 94%,
with false negative results occurring particularly in specimens with low toxin titres (see
sections 3.2.1 and 3.2.3). The kit is easier to use than ELISAs and more amenable to single
tests. Positive results appear accurate, although negative results are not as reliable and so
confirmatory tests may be prudent for negative results if C. difficile disease is clinically felt
to be likely.
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1.4.3.5 Polymerase chain reaction (PCR)
The most recent diagnostic technique to be developed is PCR. Most of the methods
designed so far are aimed at detecting toxin genes directly from clinical samples, but early
methods were attempted on cultures of C. difficile. These were shown to compare very well
with cytotoxin detection methods (Alonso et al. 1997); (Kato et al. 1991), although some
were also positive with toxigenic C. sordellii strains (Wren et al. 1990). One alternative
method described replica plating of a culture followed by toxin B gene probing (Wolfhagen
et al. 1993).
Direct detection by PCR of C. difficile in stool samples was developed by a number
of investigators (Arzese et al. 1995); (Boondekhun et al. 1993); (Green et al. 1994);
(Gumerlock et al. 1993); (Kato et al. 1993a). These tests have been demonstrated to
correlate well with cytotoxicity testing, and can be positive in cases where cytotoxicity tests
are negative. This is claimed to be due to increased sensitivity, but there have been no large
enough studies performed to truly determine the false positivity rate of such sensitive
techniques, which can detect as little as 1 pg ofDNA (Gumerlock et al. 1993). Inhibitory
substances in stool specimens have been found to cause problems, requiring complex
neutralisation and extraction procedures (Gumerlock et al. 1993); (Kato el al. 1993a). One
investigator used monclonal antibodies bound to magnetic material to remove any C. difficile
present in the sample prior to DNA extraction and PCR (Wolfhagen et al. 1994). This
method was called magnetic immuno-PCR assay (MIPA) and compared well with isolation
of a toxigenic strain of C. difficile. The most beneficial use for PCR technology at present is
probably for the epidemiological typing and investigation of the variant toxin genes (see
sections 1.6.2.4, 1.6.2.5 and 1.6.2.6).
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1.4.4 Clinical detection methods
In addition to standard history taking and examination, several further investigations
have shown some benefit in the diagnosis of CDI. Sometimes, experienced nursing staffwill
indicate that a patient is suspected to have CDI due to a characteristic smell of the diarrhoea
(Brazier, 1998a). More technological help can be obtained by using radiology and
endoscopy. Plain abdominal X-rays may reveal colonic wall thickening, 'thumbprinting'
and in severe cases 'toxic megacolon'. These features, along with nodular mucosal
thickening, pericolonic oedema and ascites, may also be detected by CT scanning (Boland et
al. 1995). Several investigators have found CT scanning useful as a diagnostic aid
(Kawamoto et al. 1999); (Wilcox et al. 1995); (Zamora et al. 1996) including in CF patients
without symptoms of diarrhoea (Binkovitz et al. 1999). However, specific features such as
the 'accordion sign' are not specific to CDI but merely indicate severe colonic inflammation
(Macari et al. 1999). In addition, presence of abnormal CT findings has not been found to
correlate with increased severity ofCDI (Boland et al. 1995). Sigmoidoscopy and
colonoscopy can provide useftil information about the severity of colitis and may suggest the
diagnosis if classical, raised, yellow-white pseudomembranes are visualised (Fekety and
Shah, 1993); (Wei etal. 1997).
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1.5 EPIDEMIOLOGY OF CLOSTRIDIUM DIFFICILE COLONISATION
AND INFECTION
1.5.1 Distribution of C. difficile
C. difficile is a fairly ubiquitous organism and can be found in many environments.
It is noted to have been isolated from soil, sand and mud, as well as camel, horse and donkey
dung (Hafiz, 1974). More recently, detailed environmental analysis was carried out in South
Wales, resulting in C. difficile isolation from river water, sea and lake water, swimming
pools and even tap water (A1 Saif and Brazier, 1996). Notably 14 of 16 (87.5%) samples of
river water were positive compared to 7 of 15 (46.7%) samples of sea water and the same
proportion of lake water specimens. It was found in soil and on raw vegetables.
Nevertheless, some investigators have been unsuccessful in attempts to isolate C. difficile
from soil (Kim etal. 1981); (Riley, 1994), and Oishi etal. (1983) failed to detect C. difficile
in foods. Discussion regarding the presence of C. difficile in the hospital environment can be
found in section 1.5.2.2.2.
1.5.2 Colonisation with C. difficile
1.5.2.1 Animals
Carriage has been demonstrated in the faeces of dogs and cats, horses, sheep and
poultry, but not in cattle, pigs or fish (A1 Saif and Brazier, 1996). A range of other animals
have also been noted to be potential reservoirs of C. difficile (Riley, 1994) (see table 7).
When isolates from both animals and humans were compared in one study by restriction
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endonuclease analysis (REA) and restriction fragment length polymorphism (RFLP) typing,
no common types were demonstrated (O'Neill et al. 1993). It remains unclear whether there
is an epidemiological link between carriage in animals and subsequent acquisition in
humans, but cats and dogs appear to be the animals most frequently colonised with C.
difficile (Borriello et al. 1983); (Riley et al. 1991b). Such carriage does however, seem to
relate to antibiotic use (Madewell et al. 1999); (Riley et al. 1991b) and this observation
forms a parallel with the situation in humans. Although Borriello et al. (1983) found most
strains recovered in pets to be non-toxigenic, Riley et al. (1991b) found both cytotoxigenic
and non-cytotoxigenic strains.










Table adapted from (Riley, 1994), Table 2
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In addition to carriage of C. difficile, animals may also suffer with C. difficile disease
and a great deal of research has been performed using hamster, guinea pig, rabbit, mouse and
rat models to try and understand more about this illness in humans. CDI has been reported
in horses (Madewell et al. 1995); (Teale and Naylor, 1998), ostriches (Frazier el al. 1993),
and in one report dogs (Berry and Levett, 1986), although this was not corroborated by the
work of two other investigators (Borriello et al. 1983); (Struble et al. 1994).
1.5.2.2 Humans
Colonisation rates with C. difficile amongst human subjects differ significantly with




Neonatal carriage of C. difficile has been recognized since 1935, when Hall and
O'Toole isolated a bacterium, known then as Bacillus difficilis, from the stools of 4 out of 10
asymptomatic newborn infants (Hall and O'Toole, 1935). Numerous studies have since been
conducted, and the colonisation rates reported amongst neonates range from 2-71% (Al-
Jumaili et al. 1984); (Blakey et al. 1982); (Bolton et al. 1984); (Donta and Myers, 1982); (el
Mohandes et al. 1993); (Larson et al. 1978); (Larson et al. 1982); (Lishman et al. 1984);
(Phua et al. 1984); (Richardson et al. 1983); (Rotimi and Duerden, 1981); (Snyder, 1940);
(Tabaqchali et al. 1984a); (Viscidi et al. 1981). Rates of colonisation at birth are low, rising
during hospital stay (Bolton et al. 1984), presumably due to nosocomial transmission
84
(el Mohandes et al. 1993); (Phua et al. 1984); (Sherertz and Sarubbi, 1982); (Zedd et al.
1984). Further evidence to support this theory was provided by the isolation of C. difficile
from environmental sources (Larson et al. 1982); (Malamou-Ladas et al. 1983), whilst the
mothers of colonised infants were shown not to be the source of the organism (Larson et al.
1982). There is some work to suggest that maternal transmission plays a part in infant
colonisation with C. difficile (Tabaqchali et al. 1984a), when 8 out of 9 babies from C.
difficile colonised mothers were found to be colonised compared with 23 out of 41 babies
from non-colonised mothers. However, this also suggests that cross-infection may be
occurring in a large number of those babies bom to non-colonised mothers. Others have not
found evidence for maternal colonisation to be significant (Bolton et al. 1984), although this
may be due to differences in culture methodology.
Colonised neonates are often found to have high toxin titres in their stools, but are
usually asymptomatic (Al-Jumaili et al. 1984); (Donta and Myers, 1982); (el Mohandes et al.
1993); (George, 1986); (Viscidi et al. 1981), despite these toxin levels being equal to those
in adults with PMC (Stark et al. 1982). The reasons for this finding still remain somewhat
unclear but several hypotheses have been proposed.
Lower rates of colonisation have been seen by some investigators in breast fed
versus bottle fed infants (Cooperstock et al. 1982); (Cooperstock et al. 1983); (Tullus et al.
1989), suggesting a possible protective role for immunoglobulin in the mother's milk. Other
studies, however, did not find any difference between colonisation rates in breast or bottle
fed infants (Bolton et al. 1984); (Stark et al. 1982); (Viscidi et al. 1981), although Stark and
Lee, (1982) report a delay in colonisation in breast fed babies. Breast milk was shown to
have neutralising activity against C. difficile toxins in 30-60% of the samples tested in two
studies (Kim et al. 1984); (Wada et al. 1980). Kim etal. (1984) demonstrated that antitoxin
A activity was due to IgA, whilst anti toxin B activity was not due to IgA, IgG or IgM.
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Subsequent work has also demonstrated a non-immunoglobulin component to the anti toxin
A activity ofhuman colostrum (Rolfe and Song, 1995). Although protective factors in
human milk may play a role in the protection of infants from CDI, they cannot account for
protection in infants who are not breast-fed. Rolfe and Song (1995) have observed that
infant formula based on cows milk can also inhibit the binding of toxin A to hamster BBMs,
which could provide the explanation.
A second possible mechanism for protection is that the intestinal mucosa of the
neonate may be devoid of the receptors for toxin A (Kotloff et al. 1988). This phenomenon
has been found to explain the non-susceptibility ofnewborn rabbits to the effects of toxin A
(Eglow et al. 1992) and proposed as the mechanism for a similar observation in hamsters
(Borriello, 1990).
Other suggested protective mechanisms in neonates include reduced sensitivity of
neonatal intestinal cells to toxins compared with adult cells (Chang et al. 1986), or
production of a thicker layer of protective mucus at the mucosal surface interfering with
toxin binding (Lyerly et al. 1988).
1.5.2.2.1.2 Infants
Colonisation rates amongst children under the age of one remain high at 30-65%
(Cooperstock et al. 1982); (Hall and O'Toole, 1935); (Hoist et al. 1981); (Stark et al. 1982),




In young, asymptomatic adult subjects, gastrointestinal tract colonisation rates with
C. difficile have been generally found to range from 0-3% (Aronsson el ctl. 1985b); (Bartlett
etal. 1980); (George etal. 1978b); (Falsen et al. 1980); (Larson etal. 1978); (Marrie et al.
1982), although in one Japanese study, colonisation rates were 15.4% in healthy adults
(Nakamura et al. 1981). It is not clear whether this group had been exposed to antibiotics, or
had more exposure than average to C. difficile. The use of different culture methodologies
may also lead to discrepancies between the results of colonisation studies performed in
different centres. Colonisation of adults at other sites, such as the genitourinary tract
remains a contentious issue. Some investigators have shown antenatal carriage rates of 18-
24% using enrichment broth culture techniques (O'Farrell et al. 1984); (Tabaqchali et al.
1984a); (Thirkell et al. 1984), whilst others demonstrated carriage rates of zero (Al-Jumaili
et al. 1984); (Bolton et al. 1984); (Hoist et al. 1981). Similarly, discrepancies exist between
the results of screening genitourinary clinic patients by Hafiz et al. (1975), O'Farrell et al.
(1984), and Thirkell et al. (1984) who found carriage rates of 12-100%, and those of Levett,
(1984b) and Moss, (1983) who found no carriers. These diverse results may reflect varying
geographical colonisation rates, the variable sensitivity of enrichment broths for isolating
small numbers of organisms or possibly indicate the presence of spores.
Elderly adults demonstrate higher asymptomatic colonisation rates with C. difficile
than their younger counterparts (Aronsson et al. 1985b); (Brazier et al. 1999b); (Rudensky et
al. 1993); (Settle et al. 1999), with rates of 10-12% not being uncommon. Interestingly in
the study by Nakamura et al. (1981) in which the colonisation rate in healthy adults was so
high, healthy elderly patients had a colonisation rate of 7.0%, whilst elderly patients with
cerebrovascular disease had a rate of 15 .9%. Nevertheless, these rates are still much higher
than colonisation rates for adults in many countries. Two reports did indicate low rates of
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C. difficile colonisation amongst elderly patients (Campbell etal. 1988); (Corrado et
al. 1990), although they were both on small groups. Such findings are very different from the
norm and may just relate to the specific circumstances in those units at that time. High rates
of colonisation in elderly patients may result from their possibly reduced immune responses
to infection, or because their bowel flora is less able to resist colonisation by C. difficile,
which has been demonstrated by Borriello et al. (1986).
Hospitalised patients are the group who demonstrate the highest rates of C. difficile
colonisation, with reports of 20% or more being common (Bender et al. 1986); (Bennett et
al. 1984); (Burdon, 1982); (Gerding et al. 1986); (Johnson et al. 1990a); (McFarland et al.
1989); (Pierce et al. 1982); (Rudensky et al. 1993); (Varki and Aquino, 1982). This may be
as a result of the fact that they are often treated with antibiotics, and are more likely to be
exposed to C. difficile in hospital than at home. However, some of the higher rates were
observed in outbreak situations.
1.5.2.2.2 Exposure to C. difficile
Exposure to the organism, or more usually its spore is a prerequisite for developing
C. difficile colonisation or disease. Acquisition of the organism from the environment was
suggested by the early reports of clusters of cases of PMC (Kabins and Spira, 1975);
(Keighley etal. 1979); (Ramirez-Ronda, 1974); (Tedesco et al. 1974). Animal studies also
indicated the significance of environmental contamination (Fekety et al. 1979); (Larson et al.
1978). More recently, the presence of C. difficile in the hospital environment has been well
documented. Mulligan et al. (1980) documented that 32.5% of environmental culture sites
were positive in areas where symptomatic patients with C. difficile diarrhoea were being
cared for compared with 1.3% of sites in control areas. The most common positive sites for
C. difficile were bathroom floors, toilet seats, toilet bowl rims and bed handrails.
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Kim et al. (1980) also found that environmental sites in the vicinity of symptomatic C.
difficile infected patients were more likely to become contaminated than similar sites in
control rooms. Fekety et al. (1980), screened environmental sites in rooms of patients with
symptomatic CDI, asymptomatic C. difficile colonisation and C. difficile negative diarrhoea.
They found C. difficile on the patients' blankets, the floor of the patients' rooms, the
bathroom floor, the toilet seat and the sink cabinet, but not in the air or on food. C. difficile
was isolated from the hands of staff. In the room of a patient with symptomatic CDI, 19.6%
of environmental sites were positive. Only 6.8% of sites were positive in the room of an
asymptomatic C. difficile colonised patient and just 2.6% of sites were positive in the room
of a patient with C. difficile negative diarrhoea, suggesting that greater environmental
contamination is likely when patients are symptomatic.
Another significant study was performed by McFarland et al. (1989). This group
prospectively monitored C. difficile acquisition and transmission on a medical ward, using
rectal swabs rather than relying on faecal specimens. Over an 11-month period, 428 patients
were studied and 6.7% were C. difficile positive on admission. Of those who were negative
on admission, 21% had nosocomial acquisition of C. difficile with 63% of these exhibiting
asymptomatic carriage only. Patients were found to be at higher risk of aquiring C. difficile
if they were co-occupying a room with a colonised patient. In total, on 87% of occasions
where acquisition by one patient was felt to be due to exposure to another positive patient,
the strains were identical using an immunoblotting method described by Mulligan et al.
(1988). In these cases, the initially positive patient who was thought to have led to another
patient aquiring C. difficile was a carrier on 61% of occasions and had diarrhoea 39% of the
time. This discrepancy may just reflect the fact that carrier status was 1.7 times more
common than infection. Whenever an initially negative environment became positive, it was
with an identical strain to that of the patient already in that area. This work confirmed the
findings of other investigators, who recognised that carriage of C. difficile on the hands of
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health care workers occurs (Fekety et al. 1981); (Gerding et al. 1986); (Heard et al. 1988);
(Kim et al. 1981); (Malamou-Ladas et al. 1983); (Mulligan et al. 1980). Such colonisation
was demonstrated on the hands of 59% of personnel following patient contact.
Environmental contamination of the ward environment was also found to be significant in
this study (29% of sites overall), again in agreement with previous findings (Al-Jumaili et al.
1984); (Fekety et al. 1980); (Fekety etal. 1981); (Gerding et al. 1986); (Heard etal. 1986);
(Kim et al. 1980); (Larson et al. 1980); (Larson et al. 1982); (Mulligan et al. 1979); (Savage
and Alford, 1983); (Walters etal. 1982). Furthermore, a greater degree of environmental
contamination was noted in association with patients who had diarrhoea (49% of sites
tested), as previously described (Kim et al. 1981); (Mulligan et al. 1979) (Mulligan et al.
1980). One early study of an outbreak of PMC suggested that environmental contamination
played little or no part in such incidents, but perhaps poor infection control measures allowed
direct person to person transmission (Keighley et a/. 1979). Johnson et al. (1990) found no
spatial clustering within three wards studied, however, they detected C. difficile in 60 of 282
(21%) patients, over a 9-week period. There is no overall indication of whether patients
were C. difficile positive on admission or acquired it nosocomially, apart from the
observation that 7 out of 9 patients who developed C. difficile diarrhoea had previously
negative swabs. No environmental screening for C. difficile was performed. Consequently,
it seems difficult to be certain that hand to hand transmission alone and not environmental
contamination led to nosocomial acquisition of C. difficile. It is now recognised that
environmental contamination with C. difficile spores plays an important role in the
development of this predominantly nosocomial disease. Such spores are also able to persist
for months in the environment (Kim et al. 1981); (Mulligan et al. 1979), due to their resistant
nature. At present, the infective dose in humans has not been determined, but may be very
low, as work in the hamster model indicates that administration of as few as 2 colony
forming units can lead to disease (Larson et al. 1978).
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In addition to hospitals, care facilities such as residential or nursing homes for the
elderly are at risk of becoming heavily colonised with C. difficile, which may in turn lead to
outbreaks occurring. McFarland et al. (1989) showed that 82% of patients who became
positive for C. difficile in hospital remained positive at the time of discharge. Of the patients
investigated in the study, 17% who were negative for C. difficile on admission were positive
when discharged. Patients with C. difficile positive stools were noted to be discharged
significantly more often to extended care facilities than C. difficile negative patients (27% vs.
12%, p<0.01), thus highlighting the risk to these facilities. Outbreaks of C. difficile infection
in nursing homes have been described (Bender et al. 1986).
1.5.2.2.3 Antibiotic exposure
Exposure to antimicrobial agents is usually the inciting agent for CDI as discussed in
section 1.3.2.3. It is also associated with increased risk of C. difficile colonisation, as
indicated by Johnson et al. (1990) in their work on nosocomial C. difficile colonisation and
disease. Viscidi et al. (1981) report a rate of asymptomatic colonisation with C. difficile of
21% in patients receiving antibiotics. Kyne et al. (2000), in a study on acute medical
patients, found that 31% of those who received antibiotics were colonised by C. difficile and
56% ofthis group developed CDI. Several other investigators have reported increased
asymptomatic colonisation rates in patients who have received antibiotics (Bartlett et al.
1978c); (George et al. 1982); (Greenfield et al. 1983); (Viscidi et al. 1981); (Wu et al. 1983).
Studies of the effects of antibiotics on the gastrointestinal flora of healthy volunteers have
also indicated an increase in C. difficile colonisation rates, see section 1.3.2.3.2. One study
showed an asymptomatic C. difficile colonisation rate of 48% in subjects following
administration of antibiotics (George, 1988).
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1.5.2.2.4 Immune function
As discussed in section 1.3.2.2, an effective immune response is thought to be an
important factor in protection from CDI and higher serum antibody levels have correlated
with milder illness or colonisation (Aronsson et al. 1983); (Aronsson et al. 1985a);
(Mulligan et al. 1993). Secretory IgA is also capable of neutralising toxin A (Kelly et al.
1992) and Stubbe et al. (2000) demonstrated that monoclonal IgA antibodies could protect
human colonic carcinoma derived T84 monolayers from the effects of toxins A and B. In the
very elderly, the immune system is not thought to be as effective, which may reduce their
protection against C. difficile disease or colonisation (Mulligan et al. 1993). This is
supported by the observation of Viscidi et al. (1983) that although antitoxin antibodies were
detected in those aged over 70, they had no toxin neutralising capability.
1.5.2.2.5 Other risk factors
Apart from elderly patients, other groups who appear more likely to develop
C. difficile colonisation than normal include patients with cystic fibrosis (Peach et al. 1986);
(Wu et al. 1983), and those with inflammatory bowel disease (Dorman et al. 1982);
(Greenfield et al. 1983); (Keighley etal. 1982); (Meyers et al. 1981). It is possible that these
findings relate to an increased antibiotic usage in such groups. Presence of a nasogastric or
gastrostomy tube has also been linked with an increased risk of asymptomatic C. difficile
acquisition (Simor et al. 1993). This may relate to an increased risk of transmission via the
hands of caregivers, who become colonised due to environmental contamination. One study
found a significant link between H2 antagonists and C. difficile colonisation in elderly
patients (Walker et al. 1993), but this finding needs to be confirmed.
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1.5.3 C. difficile infection
1.5.3.1 Hospitals and extended care facilities
C. difficile is currently the most important cause of nosocomially acquired,
diarrhoea-associated infection (Djuretic et al. 1996); (Silva, 1994); (Wilcox, 1996). It has
been reported to account for 75% or more of such cases (Gerding et al. 1995) and is ofgreat
importance in both hospitals as well as nursing or residential homes. Detailed discussion
regarding the epidemiology of C. difficile colonisation in hospitals and extended care
facilities takes place in the sub-sections of section 1.5.2.2 and also relates to CDI. One
additional finding of interest is that patients who have asymptomatic colonisation with C.
difficile on admission to hospital, albeit with toxigenic strains, appear less likely to develop
C. difficile disease (Shim et al. 1998). This observation may be explained on the basis that
some patients with robust immune responses could inactivate toxin produced in the intestine
and thereby arrest the development of symptoms. Mulligan et al. (1993) described serum
IgA and IgM levels in asymptomatic carriers which were significantly higher than levels in
either patients with disease or in controls. Secretory IgA levels in this group of patients were
not determined.
In addition to significant morbidity, CDI results in significant extra costs to care
institutions and may also lead to mortality (Eriksson and Aronsson, 1989); (Lesna and
Parham, 1996); (Monti etal. 1992); (Spencer, 1998); (Wilcox et al. 1996). As mentioned in
section 1.5.2.2.1.1, children under the age of one appear relatively immune to the effects of
C. difficile toxins, but disease can occur (Adler et al. 1981). Older children often have
diarrhoea after taking antibiotics, but PMC is rare (Gryboski et al. 1991). However, cases of
PMC have been described (Donta et al. 1981); (Mandal et al. 1982); (Qualman et al. 1990).
CDI in adults is predominantly an illness of those aged over 60 (Aronsson et al. 1984a);
93
(Nash et al. 1982). The Communicable Diseases Surveillance Centre (CDSC), UK (2000)
reported that 80% of cases occur in patients over the age of 65. Kyne et al. (1999) reported
that the patients at highest risk of CDI are those over the age of 75 with severe co-existing
illness.
Rates of C. difficile disease have increased markedly in the last two decades (Brown
et al. 1990); (CDSC, 1998); (Olson et al. 1994), and although increased reporting may
account for part of this, a true increase in the incidence ofCDI in various hospitals appears
to have occurred (Wilcox and Smyth, 1998). As discussed in section 1.5.2.2.2,
environmental contamination appears to be the main factor leading to subsequent patient
acquisition. The increase in patient susceptibility is probably a combination of factors and
may include increasing antibiotic usage, particularly of 'third generation' cephalosporins and
increasing age of the patient population. An increased exposure to C. difficile may also arise
due to understaffing ofhospital facilities, with consequent suboptimal levels of infection
control. Acquisition rates in hospitals have been reported to be from 6-20% (Brazier et al.
1999b); (McFarland et al. 1989); (Rudensky et al. 1993); (Samore et al. 1994a).
1.5.3.2 Community
Far less information is available on C. difficile disease and carriage in the
community, but it does still appear to be a significant pathogen. Samore et al. (1994b)
investigated patients admitted to a medical ward, a surgical ward or an ICU. Cultures were
performed within 72 h of admission and an asymptomatic colonisation rate of 7% was found.
The mean age of patients was 61 years. A review of 73 cases of C. difficile infection in
Ireland revealed that 10.9% were thought to be community acquired. Two larger studies
have been performed in Australia, one demonstrated that 4.7% of diarrhoeal stool samples
from this source were C. difficile positive accounting for 30.3% of all enteropathogenic
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organisms isolated (Riley et al. 1986). The other showed a C. difficile positivity rate of 5.5%
(16 of 288 samples), which represented the most common enteric pathogen found (Riley et
al. 1991a). More recently, the Swedish C. difficile study group carried out a prospective
study of all cases ofCDI during 1995. They found that 28% of cases were apparently of
community origin (Karlstrom et al. 1998). When Wheeler et al. (1999) prospectively
studied the causes of infectious intestinal disease in the community, they found relatively
low levels of CDI at less than 1% of all diarrhoeal cases. However, there are far more
individuals in the community than in hospitals. Consequently, 1% of the total number of
patients with diarrhoeal symptoms in the community might represent a large percentage of
people with CDI overall, when hospital cases are added. These reports suggest that there is a
significant burden of C. difficile disease in general practice.
1.5.3.3 Risk factors
Exposure to antibiotics is the greatest risk factor for development of CDI, with 'third
generation' cephalosporins or multiple courses of antibiotics being most dangerous.
Duration of treatment may also be a factor (Brown et al. 1990). Antibiotics as a risk factor
are comprehensively discussed in section 1.3.2.3 and its subsections, whilst environmental
contamination is discussed in section 1.5.2.2.2. Age is an important risk factor (Aronsson et
al. 1984); (Borriello and Larson, 1981); (Brown et al. 1990); (McFarland et al. 1990), with
80 % of cases ofCDI occurring in those aged over 75 (see section 1.5.3.1). Analysis of
other risk factors suggests that gastrointestinal procedures and intensive care residence
(Brown et al. 1990), as well as tube feeding (Bliss et al. 1998); (Talon et al. 1995), are
significantly associated with C. difficile disease. Similarly, increased length ofhospital stay
(Gerding et al. 1986) and more severe underlying illness (McFarland et al. 1990), have also
been associated with an increased risk ofCDI development.
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Starr et al. (1997) proposed what they termed the 'herd immunity' model. This
states that the collective susceptibility of a ward group is the important factor in determining
whether an outbreak will occur. Four groups of patients exist in this model: resistant
uncolonised, resistant colonised, susceptible uncolonised and susceptible colonised. Disease
can only progress from the susceptible colonised state, but all the states are in continual flux.
The theory is that provided there are not very many susceptible, uncolonised patients then
exposure to C. difficile will not result in many cases of disease. Reduction of exposure to C.
difficile will also reduce the chance of susceptible uncolonised patients becoming colonised.
If, on the other hand, levels of susceptible uncolonised patients rise, then once they are
exposed to C. difficile there is the risk of an outbreak occurring. Risk of susceptibility is
highest whilst on antibiotics, and according to Starr's estimate, falls relatively rapidly after
they are stopped. Hence, he argues that it is of greatest benefit to stop antibiotics as early as
possible, thereby minimising the number ofpatients who are very susceptible to colonisation
and so to disease. In reality this seems to be a complicated way of explaining a phenomenon
with which we are already acquainted, namely that it is wise to minimise the use of
antibiotics. However, there is slightly more to the theory than that, as Starr argues that
keeping patients in hospital for longer, after their antibiotics are finished, would be helpful as
it would potentially elevate the 'herd immunity' to CDI.
1.5.4 Prevalence of different C. difficile types in the UK and abroad
Most of the typing data for C. difficile in England and Wales is co-ordinated by the
PHLS Anaerobe Reference Unit, CardiffPHL, where 117 different ribotypes (see section
1.6.2.6) have been described. Their data indicate that 90% of hospital patient isolates belong
to one of 16 types. Ribotype 1 isolates represented 57% of the total number of over 1000
strains. This ribotype was also demonstrated to be endemic in 33 of 58 hospitals surveyed
(Brazier, 1998b). Upon testing 40 ribotype 1 isolates from 20 different hospitals, Brazier's
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group, using 11 different restriction enzymes, were unable to distinguish between isolates
(Brazier et al 1997a). The international typing study (Brazier et al. 1997b), indicates that
this ribotype is also causing problems in the USA. Ribotype 1 has been found to correspond
to Delmee's serogroup G, but this serogroup has not been found to be the predominant strain
in Belgium (Van Dijck et al. 1996) or France (Barbut et al. 1996).
Increasing numbers of reports are being made about toxin A-B+ strains in
association with clinical disease. These strains have been found to correspond mostly to
serogroup F (Depitre et al. 1993), but a few strains appear to be serogroup X (Kato et al.
1998); (von Eichel-Streiber et al. 1999). They also correspond to ribotype 17 (O'Neill et al.
1996). Kato et al. (1997), report a high prevalence of 33% toxin A-B+ strains amongst 143
toxigenic isolates tested. The small amount of data available from England and Wales
suggests a much lower incidence rate of 3% amongst hospital isolates submitted to the PHLS
Anaerobe Reference Unit, CardiffPHL (Brazier, 1998b).
In contrast to the findings with hospital strains, the PHLS Anaerobe Reference Unit,
Cardiff PHL reports that the most prevalent community strain was non-toxigenic (ribotype
10) and accounted for 15.9% of 390 isolates typed. The most frequent hospital isolate,
ribotype 1 accounted for only 7.4% of these community strains (Brazier, 1998b).
1.5.5 Cross Infection
As discussed earlier in section 1.5.2.2.2, environmental contamination has been well
documented in the ward environment, particularly near patients with diarrhoea. Carriage of
C. difficile on the hands of staff is also well known to occur and cross-infection has been
well described by research using epidemiological typing methods (Heard et al. 1986);
(Magee et al. 1993); (McFarland et al. 1989); (Savage and Alford, 1983);
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(Testore et al. 1988). Strategies aimed at reducing the risk of cross infection are based on
two principles. Firstly, reducing environmental contamination by a combination of patient
isolation and frequent cleaning of at risk clinical areas, and secondly by reducing person to
person transmission. Barrier nursing and isolation of CDI cases has been shown to be
effective in some, but not all reports (Bender et al. 1986); (Brown et al. 1990); (Nolan et al.
1987). Nevertheless, it does originate from sound basic principles, as we know that local
environmental contamination with spores is worst around diarrhoeal patients and that
environmental contamination can play a part in the perseveration of C. difficile outbreaks
(McFarland et al. 1989); (Samore et al. 1996). Environmental cleaning using hypochlorite
seems most effective (Kaatz et al. 1988), and when other disinfectants are used it is the
dilutional effect which seems important (Struelens et al. 1991), along with physical removal
of spores. Reducing person to person transmission usually involves the the use ofgloves and
aprons for staff involved in physical patient care and rigorous attention by everyone to
handwashing between all patient contacts. The use of gloves for those directly involved in
patient care has been recommended in several studies as beneficial (Johnson et al. 1990b);
(McFarland et al. 1989). Handwashing after patient contact has also been demonstrated to
be an important control measure (Kaatz et al. 1988); (McFarland et al. 1989), although liquid
soap appears as useful as chlorhexidine (Bettin et al. 1994). Another practice which has
been found to reduce cross infection is the use of disposable thermometers (Brooks et al.
1992); (Jemigan et al. 1998).
1.5.6 Relapse
Rates of recurrence following successful treatment of CDI with either metronidazole
or vancomycin reported in the literature range from 5-24% (Wilcox and Spencer, 1992).
Whilst these were originally felt to be due to persistence of spores and subsequent true
'relapse' of the inadequately treated infection, this no longer appears to be the case. Several
98
studies have now demonstrated that in a large proportion of cases, such 'relapses' are due to
genetically different strains and are therefore really re-infections (Barbut et al. 2000);
(Johnson et al. 1989); (O'Neill etal. 1991). Furthermore, whilst endemic strains of C.
difficile exist at some institutions, some of the 'relapses' with identical genetic strains may
also be reinfections, merely with the same strain as before (Wilcox et al. 1998). Re-infection
rather than relapse in now felt to be the most likely cause of recurrent CDI.
1.6 TYPING OF CLOSTRIDIUM DIFFICILE
Since the identification of C. difficile as the cause ofmost cases of antibiotic
associated colitis (Bartlett, 1990), there have been numerous attempts to try and develop a
satisfactory method for typing the organism. Many different typing and fingerprinting
methods have been tried and have been shown to be extremely useful for epidemiological
typing. However, no standardised method was accepted which could be employed anywhere
in the world allowing comparison of results. Now, a method may have been achieved which
will be universally accepted as the best way of typing C. difficile, allowing comparison of
results worldwide.
1.6.1 Phenotypic methods
1.6.1.1 Antibiotic sensitivity pattern
Antibiotic sensitivities were one of the first methods used to try to relate strains of C.
difficile in potential outbreak situations. Investigation of the sensitivities of C. difficile
revealed that most strains were either highly sensitive or highly resistant, with MICs falling
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into a narrow range (Burdon, 1982); (Dzink and Bartlett, 1980); (Gianfrilli et al. 1984b).
Use has been made of resistance patterns during the investigation of outbreaks (Burdon,
1982); (Climo et al. 1998); (Wust et al. 1982). Although being a relatively simple test to
perform, its use is limited by the fact that there is little variability in sensitivity between C.
difficile strains. Wust et al. (1982) used antibiograms along with plasmid analysis,
counterimmunoelectrophoresis of toxins and polyacrilamide gel electrophoresis (PAGE) of
soluble proteins to show that 12 of 16 isolates in an outbreak were identical.
1.6.1.2 Bacteriophage and bacteriocin susceptibility
The use of phages and bacteriocins to type C. difficile was described by Sell et al.
(1983). At least 40 different patterns are known to exist (Tabaqchali, 1990). This system
has been used to study the epidemiology of an outbreak in a hospital in Zurich (Hachler and
Wust, 1984) as well as a neonatal unit outbreak (Zedd et al. 1984), where 30 out of 31
isolates were found to be identical. This included environmental as well as staff and patient
isolates. Bacteriocin, bacteriophage and plasmid profile typing methods were combined by
Mahony et al. (1991), but were only able to type 84% of 114 isolates. There is no
widespread expertise in the use of these techniques.
1.6.1.3 Electrophoretic protein profiles
This technique relies on variations in cellular and surface proteins to distinguish
different strains of C. difficile. Proteins are first extracted and then separated by sodium
dodecyl sulphate-polyacrilamide gel electrophoresis (SDS-PAGE). Various detection
methods of the protein profiles are described depending on whether [j5S] methionine is
incorporated into the cellular proteins before separation. This method, known as radio-
PAGE, requires autoradiographic detection methods. Other methods rely on staining
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techniques such as Coomassie blue to visualise the separated protein bands. Staining
methods were reported by Poxton et al. (1984), Wexler et al. (1984) and radio-PAGE
methods by Tabaqchali et al. (1984b). Further weight was added to the suggestion that
radio-PAGE was a useful typing scheme when newer detection methods also confirmed the
specific radio-PAGE types as distinct. This was described using DNA restriction
endonuclease analysis (Wren and Tabaqchali, 1987), and arbitrary primer PCR (AP-PCR)
patterns (Wilks and Tabaqchali, 1994). Some radio-PAGE types have also been reliably
demonstrated to be toxigenic (Wren et al. 1987). Despite radio-PAGE being heralded as a
very useful technique, it does suffer from the disadvantage of involving radioactivity, and
whole cell EDTA-extracted protein SDS-PAGE patterns are claimed to be even more
discriminatory (Costas et al. 1994). Ogunsola et al. (1995a) found that SDS-PAGE of
EDTA-extracted cell surface proteins compared favourably with serogrouping for 61 isolates
tested. All these methodologies produce profiles with numerous bands and can prove
difficult to interpret without computer assistance (Ehret et al. 1988); (Tabaqchali et al.
1987).
1.6.1.4 Immunoblotting
Western blotting (immunoblotting) techniques involve protein antigen extraction and
PAGE electrophoresis followed by blotting onto a nitrocellulose membrane, with detection
by a second antibody conjugated to an enzyme which allows chromogenic detection.
Immunoblotting was compared by Mulligan et al. (1988) with plasmid fingerprinting,
serotyping and PAGE. They determined immunotyping to be the most discriminatory
method ofthis group, however it has not been widely adopted for the typing of C. difficile.
The technique is likely to be of greater benefit when more than one or two antisera are used
(Kato et al. 1993b). However, they noted that not all strains of 114 tested were typeable
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even using all 10 currently available antisera. New antisera require to be made before this
method can type all strains.
1.6.1.5 Serogrouping
This method uses antibodies, which are raised in laboratory animals, to cell surface
proteins. The sera are then mixed with formol-treated cells with agglutination indicating a
positive result. Ten different serogroups have been described and all groups except
serogroup A appear homogenous by PAGE typing, which splits serogroup A into 12
different strains (Delmee et al. 1986). Serogroup D was found to be non-toxigenic, whilst
serogroup F and X produce toxin B but no detectable toxin A (Delmee and Avesani, 1990);
(von Eichel-Streiber et al. 1999). The lack of standardised reagents between laboratories
means that it is difficult to compare serogrouping results from different centres.
1.6.1.6 Pyrolysis mass spectrometry (PyMS)
PyMS is a highly discriminatory method that is capable of testing a high throughput
of samples, making it useful for outbreak investigation (Cartmill et al. 1992); (Magee et al.
1993). It involves the production of volatile bacterial products by thermal degradation,
known as the pyrolysate, and then analysis using a mass spectrometer. It does not type but
rather 'fingerprints' strains because whilst it can compare all the isolates in one batch,
distinguishing well between them, the results cannot be compared to earlier or later batches.
Inclusion ofpreviously isolated strains of known types can overcome this drawback to a
certain extent. This technique has also shown good correlation with both SDS-PAGE
profiles ofouter membrane proteins (Ogunsola et al. 1995b), and PCR ribotyping (O'Neill et
al. 1996). One drawback is that the machinery needed to perform the technique is extremely
expensive, effectively limiting its use to reference laboratories.
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1.6.2 Genotypic methods
Genotypic methods are generally more discriminatory than phenotypic ones because
whilst organisms may change their phenotypic characteristics fairly readily, it is much harder
to alter their genetic make-up. Therefore, it is normally possible to delineate a greater
number of types in a species with genotypic tools. Various such methods have been applied
to the typing of C. difficile.
1.6.2.1 Plasmid analysis
Plasmid analysis was one of the first genotypic methods to be attempted for typing
C. difficile (Wust el al. 1982) and has been used for C. difficile typing on several occasions
(McKay et al. 1989); (Steinberg et al. 1987). For strains that carried plasmids it was found
to be very discriminatory (Mulligan et al. 1988), but they are only found in 18-60% of
strains (Clabots et al. 1988a); (Clabots et al. 1988b); (Muldrow et al. 1982). Reproducibility
may suffer due to the unstable nature of plasmids and consequently it is of limited use in
typing C. difficile.
1.6.2.2 Restriction endonuclease analysis (REA)
REA involves DNA extraction followed by restriction endonuclease digestion and
then electrophoresis of the product, staining or using autoradiography to visualise the
banding patterns according to the method being used. REA using Hind\\\ was able to
demonstrate cross-infection between two patients in a study by Kuijper et al. (1987). Other
investigators have found REA to be a discriminatory method (Devlin et al. 1987);
(Peerbooms et al. 1987); (Samore et al. 1994b) and when used by O'Neill et al. (1991) to
investigate recurrent CDI, more than half the cases were shown to be caused by new strains.
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One ofthe reasons that this method is so discriminatory, is that it produces digests with up to
50 or more bands. Consequently, these are very difficult to analyse with the naked eye and
computer assistance is required (Tabaqchali et al. 1987). The method is also time-
consuming and laborious, so is best performed by laboratories with plenty of experience.
1.6.2.3 Restriction fragment length polymorphism (RFLP) analysis
This method involves the same procedures as for REA but instead of staining the
digests immediately after electrophoresis, a blotting procedure is performed and 16S or 23S
ribosomal RNA probes are used to hybridise with the digest. This results in far fewer bands
to be interpreted, making analysis easier. The method was described by Bowman et al.
(1991) for the typing of C. difficile. Subsequently, a comparison with REA was made on
116 strains and RFLP analysis was found to be less discriminatory, with only 6 types
demonstrated vs. 34 types for REA (O'Neill et al. 1993). RFLP analysis is therefore not
regarded as particularly useful for C. difficile typing.
1.6.2.4 PCR with arbitrary primers (AP-PCR)
Arbitrarily primed PCR refers to the use of a single, short primer that is not targeted
at any specifically known sequence in the genome, and which hybridizes at random to
complementary sites. This process occurs in both directions along the DNA, and produces a
number of amplified DNA fragments. These differ in number and size, depending on how
genetically similar the different test strains are, and can be visualised by electrophoretic
separation. This type of PCR is usually performed using conditions of low stringency, with
low annealing temperatures and high MgCl2 concentrations. Due to the arbitrary nature of
the primer, no knowledge of the target nucleotide sequence is required for AP-PCR.
However, because both ends of the amplimer are complementary (palindromic), hairpin loop
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formation is possible instead of primer binding and this may reduce the efficiency of the
PCR reaction. It can also result in a reduction in the reproducibility of the method.
Consequently, primer and template concentrations are very important and can influence the
success of the technique.
This method was first described as a technique for typing C. difficile by McMillin
and Muldrow, (1992), who demonstrated that differentiation between six C. difficile strains
was possible. Later, the technique was modified and used as a rapid typing method on
colonies of C. difficile directly, without DNA extraction (Wilks and Tabaqchali, 1994). The
genotypes demonstrated using this method by Wilks and Tabaqchali coincided with nine
previously described radio-PAGE types. Other investigators have also described the use of
AP-PCR for typing C. difficile (Silva et al.. 1994); (Tang et al. 1995).
Another method, closely related to AP-PCR is randomly amplified polymorphic
DNA (RAPD) PCR. This method uses two short arbitrary primers rather than the single
longer primer used in AP-PCR. In some publications, these terms have been used
interchangeably regardless ofprimer length or number (Power, 1996). RAPD PCR was used
by Killgore and Kato, (1994) to type 41 C. difficile isolates from a hospital outbreak, and
was found to be more discriminatory than immunoblot typing methods.
1.6.2.5 Standard PCR methods
Early work on PCR methodology was performed by Kato et al. (1991), who used
paired primers derived from both the repeating and non-repeating regions of the toxin A
gene. Using three different primer pairs, fragments of 546- 242- and 1266-bp were
generated when toxin positive strains were tested. It was possible to differentiate 26 non-
toxigenic from 35 toxigenic strains of C. difficile. These methods did not produce any
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product with 20 other clostridial species, including C. sordellii. Wren el al. (1990) also
tested a method that relied upon amplification of an area in the repeating region of the toxin
A gene. They successfully distinguished between 17 non-toxigenic and 58 toxigenic strains
of C. difficile but did obtain a positive result with a strain of C. sordellii.
1.6.2.6 Ribo-spacer polymerase chain reaction (RS-PCR)
The use of a PCR method, which demonstrates differences between thel6S-23S
ribosomal RNA intergenic spacer region of C. difficile strains was first described by Gurtler
(1993). Using a paired oligonucleotide PCR system, he demonstrated 14 reproducible DNA
fingerprints amongst 24 test strains. Cartwright, el al. (1995) modified this technique and
went on to demonstrate 41 distinct ribotypes amongst the 102 strains of C. difficile tested.
Strains were classified as genetically distinct if their PCR profiles differed by more than one
band. Another group to successfully type various bacterial species using RS-PCR was
Jensen et al. (1993). Subsequent work comparing pyrolysis mass spectrometry and
serotyping with PCR ribotyping has shown favourable results (O'Neill et al. 1996), and this
method is now in use by the PHLS Anaerobe Reference Unit, Cardiff PHL to type C.
difficile (Brazier, 1998b). It is this method which could be universally accepted for C.
difficile typing in future.
1.6.2.7 PCR on faecal specimens
In contrast to the methods described in sections 1.6.2.4, 1.6.2.5 and 1.6.2.6, which
are usually performed on culture isolates, some investigators have explored the possibility of
direct testing of stool specimens. Some of the earliest work on these methods was carried
out by Gumerlock et al. (1991), who used a pair ofprimers complementary to regions in the
16S rRNA gene, to amplify a 270-bp fragment of genomic DNA. Production of the correct
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fragment was confirmed by gene probing a Southern blot. The method was reportedly very
sensitive. Green et al. (1994) performed an oligonucleotide probe method to detect toxigenic
C. difficile in stool specimens. It was found to compare favourably with stool cytotoxicity,
as well as with a commercial EIA kit. The 33-bp probe used detected a sequence in the toxin
B gene. Arzese et al. (1995) and Boondeekhun et al. (1993) both designed methods to detect
the toxin A gene and Arzese claimed improved detection of toxigenic strains, whilst
Boondeekhun found one discrepant result. Similarly, Gumerlock et al. (1993) developed a
toxin B gene detection method and found two out of 18 cytotoxin negative samples to be
PCR positive. The patients concerned were symptomatic and it was claimed that the PCR
method was 10-100 times more sensitive than cytotoxin (CPE) testing. However, it is also
possible that a very sensitive detection method could detect the presence of an organism that
is colonising a patient rather than causing disease. Another potential drawback of PCR
methods on stool samples rather than on cultures of C. difficile, is that the presence of
inhibitory factors may require a complicated preparation stage before the test can be
performed. Kato et al. (1993), describe a PCR method in which a segment ofthe toxin A
gene was amplified, where prior treatment of the stool sample using an ion-exchange process
was required.
1.7 THE POLYMERASE CHAIN REACTION (PCR)
The following sections are derived from information obtained from the following
references (Anderson, 1990; Persing, 1993).
Having been developed by Kary Mullis in 1983, the PCR allows the exponential
amplification of specific target sequences ofgenomic DNA. After further improvements,
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including automated oligonucleotide synthesis, automated thermal cycling and a heat stable
DNA polymerase from Thermus aquaticus, publication of a practical application for the
technique occurred in 1985 (Saiki et al. 1985). Since this time, the importance of PCR as a
research tool has increased significantly, along with its more frequent application in clinical
diagnostic microbiology.
1.7.1 Principles of the polymerase chain reaction
In this technique, DNA synthesis is achieved by repeated cycles of oligonucleotide
directed DNA replication. When the genome of the organism to be tested is known, a pair of
oligonucleotide primers is designed which can bind to specific sites on the 3' and 5' DNA
strands. The primers are usually around 20-bp in length and the distance between annealing
sites determines the amplimer fragment size. Fragments of between 50 and 1500-bp are
generally preferred for diagnostic assays.
The PCR cycle is usually composed of three stages. Firstly, denaturation of the
target DNA, which usually requires a temperature of around 90°C. This is required to form
single strands ofDNA and expose the sites where the primer can anneal. The second stage is
annealing of primers to the DNA strand, which usually occurs at 40-60°C. Lower annealing
temperatures reduce the stringency of the reaction by increasing the possibility of non¬
specific primer binding. Finally, comes the extension phase, where the primer is extended
along the target by a thermostable DNA polymerase. This generally takes place at 72°C. In
a typical PCR protocol, there will be 30-50 of these cycles performed, producing a double
stranded DNA amplimer identical to the DNA sequence between the two primer binding
sites on the original target.
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1.7.2 Oligonucleotide primers
The choice ofprimer sequence will be depend on the region of the gene that is to be
amplified. For PCR where a specific genetic element is to be amplified, the primer needs to
be long enough to be specific to that section of DNA, and not to bind to multiple regions
along the genome. This usually requires a primer of 18-25 bp length. Longer primers will
increase cost significantly without any significant increase in specificity. In addition, it is
wise to avoid primers which include areas of self complementarity, as this can lead to
binding of the primers to each other and elongation along their length. This results in double
stranded fragments of a length similar to the sum of the primers, known as primer dimers.
Formation ofprimer dimers will tend to reduce the efficiency of the PCR in producing the
desired amplimer.
1.7.3 Application of the polymerase chain reaction to C. difficile typing
This is discussed in the following sections: 1.6.2.4, 1.6.2.5, 1.6.2.6, and 1.6.2.7.
1.8 AIMS OF THE RESEARCH
1.8.1 Antibiotics and their contribution towards CDI
As discussed in section 1.3.2.3 and its subsections, antibiotics are known to have a
significant impact on the bowel flora of a recipient. Exposure to antibiotics is one of the
most important factors in the development of CDI and some antibiotics are thought to be
more likely than others to lead on to CDI (see section 1.3.2.3 and subsections). Levels of
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CDI were very high on the care of the elderly wards at our institution and at the same time,
concern was being raised in the scientific community over 'third generation' cephalosporins
and their contribution towards the development ofCDI (see section 1.3.2.3.2). It was
decided that it would be useful to ascertain whether an alternative antibiotic would pose less
of a threat to elderly patients. Some data indicate that anti-pseudomonal penicillins, with or
without beta-lactamase inhibitors such as clavulanic acid or tazobactam, may have a reduced
propensity to induce CDI compared with 'third generation' cephalosporins, (see section
1.3.2.3.3). However, there have been no prospective studies to date, controlled for exposure
to C.difficile, which directly compare two broad spectrum antibiotic agents, in order to
determine their influence on the risk of developing CDI. Consequently, piperacillin-
tazobactam (PT) was selected as the alternative agent to cefotaxime (CTX), for the empirical
treatment of serious infection in the elderly. A study in which environmental exposure to C.
difficile was controlled for was designed, in order to compare the propensity of elderly
patients to develop C. difficile colonisation or CDI after therapy with CTX or PT.
1.8.2 Methods of diagnosing CDI
New methods continue to be developed for the detection of C. difficile toxins, in
order to diagnose CDI. These are usually designed to be simple to use and allow a rapid
result to be obtained. One such test is the Oxoid toxin A test (Unipath, Basingstoke, UK),
which is a dot-immunobinding assay method, capable of producing a result in 30 min. There
was no published evaluation of this test, although the multicentre trial originally used to
evaluate the kit was published in 1998 (Bentley et al. 1998). A study was designed to
evaluate the accuracy of the Oxoid toxin A test, using a cytopathic effect method to detect
toxin B as the comparator. The CPE method used HEp-2 cells and toxin B titres of the stool
specimens were measured. This was to see whether there was a correlation between the
toxin B level (assumed to be similar to the toxin A level) and the ability of the Oxoid test to
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detect toxin A. In addition, all samples were cultured and any non-toxigenic isolates
identified. Combining the information from all tests carried out was intended to allow the
reasons for any discrepancies between tests to be understood.
1.8.3 Epidemiological study of CDI
As discussed in sections 1.2.4.1.7 and 1.5.4, there is increased recognition of C.
difficile strains that produce toxin B but no detectable toxin A (A-B+). These strains have,
nevertheless been associated with clinical disease. This gives rise to concern regarding the
diagnosis of CDI, because tests for toxin A alone will be negative on stools from such
patients, perhaps leading to misdiagnosis. Data from the PHLS Anaerobe Reference Unit,
Cardiff PHL indicates that such strains account for 3% of those referred to them, however,
from one hospital these strains did represent 10% of the number submitted (Brazier el al.
1998b). Determination of the percentage of A-B+ strains in Leeds and Bradford has not
been performed to date, and this was the aim of the author's investigation.
Another area of C. difficile epidemiology that is not well researched is that of
infection and colonisation rates in the community (see section 1.5.3.2). Neither is it
currently clear whether the strains responsible for CDI in hospital patients also cause disease
in the community. Cases of CDI from two elderly care wards at our institution were
previously shown to be due to a single strain (known as p24) on 87% of occasions, (Fawley
and Wilcox, 2001). In addition, this strain has been shown to predominate throughout the
UK, and is designated ribotype 1 (Stubbs et al. 1999). However, limited data from PHLS
Anaerobe Reference Unit, CardiffPHL indicates that strains from community patients are
diverse and do not mimic strains causing hospital infection (see section 1.5.4). Furthermore,
it is not known whether disease in the community results from the same strains in different
parts of the country. In particular, it was of interest to compare strains from an urban centre
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like Leeds which were causing disease in the community with similar strains from a rural
area. A study was in progress to compare rates of community CDI in Leeds and Truro, and
so permission was obtained from Dr MarkWilcox and Dr Richard Bendall to allow
genotypic comparison ofthe strains from each centre. The author sought to assess whether
strains isolated from community patients with disease in Truro were the same as those




2.1 REAGENTS AND CHEMICALS
All chemicals used were purchased from BDH (Poole, Dorset, UK ) unless
otherwise stated and were of the highest grade available. Oligonucleotide primers from
previously published methods were used (Gumerlock et al. 1993); (Jensen et al. 1993); (Kato
et al. 1998); (Killgore and Kato, 1994); (Tang et al. 1994). Primers were purchased from
MWG-Biotech AG, (Ebersberg, Germany), and were stored at -70°C prior to use.
2.2 STRAINS AND MEDIA
All materials for media preparation were purchased from Oxoid (Basingstoke,
Hampshire, UK), unless otherwise stated and media was prepared according to the
manufacturers directions. A toxin A-B+ strain of C. difficile (Bz 17) was kindly supplied by
Dr J.S. Brazier, PHLS Anaerobe Reference Unit, CardiffPHL, UK. Human epithelial (HEp-
2) cells were supplied by the routine diagnostic microbiology laboratory at Leeds General
Infirmary, where they were used routinely for cytotoxin detection. Green monkey kidney
(Vero) cells were supplied by the Public Health Laboratory Service (PHLS), Leeds branch.
Stool samples for the study of the Oxoid toxin A kit (Oxoid, Basingstoke,
Hampshire, UK) were obtained from the diagnostic laboratory of the United Leeds Teaching
Hospitals Trust (ULTH). These totalled 100 in number and were collected during 1996.
After having been clinically tested, they were stored at -20°C in original containers, until
required. Stool samples for the clinical trial were collected from patients at the ULTH and
were processed immediately on receipt. Following this they were frozen, in their original
containers, at -20°C. These were collected from 1996 to 1997. Isolates of C. difficile for
toxin A gene determination were obtained from the diagnostic laboratory of St James's
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University Teaching Hospital (SJUH), Leeds as well as stool samples from ULTH and
Bradford Royal Infirmary during 1999 and 2000. Following diagnostic testing, stool
samples were stored at -20°C until required. The total number of C. difficile isolates
obtained for testing was 269. Stool samples from general practices were used in order to
characterise community strains of C. difficile. These 15 samples were received at the
diagnostic laboratory of the ULTH during 1999 and 2000 and stored at -20°C, after clinical
testing, until required. Further strains of C. difficile were obtained from Dr Richard Bendall,
PHLS, Truro, UK. These 39 isolates had been obtained during 1999 and 2000 from
specimens submitted by GP's.
Once strains were isolated from stool samples, they were stored in glycerol broth
(20% glycerol (w/v) in nutrient broth) at -70°C.
2.2.1 Cycloserine-cefoxitin eqq yolk (CCEY) agar preparation
Preparation of CCEY media was carried out according to manufacturer's
recommendations. Standard CCEY was supplemented with 1% lysed horse blood (E&O
Laboratories, Bonnybridge, Stirlingshire, UK), 250mg/L cycloserine and 8mg/L cefoxitin.
Egg yolk supplement was omitted. Lysozyme CCEY was supplemented with 2% lysed
horse blood (E&O Laboratories, Bonnybridge, Stirlingshire, UK), antibiotics as above and
lysozyme (5mg/L) (Sigma-Aldrich Company Ltd, Poole, Dorset, UK). Egg yolk supplement
was omitted.
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2.3 ISOLATION AND CHARACTERISATION OF CLINICAL STRAINS
Faecal samples submitted by GP's and those from hospital in-patients were cultured
according to the standard operating procedure of the respective laboratory. Standard
procedures for C. difficile isolation were essentially identical at both diagnostic laboratories.
A pea-sized piece of faeces was spread on lysozyme CCEY or Brazier's CCEY agar (Lab M,
Bury, Lancashire, UK) which had the egg yolk omitted (modified CCEY). A similar amount
was placed into a 5ml bijou bottle containing 2ml of 80% alcohol and left for 1 h before
being plated out in a similar fashion. Incubation was performed at 37°C, in an anaerobic
cabinet (Don Whitley Scientific, Shipley, West Yorkshire, UK), with an atmosphere of 80%
N2; 10% H2 and 10% C02. Plates were inspected at 48 h, and single colonies resembling C.
difficile were picked off for purity on lysozyme CCEY or modified CCEY agar (Lab M,
Bury, Lancashire, UK), as well as full blood agar plates. Colonies resembling C. difficile on
purity plates and producing the characteristic 'elephant dung' odour were subcultured into
pre-reduced brain heart infusion (BHI) broth (section 2.4.1). After 48 h anaerobic
incubation, the broth was tested by cytopathic effect (CPE), for presence of cytotoxin (see
sections 2.4.3, 2.4.5). Isolates failing to produce cytotoxin were then further identified using
the RapID ANAII kit (Innovative Diagnostics Systems, Norcross, GA, USA), which were
used in accordance with the manufacturer's instructions.
2.4 TOXIN TESTING
2.4.1 Preparation from colonies
Single colonies, morphologically resembling C. difficile on CCEY agar (Lab M,
Bury, Lancashire, UK) were subcultured in Wasserman tubes containing 2ml ofpre-reduced
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BHI broth. These were then incubated in an atmosphere of 80% N2; 10% H2 and 10% C02
inside an anaerobic cabinet (Don Whitley Scientific, Shipley, West Yorkshire, UK) at 37°C.
After 48 h incubation, 0.5 ml of broth was removed and was centrifuged at 1200 x g for 10
minutes in a 1.5 ml eppendorf tube, before the supernatant was used for toxin testing.
2.4.2 Preparation from stool samples
Approximately 0.5g of faecal specimen was suspended in 2ml of phosphate buffered
saline (PBS) producing an effective dilution of 1 in 5. Liquid specimens were diluted to the
same degree. The well-mixed suspensions were then centrifuged for 10 minutes at 1200 x g.
If the supernatants were subsequently cloudy then they were filtered through a 0 .45 pm
millipore filter (Nalge, Rochester, NY, USA). The supernatants were then used for toxin
testing.
2.4.3 HEp-2 cell monolayer preparation and cytopathic effect test
All materials and media for cell culture were obtained from Life Technologies,
(Paisley, Strathclyde, UK) unless otherwise stated. Toxin testing was performed using
HEp-2 cell monolayers in 96 well microtitre trays. HEp-2 cells were first cultured in 25 cm
flat bottomed flasks, using basal medium (Eagle) without glutamine (BME). A 100ml bottle
of BME was supplemented with 5ml newborn calf serum, 1ml L-glutamine (200mM), 1ml
antibiotic/antimycotic agent (see below) and 1ml gentamicin (4 mg/ml) (Hoechst Marion
Roussel, supplied by pharmacy Leeds General Infirmary (LGI). The proprietary lOOx
antibiotic/antimycotic agent contained 10,000 units ofpenicillin, 10,000pg of streptomycin
and 25pg of amphotericin B per ml and 1ml was added to 100ml of BME.
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Once confluent growth was achieved, growth medium was decanted and the cell
layer was exposed to 5ml of a 2.5g/L solution of trypsin in Earle's balanced salt solution.
This solution was left to stand for one minute before being decanted and the flask then
incubated for approximately 15 minutes at 37°C. Once the cells had become detached they
were re-suspended in BME (with enrichments as above) and microtitre trays were inoculated
with the suspension. Test wells had 180pl dispensed into them, whilst control wells had
160pl, to allow for 20pl ofantitoxin to be added. After 2-3 days incubation aerobically, in a
wet box, at 37°C, confluent monolayers were obtained which could be used for cytopathic
effect (CPE) testing.
Tests were performed by adding 20pl of supernatant (see sections 2.4.1, 2.4.2) to
180pi of culture medium in a microtitre well. Supernatants were then stored at 4°C in case
further testing was subsequently required. All microtitre trays were controlled using a
known weakly positive cytotoxin containing filtrate in one well, no additions to one well,
and just antitoxin to another. Incubation of the microtitre trays was carried out in a
moistened box in a 37°C incubator. Inspection for CPE was carried out at 24 h and 48 h
unless otherwise stated. All supematants were simultaneously tested with C. sordellii
antitoxin (Pro-Lab Diagnostics, Neston, Cheshire, UK) protected controls. Positive results
were apparent as actinomorphic changes in cell structure comprising rounding and
detachment from each other. Greater than 50% of cells were required to have been affected
at or before 48 h for a result to be classified as positive. The changes also had to be
neutralised in the control well for the result to be accepted. In cases where non-specific toxic




Toxin titres were measured by carrying out serial dilutions from the original toxin
test well. Following addition of supernatant to a well and mixing, 20pi was removed and
added to the well vertically below (also containing 180pl of culture media). After mixing,
_gthe process was repeated for a total of 7 dilutions. This resulted in a final dilution of 2x10
(including the initial five-fold dilution of the faecal specimen). The toxin titre was expressed
as the reciprocal of this dilution. It should be remembered that even in the initial test well
there was a dilutional effect of lOx on the supernatant added.
2.4.5 Vero cell line culture
Vero cell culture was performed in a very similar fashion to HEp-2 cell culture,
except that some of the reagents used were different. The growth medium was Dulbecco's
modified Eagle medium, cell sheets were trypsinised with 0.5g/L trypsin/EDTA in Hank's
balanced salt solution and gentamicin was not added to the culture medium. In all other
respects, culture and passage of the cell line was carried out in the same manner as with
HEp-2 cells. Manipulation of Vero cell lines, prior to use for toxin tests was carried out in a
class II microbiological safety cabinet (Envair (UK) Ltd, Haslingden, Lancashire, UK).
Vero cell monolayers were used for C. difficile cytotoxin testing during the year 2000 and
thereafter, using the same procedures as for HEp-2 cells (see section 2.4.3).
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2.5 DEVELOPMENT OF C. difficile COLONISATION AND INFECTION IN
ELDERLY PATIENTS. FOLLOWING CEFOTAXIME (CTX) OR
PIPERACILLIN-TAZOBACTAM (PT) THERAPY
2.5.1 Study design
Initially, a randomised, double-blind pilot study was planned, and ethical approval
was obtained. Recruitment was extremely poor (one patient in six months), because most
eligible patients were found to be unable to give informed consent due to confusion and this
led to a change in study design. With ethical approval, the protocol was changed to a ward
crossover design without randomisation, so that individual patient consent would not be
required.
Patients on one elderly care ward (A), received intravenous (IV) cefotaxime (CTX),
lg tds when broad spectrum antibiotic therapy was deemed to be clinically required, as was
normal hospital practice. On a second, similar ward (B), IV piperacillin-tazobactam (PT)
4.5g tds was prescribed instead. Broad spectrum IV antibiotics were generally only
prescribed where clinical suspicion ofmoderate to severe sepsis of unknown origin was
high. No other changes were made to antibiotic prescribing protocols. Patients with a
history of penicillin allergy were given CTX instead of PT.
The two wards were of similar size (ward A, 32 beds, ward B, 28 beds) and had
comparable admission policy and patient mix. Screening in the 8 months prior to study
commencement indicated that ward B had twice the level of environmental C. difficile
contamination and the incidence of CDI was 47% greater than on ward A. Ward B was
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therefore selected for initial PT use in order to minimise bias in favour of PT. Study end
points were discharge or death. CDI was defined as documented loose stools (once or more
per day for at least two days), which was not attributable to another cause, in patients with
concurrent C. difficile cytotoxin-positive faeces. The initial aim was to study around 40
patients and then carry out analysis to determine whether or not it was worth continuing to
obtain larger numbers. Ward cross-over took place after 10 months instead of one year
because plans to move the wards became apparent. Following cross-over the wards were
moved to another location after only 4 months, due to a major hospital building
development. An analysis of results was performed at this time, and the study was
terminated due to ethical considerations. The plan for a change in ward location did not
become apparent until late in the study.
2.5.2 Study implementation
Any patient who was prescribed CTX or PT was eligible for study entry unless they
had previously been treated with one of those agents. A faecal specimen was obtained from
patients as soon as possible after the prescription of the study antibiotic, and then weekly
during their hospital stay where feasible. Records were kept of patient's daily maximum
temperature, nature and frequency of stools, biochemistry, haematology and microbiology
results, and all drugs received. Culture of stool samples for C. difficile was performed as
described in section 2.3. Cytotoxin detection and any further identification procedures were
performed as described in section 2.4.3 or 2.4.5.
Environmental contamination with bacterial spores was also monitored in order to
assess the relative risk of C. difficile exposure ofpatients on each ward. This was achieved
by swabbing certain environmental sites on each ward on a monthly basis (Fawley and
Wilcox, 2001). Sites selected were: floor of patient bays, floor of toilets, floor of sluices,
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commodes, radiators and air vents. The same sites on each ward were sampled each month,
by swabbing a 10cm x 10cm area, using a cotton swab moistened with 0.25% Ringer's
solution (Oxoid, Basingstoke, UK). Swabs were then cultured immediately onto modified
CCEY as well as into Robertson's cooked meat broth, and incubated anaerobically at 37°C
for 48 h. Sub-culture of broths was performed onto modified CCEY agar, as described in
section 2.3. All environmental and patient strains were fingerprinted using PCR
amplification of 16S-23S ribosomal RNA gene interspacer region (see section 2.7.2.3).
Two-tailed Fisher's exact probability and Mann-Whitney U tests were used for
statistical analyses of data.
2.6 COMPARISON OF THE OXOID TOXIN A TEST WITH CYTOTOXIN
DETECTION USING A CYTOPATHIC EFFECT METHOD
2.6.1 Sample preparation
As mentioned in section 2.2, previously tested, frozen stool samples were used in an
evaluation of the Oxoid Toxin A test (Unipath, Basingstoke, Hampshire, UK). Samples
were selected so that 50% were previously positive for C. difficile cytotoxin and 50% were
previously negative. Samples had been stored at -20°C since original CPE testing and were
tested immediately after thawing. All samples were from patients with diarrhoeal illness,
where no other infective cause was identified. The 100 samples were randomly arranged to
ensure that positives were indistinguishable from negatives. They were then thawed in
batches of 10 and roughly 0.5g was suspended in the kit diluent or in 2ml of PBS (see
section 2.4.2). The well-mixed suspensions were then centrifuged for 10 minutes at
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1200 x g, before being used for either the kit test (according to the instructions), or kept in a
refrigerator at 4°C (for < 30 min) until the CPE test was set up.
2.6.2 C. difficile culture and identification
In addition to testing for toxins A and B, each specimen was cultured for C. difficile
(see section 2.3) and isolates from CPE negative stool samples were tested for cytotoxin
production as described in section 2.4.3. Further identification was carried out ifnon-
toxigenic strains were encountered (section 2.3).
2.6.3 Oxoid toxin A test
The principle of the test is that monoclonal anti toxin A antibody, labelled with blue
latex particles, binds to any toxin A in the specimen when it is added to the sample well. The
complex diffuses along the test strip and is bound to an immobilised line of anti toxin A
monoclonal antibody, forming a blue line in a positive result. Immobilisation of unbound
latex particles occurs in a second window to indicate that diffusion past the test window has
occurred. The kit was used to test faecal specimens in accordance with the manufacturer's
recommendations. A I25pl volume of faecal supernatant was added to the sample window
of the test strip. This was left for 30 min and was then examined for evidence of a blue line
in the result window. Tests where the control window had a blue line and there was any sign
of a blue line in the result window were classified as positive.
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2.6.4 Cvtopathic effect test (CPE)
This test makes use of the cytotoxic nature of toxin B (see section 1.2.4.1.1). CPE
testing was performed using a HEp-2 or Vero cell line, as described in sections 2.4.3 and
2.4.5. Cell monolayers were examined for CPE at 4, 6, 24 and 48h, independently by two
individuals. CPE consisted of a discernible, neutralizable rounding-up of cells, often quite
subtle at 4h and sometimes 6h, but always affecting >10% of cells initially and >50% of
cells by 48h.
2.6.5 Toxin titre estimation
The supematants used for CPE testing in this study were frozen at -20°C
immediately after the cytotoxin test was set up. Cytotoxin titres in these samples were
determined after 4 weeks, due to time constraints at the time of initial cytotoxin testing. They
were tested for CPE neat (1 in 50 dilution) and at seven further 10-fold dilutions. The toxin
titre was designated as the reciprocal of the highest dilution which caused a readily
discernible, classical CPE at 48h (although in a few cases, at the highest dilution, these
changes did not quite affect 50% of the cell monolayer).
2.7 PCR TYPING AND TOXIN GENE DETECTION OF C. difficile
PCR toxin A gene detection was performed on 269 C. difficile strains using primers
NK9/NK11, described by Kato et al. (1998). Some strains were additionally tested using
primers described by Gumerlock et al. (1993), and Tang et al. (1994). Ribo-spacer (RS)
PCR typing of 54 C. difficile isolates from community patients was carried out using primers
described by Jensen et al. (1993) and randomly amplified polymorphic DNA (RAPD)
primers described by Killgore and Kato, (1994).
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2.7.1 Extraction of PIMA
Isolates of C. difficile were obtained from clinical specimens as described in section
2.3. Subculture was performed by picking a single colony from the selective medium and
culturing it on a non-selective medium, incubated under optimal conditions. A single colony
from the non-selective plate was transferred to the extraction solution using a sterile loop.
Culture of C. difficile strains that had been saved in broth was performed on selective and
non-selective media. Once a pure culture was obtained on non-selective medium, a single
colony was selected for extraction as above.
2.7.1.1 Boil extraction
A single colony was emulsified in 25pi of sterile water in a 0.5ml microcentrifuge
tube (Eppendorf-Netheler-Hinz-GmbH, supplied by Merck, Poole, Dorset, UK), giving a
slightly milky suspension. This was heated at 99°C for 10 minutes. New extractions were
performed for each PCR. If PCR was not being performed immediately, then the extract was
stored at -20°C.
2.7.1.2 Lysozyme and proteinase K extraction
25pl of lysozyme (0.1 mg/ml) in 0.1 M TR1S buffer (Tris base 0.53g/L, Tris HC1
0.88g/L, EDTA 0.37g/L) adjusted to pH 8.0, was placed in a 0.5 ml microcentrifuge tube
(Eppendorf-Netheler-Hinz-GmbH, supplied by Merck, Poole, Dorset, UK). A single colony
of C. difficile was emulsified in this, to give a slightly milky suspension. The tube was then
incubated for 10 minutes at 37°C, before 25pl ofproteinase K (0.1 mg/ml) in 0.1 M TRIS
buffer (as above) at pH 8.0 was added and the tube agitated to allow mixing. Incubation for
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a further 10 minutes at 37°C was followed by incubation for 10 minutes at 99°C to denature
the proteinase K and lysozyme.
2.7.2 Preparation of PCR pool (mastermix)
Preparation ofmastermix was performed in a clean area away from sites of bacterial
culture and DNA extraction to minimise potential for contamination. Aerosol resistant
pipette tips (Molecular BioProducts Inc., supplied by Merck, Poole, Dorset, UK) were used
for all PCR preparation steps. The mechanics ofpreparation were the same for all
mastermixes, although quantities ofprimer, tog polymerase and magnesium (MgCl2)
differed for each particular method. During mastermix preparation, sufficient was prepared
for all the PCR reactions required on that day. Ifany tubes of mastermix were not used, then
they were stored at -20°C, having been adequately labelled.
2.7.2.1 Toxin gene detection PCR (Kato)
For this PCR method, described by Kato et al. (1998), each 23pl aliquot of
mastermix contained 0.2pl primer mix (10 pmoles of each primer), l.Opl MgCl2 (2.0mM,
HT Biotechnology Ltd, Cambridge, UK), 2.5pi lOx Supertog reaction buffer (HT
Biotechnology Ltd, Cambridge, UK), 4pl dNTP mix (made up in sterile water for injection
from the Ultrapure dNTP set, Pharmacia Biotech UK Ltd, Little Chalfont, UK) yielding 1.25
mM of each dNTP, 0.2pl (1 unit) Supertog (HT Biotechnology Ltd, Cambridge, UK) and
15.1 pi sterile water for injection. Initial attempts at the method were made using Amplitaq
gold taq polymerase and buffer (Perkin Elmer Applied Biosystems, Bucks, UK), but this did
not produce reliable results and so Supertog and buffer (HT Biotechnology Ltd, Cambridge,
UK) were substituted. Late in 2000, new batches of Supertog (HT Biotechnology Ltd,
Cambridge, UK), were also found to be unreliable and so a ready-prepared l.lx mastermix
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(Abgene Ltd, Epsom, Surrey, UK) was used. For each PCRtube, 22.5pl of l.lx Master Mix
with 1,5mM MgCl2 (Abgene Ltd, Epsom, Surrey, UK), 0.2pl of primer mix (NK11-NK9)
and 0.3pl ofwater for injection were added, to bring the final volume to 23pi Again,
sufficient PCR pool was made up for all the reactions to be performed on that day and 23pi
aliquots were placed into 0.5ml microcentrifuge tubes ready for use. Once aliquots were
measured out, tubes were stored at -20°C until required.
2.7.2.2 Toxin gene detection (Cohen)
A multiplex PCR reaction to detect the presence of tedA and tccfB, as described by
Cohen et al. (2000) and using primers described by Gumerlock et al. (1993) and Tang et al.
(1994), was performed on two strains with unusual results from the Kato toxin gene
detection PCR. The PCR pool for this method contained 1.2pl primer mix (30 pmoles of
each primer), 1.25pl MgCl2 (2.5mM, HT Biotechnology Ltd, Cambridge, UK), 5.0pl lOx
Supertax reaction buffer (HT Biotechnology Ltd, Cambridge, UK), 6pi dNTP mix (made up
in sterile water for injection from the Ultrapure dNTP set, Pharmacia Biotech UK Ltd, Little
Chalfont, UK) yielding 0.94 mM of each dNTP, 0.4pl (2 units) Supertax (HT Biotechnology
Ltd, Cambridge, UK) and 34.15pl sterile water for injection, giving a 50pl reaction volume
(with the addition of 2pl template DNA).
2.7.2.3 16-23S ribosomal interspacer region (RS-PCR)
This method was described by Jensen et al. (1993) and 50pl reaction volumes were
used. There were 54 strains of C. difficile which were recovered from specimens sent for
testing by General Practitioners. Of these, 15 were from Leeds and 39 from Truro.
Mastermix was prepared and 48pl aliquots dispensed into 0.5ml microcentrifuge tubes
(Eppendorf-Netheler-Hinz-GmbH, supplied by Merck, Poole, Dorset, UK). Each 48pl
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aliquot contained 0.75pl primer mix (37.5 pmoles of each primer), 1.75pl MgCl2 (3.5mM,
HT Biotechnology Ltd, Cambridge, UK), 5.0pi lOx Supertax reaction buffer (HT
Biotechnology Ltd, Cambridge, UK), 8pl dNTP mix (made up in sterile water for injection
from the Ultrapure dNTP set, Pharmacia Biotech UK Ltd, Little Chalfont, UK) yielding 1.25
mM of each dNTP, 0.5pi (2.5 units) Supertax (HT Biotechnology Ltd, Cambridge, UK) and
32pl sterile water for injection.
2.7.2.4 RAPD PCR
RAPD PCR was used to determine whether community isolates demonstrating the
same profile as our endemic C. difficile strain (p24) were indeed identical or not. The
method was performed using primers described by Killgore and Kato, (1994). Reaction
volumes were once again 50pl, with each 48pl aliquot containing 1.5pi primer mix (25
pmoles of each primer), 1.5pl MgCl2 (3.0mM, HT Biotechnology Ltd, Cambridge, UK),
5.0pl lOx Supertax reaction buffer (HT Biotechnology Ltd, Cambridge, UK), 8pl dNTP mix
(made up in sterile water for injection from the Ultrapure dNTP set, Pharmacia Biotech UK
Ltd, Little Chalfont, UK) yielding 1.25 mM of each dNTP, 0.5pl (2.5 units) Supertax (HT
Biotechnology Ltd, Cambridge, UK) and 31.5pi sterile water for injection.
2.7.3 Preparation of the PCR reaction
To each 0.5ml microcentrifuge tube (Eppendorf-Netheler-Hinz-GmbH, supplied by
Merck, Poole, Dorset, UK) containing a mastermix aliquot was added 2pl of extracted
template DNA. This brought the reaction volume to either 25pl or 50pl, depending on
which method was being used. For toxin gene detection, boil extractions were adequate but
for RAPD and RS-PCR, lysozyme/proteinase K extractions were preferred. Each PCR series
was controlled with a reagent control (no target DNA added to mastermix), an extraction
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control (extraction buffer only added to mastermix) and an organism control (extract of
known of C. difficile strain added to mastermix). The control strain used was dependent
upon the particular PCR being performed. For toxin gene detection PCR, a toxin A+B+
strain, a toxin A-B+ strain (Bz 17) and a non-toxigenic strain were used. For RS and RAPD
PCR methods, our local endemic strain (p24) was used for reference. The reaction tubes
were then placed in the thermocycler (Techne Genius, Techne (Cambridge) Ltd, Duxford,
Cambridge, UK) and cycling conditions programmed according to which method was being
used. For toxin gene detection (Kato), cycling conditions were: one cycle at 94°C for 3 min
followed by 35 cycles of 95°C for 20 sec and 62°C for 2 min (two step only). Tubes were
then held at 4°C until the product was electrophoresed or frozen at -20°C. For toxin gene
detection (Cohen), cycling conditions were: one cycle at 94°C for 3 min followed by 40
cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec. For RS-PCR (Jensen),
cycling conditions were: one cycle at 94°C for 3 min followed by 34 cycles of 94°C for 1
min, 45°C for 1 min, 72°C for 1 min and finally one cycle of 72°C for 7 min. For RAPD
PCR (Killgore and Kato), cycling conditions were as follows: one cycle at 94°C for 3 min
followed by 35 cycles of 94°C for 1 min, 36°C for 1 min, 72°C for 2 min.
2.7.4 Optimisation of PCR reactions
The PCR reactions were optimised by performing magnesium titrations from 1 .OmM
to 3.OmM.
2.7.5 Detection of the amplimer
The PCR products were visualised following electrophoresis of a 15p.l aliquot, by
staining with ethidium bromide. For the toxin gene detection methods, where only one or
two bands were being detected, 2% (w/v) molecular biology grade agarose (Life
Technologies, Paisley, UK) was made with TAE buffer (Sigma-Aldrich Company Ltd,
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Poole, Dorset, UK) containing 0.2mg/L of ethidium bromide. For the PCR typing methods,
where numerous bands were produced, 2% (w/v) Metaphor™ agarose (Flowgen, Lichfield,
Staffs, UK) was made up with TBE buffer (Tris base 10.8g/L, orthoboric acid 5.5g/L, plus
4ml of 0.5M EDTA solution). The buffer was made up using distilled water and adjusted to
pH 8. The gels were stained for 10 minutes with ethidium bromide solution (0.5mg/L) after
electrophoresis. The stained gels were viewed with either a Chromato-Vue TM-20 UV
transilluminator (UVP, San Gabriel, CA, USA), when photographs were taken using a
Polaroid DS34 camera fitted with an orange (Wratten 16) filter and using Polaroid 667 film
or by using an ImageMaster VDS camera system (Pharmacia Biotech UK Ltd, Little
Chalfont, Bucks, UK). For interpretation purposes, AP-PCR profiles differing by 3 or more
bands were considered to be gentically distinct, whilst 2 or more bands difference was
adequate for RS-PCR (Cartwright et al. 1995).
2.7.5.1 Agarose gels
For the standard agarose gels, 60ml of TAE buffer (Sigma-Aldrich Company Ltd,
Poole, Dorset, UK) was used with 1,2g of agarose. A microwave oven was used to melt the
agarose, which was cooled to around 55°C before being poured into the 11 x 12.8cm gel tray
(Northumbria Biologicals Ltd, Cramlington, UK) which was sealed at both ends with
autoclave tape. One or two 16 well combs were used, allowing 14 or 28 reactions per gel (A
100 bp ladder was included in the first and last wells of each gel to allow sizing of the
product). The gel was allowed to set at room temperature and was then cooled to 4°C in a
refrigerator. On removal from the refrigerator, the combs were carefully removed followed
by the autoclave tape. The gel tray (Northumbria Biologicals Ltd, Cramlington, UK) was
then placed in the electrophoresis tank (Northumbria Biologicals Ltd, Cramlington, UK) and
TAE buffer (Sigma-Aldrich Company Ltd, Poole, Dorset, UK) added until the gel was
covered. Care was taken to avoid air bubbles remaining under the gel tray. The gel was
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placed with the wells nearest the anode end of the tank. Once in position, 15pi aliquots of
PCR product were loaded under the buffer, after having been mixed with xylene cyanol-
bromophenol blue loading dye (Helena Biosciences, Sunderland, UK). A 100 bp ladder
(Helena Biosciences, Sunderland, UK) was included at each end of the gel as mentioned
above. Electrophoresis was carried out at 250 Volts and 200 Amps for 45 min using an
E455 power pack (Flowgen, Lichfield, Staffs, UK) or an EPS 200 power pack (Pharmacia
Biotech UK Ltd, Little Chalfont, UK).
Some standard agarose gels were also made in a larger 14 x 23cm gel tray (Owl
Separation Systems, Portsmouth, NH, USA) allowing 25 large or 50 small wells per gel.
This enabled either 20 or 44 strains to be tested on one gel, as it had to be split into two for
staining, and required a ladder at both ends of each half, as well as the loss of one large or
two small lanes for cutting of the gel. The larger gels were made in exactly the same way as
the smaller ones but required 150ml ofTAE buffer (Sigma-Aldrich Company Ltd, Poole,
Dorset, UK) and 3g of agarose (Life Technologies, Paisley, UK). Electrophoresis was
performed in a large electrophoresis tank (Owl Separation Systems, Portsmouth, NH, USA)
with the same current and voltage as above. Large gels were cut in half between the two
central lanes containing 100 bp ladder, prior to staining, UV transillumination and
photography.
2.7.5.2 Metaphor"" gels
Metaphor™ (Flowgen, Lichfield, Staffs, UK) gels for the RS and RAPD PCR
methods were manufactured in a very similar way to the standard agarose gels mentioned
above. Significant differences were that cooled TBE buffer was used in their manufacture,
and the gel was kept at 4°C for a minimum of 30 min before use. Ethidium bromide was not
added to the gel during manufacture. Electrophoresis with these gels was performed using
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TBE buffer. Gels of both sizes were used. Gel loading was performed under buffer and the
electrophoresis was performed at 200 Amps, 180 Volts for 2-4 hours depending on the time




3.1 DEVELOPMENT OF C. difficile COLONISATION AND INFECTION IN
ELDERLY PATIENTS. FOLLOWING CEFOTAXIME (CTX) OR
PIPERACILLIN-TAZOBACTAM (PT) THERAPY
3.1.1 Clinical trial
Using the initially designed randomised controlled trial method, only one patient
was enrolled over a six-month period and it was decided to review the trial design. Under
the new non-randomised, ward crossover design, forty-eight patients were enrolled over a
14-month period. Of these, 34 received cefotaxime (CTX) and 14 piperacillin-tazobactam
(PT) (Table 8). The two groups were well matched for age (median 82 and 84.5 years, for
CTX and PT groups respectively), and primary diagnosis. The most frequent two diagnoses
in both groups were chest infection and stroke. The proportion of females in each group was
higher than that of males, but did not differ significantly between groups (23/34 (CTX) vs.
13/14 (PT), p= 0.13). Patients who received CTX had a significantly shorter total hospital
stay compared with the PT patients (median 33 (CTX) vs. 69 days (PT), p=0.04). However,
this was mostly accounted for by the length of stay before study entry (median 1 (CTX) vs.
11 days (PT), p=0.07). Duration ofhospital stay after study entry was similar in each group
(median 27.5 (CTX) vs. 34.5 days (PT), p=0.51). The total number of days before study
admission on which patients received an antibiotic did not differ significantly between
groups (117 (CTX, n=34) vs. 35 (PT, n=14), p=1.00), and antibiotic days in the 72h
immediately prior to study entry were also similar (20 (CTX, n=34) vs. 8 (PT, n=14),
p=0.93). (When patients were treated concurrently with more than one antibiotic, one day
was recorded for each antibiotic taken for a full day). The antibiotics most frequently
administered in the CTX group before study entry were ciprofloxacin, ampicillin and
erythromycin, compared with ampicillin, trimethoprim and cephradine in PT patients.
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Mortality rates in the two groups did not differ significantly (11/34 CTX vs. 3/14 PT,
p=0.44). Response to therapy was also similar (2/34 CTX vs. 1/14 PT had bacteriological
failure of therapy, p= 1.00).
Table 8: C. difficile colonisation and CDI before and after the crossover
on each ward

































































1 CTX = cefotaxime, PT = piperacillin-tazobactam.
2 Some patients on the ward using PT received cefotaxime due to penicillin allergy
3
Figures for C.difficile colonisation include patients with CDI.
Using Fisher's exact probability test, *p=0.001; tp=0.006
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Of 34 CTX patients, 26 were colonised with C. difficile during the study, of whom
18 developed CDI (Table 8). In the PT group, three of 14 patients were noted to be
colonised with C. difficile, ofwhom one developed CDI. There was a significant difference
between the groups for development of CDI (18/34 vs. 1/14 p=0.006) and for C. difficile
colonisation (26/34 vs. 3/14 p=0.001). Of the 18 CTX patients who developed CDI, 14 were
treated, 2 died of other causes (with diarrhoea), and 2 recovered spontaneously. The patient
who developed CDI after receiving PT did not receive specific treatment and the symptoms
resolved after 2 days.
In the 10 months before the crossover, 77% (17/22) of study patients on ward A
(CTX ) were found to be colonised by C. difficile, whilst 11 developedCDI. In contrast to
this, on ward B (PT), 20% (2/10) were discovered to be colonised by C. difficile and one
developed CDI. This represents a CDI incidence of 50% following CTX compared with
10% following PT. After the crossover, the incidence of CDI remained high (75%) on ward
A (now PT), in the patients who still received CTX (due to penicillin allergy), but was low
(0%) in those receiving PT. On ward B (now CTX), the C. difficile colonisation rate
increased from a previously low level of 20% to 71%. The incidence of CDI was 43% for
patients who received CTX (Table 8). During the study period, there was greater
consumption of oral cephalosporins (cephradine, 78 days and cefaclor, 19 days) in the CTX
group, usually as follow-on therapy, compared with in the PT patients (0 days). However, of
the 18 patients who developed CDI in the CTX group, seven received one of these
cephalosporins while 11 did not (p=0.76). Use of cephalosporins in the pre study period was
higher in the PT group. Overall, comparing patients who received cephalosporins other than
CTX either before or during the study, with those who did not, there was no significant
difference between the two groups in incidence of CDI (p=0.91).
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In 34% (10/29) of the patients colonised with C. difficile during the study, a culture-
and toxin-negative faecal sample had been obtained before any positive sample, implying
that the strains were hospital-acquired. Eight of these strains (80%) were the endemic strain
(p24). For the 19 patients whose initial sample was C. difficile positive, molecular typing
methods (see section 2.7 and its subsections) showed that the strain First isolated was
identical to strain p24 in 74% (14/19), and a non-endemic strain in 26% (5/19) of cases.
Figure 1 demonstrates discrimination between endemic and non-endemic strains. For
patients whose first sample was positive by culture or toxin detection, the average length of
time from admission until collection of the specimen was 6.6 days (median 6 days).
Figure 1: Genotypic typing using RS-PCR, demonstrating patient isolates
with endemic (p24) strain pattern and another genotypically
distinct pattern (by kind permission of Warren Fawley)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
bp
bp
lanes 1-2, 4-8, 10, 15-16: endemic strain pattern
lane 3: endemic pattern with other bands also (suspected mixed extract used)
lane 9: 100 bp ladder
lanes 11-14: genotypically distinct strain pattern
<— 1000
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The average time until collection of the first specimen for those patients who were initially
culture and toxin negative, but subsequently positive, was 6.5 days (median 6 days). The
length of time until C. difficile acquisition in patients with initially negative samples was
15.5 days on average (median 13.5 days). Amongst the 6 who developed CDI, time to
acquisition was on average 12 days (median 10.5 days). For C. difficile colonisation average
time to acquisition was 20.75 days (median 17 days). On the two wards overall, CDI rates
were almost identical over a 22 month period, 9.2 and 8.9 cases per 100 admissions for
wards A and B respectively. This period included the 8 months before the study as well as
the study period.
Environmental screening over the 22 month period resulted in 1122 swabs being
processed, with 572 from ward A and 550 from ward B (Fawley and Wilcox, 2001). Over
the whole period, 34% of sites on ward A and 36% of sites on ward B were positive. In the 8
months prior to study commencement, ward B was more heavily contaminated with C.
difficile (average of 26% vs. 13% of sites positive). In the first 10 months of the study,
contamination rates increased on both wards, averaging 56% of sites (from 13%) on ward A
(CTX) and 40% of sites (from 26%) on ward B (PT). In the last 4 month period (after
crossover), average environmental C. difficile contamination rates were 31% on ward A (PT)
and 38% on ward B (CTX). Despite the general increase in environmental contamination on
both wards during the first study period, the degree of change was highly significant on the
ward using CTX (13% to 56%, p=<0.0001, ward A) but not significant on the ward using PT
(26% to 40% p=0.17, ward B). Additionally, there was a significant decrease in
environmental contamination on ward A after changing from CTX to PT, from 56% (over 10
months) to 31% (over 4 months) of sites positive (p=0.03). There was no significant
difference in environmental contamination levels between the two wards either before
(p=0.16), during the first 10 months (p=0.08) or the last 4 months of the study (p=0.84)
(Table 9).
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Table 9: Environmental contamination with C. difficile on the two wards
before and during the study (averaged over time stated)
% COLONISED SITES
LOCATION BEFORE FIRST STUDY SECOND STUDY
STUDY PERIOD PERIOD
(8 MONTHS) (10 MONTHS) (4 MONTHS)
Ward A (CTX then PT) 13%a 56%a'° 31 %D




All probabilities in table calculated using two-tailed Fisher's exact probability test
a Change in colonisation rate from before study to first study period p=<0.0001
b
Change in colonisation rate from first to second study period p=0.03
0 Change in colonisation rate from before study to first study period p=0.17
6 Change in colonisation rate from first to second study period p=1.00
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The strains isolated from either ward environment demonstrated 6 different DNA
fingerprints, with the endemic strain (p24) accounting for 93% of isolates. Figure 2 shows a
comparison between some of the distinct patient and environmental strains with strain p24.
This strain accounts for most sporadic cases ofCDI at this hospital. C. difficile with the
endemic DNA fingerprint was isolated from 22/29 patients. In ten patients, non-endemic
strains were recovered during the study, although in three cases this was following previous
isolation of the endemic strain.
Figure 2: RS-PCR of environmental and patient isolates, demonstrating
some genotypically distinct strains, with p24 control (by kind
permission of Warren Fawley)
1000 bp
500 bp
lane 1: strain p24 control
lanes 2,3,4: genotypically distinct patient isolates
lane 6: 100 bp ladder
lanes 5,7,8,9: genotypically distinct environmental strains
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3.2 COMPARISON OF THE OXOID TOXIN A TEST WITH CYTOTOXIN
DETECTION USING A CYTOPATHIC EFFECT METHOD
3.2.1 Toxin testing
Ofthe 100 samples tested, fifty-four were CPE negative and 46 were CPE positive.
Two of the CPE positive samples, which were also found to be toxin A test positive, had
been CPE negative when originally tested. There were also six of the originally positive
samples that were found to be CPE negative in this study, although one was toxin A test
positive. This specimen, was culture positive with a toxigenic strain of C. difficile, and was
classified as a true positive. Therefore, for the purposes of specificity and sensitivity
determination, 47 samples were true positives, and 53 were true negatives.
At 4h incubation the CPE test showed 26 positive results, with 21 false negatives
(sensitivity 54%) and 5 false positives (specificity 90%). At 6h incubation the CPE test
showed 32 positive results, with 15 false negatives (sensitivity 67%) and 3 false positives
(specificity 94%). At 24h incubation the CPE test showed 44 positive results, with 3 false
negatives (sensitivity 92%) and no false positives (specificity 100%). At 48h incubation the
CPE test showed 46 positive results, with one false negative (sensitivity 98%) and no false
positives (specificity 100%).
The Oxoid Toxin A kit demonstrated 37 positive results, ofwhich 3 were false
positives (specificity 94%). Negative results were recorded for 63 specimens, of which 13
were false negatives (sensitivity 72%). One of the samples which was toxin A test positive
had no detectable toxin B by CPE (it was originally CPE positive and was included as one of
the 50 positive specimens). Sensitivities and specificities were calculated using the CPE
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result at 48h as the gold standard, with the addition of the above-mentioned toxin A test
positive/CPE negative specimen as a true positive (see Tables 10 and 11).
There was a high degree of correlation (100% agreement at 48h) between the two
individuals who read the CPE test. At 6h one investigator (the more experienced of the two)
identified 3 more positive specimens than the other investigator. One of these proved to be a
false positive.
3.2.2 C. difficile culture
All 46 CPE positive samples were C. difficile positive by culture, as well as the six
samples that were negative on CPE testing in this study, but were previously CPE positive.
One of these six samples was toxin A test positive. In addition, eight specimens that had
originally been CPE negative and were again negative in this study, were C. difficile culture
positive. Of these eight strains, all but one was toxigenic by CPE testing of culture filtrate.
In summary, C. difficile was isolated from 50 (100%) of the originally CPE positive stool
samples and from 10 (20%) of the originally CPE negative stool samples.
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Table 10: Sensitivity and specificity of CPE test for toxin B at various time
intervals and for Oxoid toxin A test
CPE at incubation false test false test sensitivity (%) Specificity (%)
times (h) negatives positives
4 21 5 54 90
6 15 3 67 94
24 3 0 92 100
48 1 0 98 100
Oxoid toxin A test 13 3 72 94
Table 11: Results for Oxoid toxin A test and toxin B detection by
cytopathic effect at 48 hours
Oxoid toxin A test CPE +ve CPE -ve
Positive 33 4*
Negative 13 50
*One of these specimens was classified as a true positive
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3.2.3 C. difficile toxin B titres in faecal supernatants
After storage of faecal supernatants at -20°C for 4 weeks, C. difficile toxin B titres
(calculated as the reciprocal of the stool filtrate dilution) were found to range between
1 8
2x10 and at least 2x10 . In seven supernatants that were previously CPE positive, no toxin
B was detected at this time. None of the samples that had been CPE negative 4 weeks earlier
had positive toxin titres. There were 11 samples with toxin B titres >2x104 and all were
toxin A test positive, although not all toxin A positive samples had titres above this level.
One toxin A test positive sample had a toxin B titre of only 2X101. Toxin A negative
samples had toxin B titres of between 2xlOJ and 2xl04.
3.3 PCR TYPING AND TOXIN GENE DETECTION OF CLOSTRIDIUM
DIFFICILE
3.3.1 Problems encountered with reagents
When toxin gene determination of C. difficile strains from Leeds and Bradford was
first attempted, the results were rather mixed. The first attempts followed the method
previously described by Kato et al. (1998) and were made using Amplitaq gold taq
polymerase and buffer (Perkin Elmer Applied Biosystems, Bucks, UK). This yielded no
detectable product, and it was not apparent whether inadequate extraction or amplification
was the problem (see figure 3). Using the lysozyme/proteinase K extraction method, but
PCR reagents from a colleague who had previously been successful with the method, both
the 1200 bp product and 700 bp were demonstrated (see figure 4).
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Figure 3: Initial result of Kato PCR, with no detectable products
100 bp ladder at each end of the gel
Figure 4: Gel using Kato PCR reagents that had previously been used
successfully, showing two distinct products (only run for 30 min)
1 2 3 4 5 6 7
lanes 1,7: 100 bp ladder
lanes 2,4: A+B+ control strains
lane 3: A-B+ strain
lane 5: non-toxigenic strain
lane 6: negative control
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Evidently, the previous problem was not due to failure of extraction and so the reason for the
failure in amplification had to be found.
Perkin Elmer had provided two different PCR buffer solutions and so the alternative
buffer was tried. This resulted in the production of 1200 bp fragments from A+B+ strains,
but no 700 bp product could be detected from A-B+ strains (see figure 5). The strain used as
non-toxigenic in fact proved to be toxigenic on CPE testing, after the PCR result showed a
1200 bp product. This was due to an incorrectly labelled stock sample. A magnesium
titration was performed in case amplification of the 700 bp product was being prevented by a
sub-optimal MgCl2 concentration (see figure 6). Alternative extraction methods did not
improve results, nor did using the primer that had worked adequately in the earlier
experiment (figure 4) to demonstrate whether extraction was working.
Finally a comparison of two different taq polymerases with appropriate PCR buffer
(Amplitaq gold taq polymerase (Perkin Elmer Applied Biosystems, Bucks, UK) and
Supertax (HT biotechnology Ltd, Cambridge, UK)) was performed with other reagents being
the same. Despite some non-specific bands, the 1200 bp and 700 bp products were detected
with the new taq polymerase but only the 1200 bp product was seen with the old taq
polymerase (see figure 7). Work then continued satisfactorily with the new brand of taq
polymerase (see figure 8).
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Figure 5: Results of Kato PCR using Amplitaq gold taq polymerase (no
products with standard buffer, lanes 2-6; 1200 bp product but
no 700 bp product using Amplitaq gold buffer, Ianes7-10)
1 23456789 10 11
lanes 1,11: 100 bp ladder
lanes 2,7: A+B+ strains
lanes 3,8: A-B+ strains
lanes 4,9: presumed A-B- strains
lanes 6,10: negative controls
Figure 6: Kato PCR gel demonstrating magnesium titration with no
700 bp products seen
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
lanes 1,8,15: 100 bp ladder
lanes 2-4: 1mM MgCh
lanes 5-7: 1.5mM MgCI2
lanes 9-11 2.0mM MgCI2
Ianes12-14: 2.5mM MgCI2
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Figure 7: Kato PCR gel showing results with Superfag (lanes 1-5) or
Amplitaq gold taq (lanes 7-11)
Lanes 1,5,7,9: negative controls,
lanes 2,8: A+B+ strain,
lanes 3,9: A-B+ strain,
lanes 4,10: A-B- strain.
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Top lanes: lane 1: negative control
lane 2: A-B+ control strain
lane 3 A-B- control strain
lane 4: A+B+ control strain
lanes 5,7,13: A-B- test strains
lanes 6,9,10,11,12,14,15: A+B+ test strains
lane 8: 100bp ladder
Bottom lanes: lane 1,11: A-B+ control strains
lane 2: A-B- control strain
lanes 3,4,5,7,8,9,10,12: A+B+ test strains
lane 6: 100 bp ladder
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After a break of several months in performing the PCR testing, new taq polymerase
(from the same manufacturer whose product was working previously) was obtained in order
to continue. Unfortunately, the 700 bp fragment could not be detected when using the A-B+
control strains. Extraction methods and reaction volumes were adjusted, but without
success. After performing another magnesium titration, a faint 700 bp band was just
discernible, but the band was much stronger with the original batch of taq polymerase (see
figure 9). Note that a faint band is also seen at 1200 bp in the A-B+ control sample with the
old taq, suggesting contamination with a fully toxigenic strain. Two alternative taq
polymerases (one as a ready-made mastermix, Abgene Ltd, Epsom, Surrey, UK) were tried,
with successful results using both boil and lysozyme/proteinase K extractions (see figure 10)
The ready-made master mix (Abgene Ltd, Epsom, Surrey, UK) was then used for the toxin






Figure 9: Kato PCR with original taq (top lanes 14,15 (neg controls) and
bottom lanes 10-14) demonstrating strong 700 bp band visible
when compared to very faint 700 bp bands using new taq (top
lanes 2-13, bottom lanes 2-9, 15)
Top Strain Mg2* Bottom Strain Mg2*
Lanes cone" lanes cone"
1 ladder 1 ladder
2 A-B+ 1.5mM 2 A+B+ 1.5 mM
3 A-B+ 1,5mM 3 A-B+ 2.5mM
4 A-B+ 1.5mM 4 A+B+ 2.5mM
5 A+B+ 1.5mM 5 A+B+ 3.0 mM
6 A+B+ 2.0mM 6 A-B+ 3.0 mM
7 A-B+ 2.0mM 7 A-B+ 3.0 mM
8 A-B+ 2.0mM 8 A-B+ 3.0 mM
9 A-B+ 2.0mM 9 A+B+ 3.0 mM
10 A+B+ 2.0mM 10 A+B+ 1.5mM
11 A+B+ 2.5mM 11 A-B+ 1.5mM
12 A-B+ 2.5mM 12 A-B+ 1.5mM
13 A-B+ 2.5mM 13 A-B+ 1.5mM
14 neg control 14 A+B+ 1.5mM
15 neg control 15 empty
16 ladder 16 ladder
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Figure 10: Kato PCR with two new taq polymerases to demonstrate




1 100 bp ladder
2 neg control Promega
3 A+B+ control Promega
4 A-B+ control Promega
5 A+B+ test strain Promega
6 A-B+ control Promega
7 neg control Promega
8 A+B+ test strain Promega
9 A-B+ control Abgene mastermix
10 A+B+ control Abgene mastermix
11 neg control Abgene mastermix
12 A-B+ control Abgene mastermix
13 A+B+ test strain Abgene mastermix
14 A+B+ test strain Abgene mastermix
15 empty
16 100 bp ladder
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Figure 11: Demonstration of 1400 bp product using Kato PCR




Ianes1,24: 100 bp ladder
lane 2: A-B+ control
lane 3: A+B+ control
lane 4: A-B-control
lane 5: neg control
lane 7: 1400 bp product from strain 72
lane 8: strain 72 (boil extract)
lane 18: extraction failure
other lanes: A+B+ test strains
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3.3.2 Toxin gene detection
Out of the 269 strains of C. difficile that were tested for presence of the toxin A
gene, all possessed either the toxin A gene or neither gene, with no toxin A negative, toxin B
positive strains being detected. The PCR findings were confirmed by culture and toxin
testing by CPE. All 9 toxin negative strains were found to produce no product on PCR
(Kato) for toxin A gene. The identity of each of these strains was confirmed to be C. difficile
by RapID ANAII kit (Innovative Diagnostics Systems, Norcross, GA, USA).
Because only St James's University Hospital (SJUH) carried out culture for C.
difficile as a routine diagnostic measure, rates of non-toxigenic carriage for patients with
diarrhoea could only be estimated from 103 samples. There were 8 non-toxigenic C. difficile
strains detected, representing 7.8% of the total number of strains from SJUH. One non-
toxigenic strain was also identified amongst the other 166 strains tested. Testing colonies of
this isolate on several occasions by PCR (Kato, Gumerlock or Tang) produced no toxin gene
products. It is of interest that the CPE test of the stool sample from which this non-toxigenic
strain was isolated was positive. On further investigation, a strain of C. difficile which
generated toxin B in broth culture and produced a 1200 bp product on toxin gene PCR
(Kato) was also detected in this sample.
One of the strains positive for toxin B by CPE testing produced a PCR toxin gene
product (Kato) of approximately 1400 bp, rather than the expected 1200 bp. This finding
was reproducible and not felt to be a non-specific phenomenon (See figures 11 and 12).
When alternative toxin gene detection primers (Gumerlock, Tang) were used, the correct size
products were generated, demonstrating that both toxin genes were present (See figure 13).
This strain was also found to produce toxin A, detectable by the Oxoid toxin A test.
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Figure 12: Confirmation of 1400 bp product from strain 72 by Kato PCR



























1/100 dilution of A+B+ extract (no product)
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Figure 13: Cohen PCR for tcdA and tcdB, showing correct size products
for strain 72






lanes 1,8: 100 bp ladder
lane 2: A+B+ control strain
lane 3: A-B+ control strain
lane 4: negative control
lane 5 A-B- control strain
lane 6: strain 72
lane 7: A-B- test strain
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3.3.3 Typing PCR
PCR profiles of all the community strains were obtained using RS-PCR, previously
described by Jensen et al. (1993). Notable differences were demonstrated when the Leeds
isolates were compared with those from Truro. Amongst 15 isolates from community
patients in Leeds, nine (60%) produced an identical RS-PCR profile (<2 bands difference) to
that of the hospital endemic clone in Leeds (strain p24). In contrast, out of 33 toxigenic
isolates from community patients in Truro, only five (15%) showed this PCR profile (see
figure 14). To further clarify whether or not these strains were indeed the same as strain p24,
RAPD PCR was carried out on all those with identical RS-PCR profiles to that strain (see
figure 15). This demonstrated that all nine strains from Leeds were identical (< 3 bands
difference) to strain p24 (see figure 16), whilst none of the strains from Truro were identical
(3 or more bands different). This difference in the incidence of p24 between populations is
highly significant (p= <0.0001).
Culture and toxin B testing of the community strains by CPE confirmed that all
those from Leeds were toxigenic, however these samples had been selected on the criterion
oftoxin B positivity. Of 39 strains from Truro, 33 (85%) were found to be toxigenic. The
rate of non-toxigenic C. difficile isolation (15%) from Truro community patients was higher
than the rate of isolation from either Leeds hospital patients (7.8%, p>0.05, <0.10), or elderly
admissions to Leeds General Infirmary (12%, Settle et al. 1999). However, these differences
do not reach statistical significance.
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strain p24 (RAPD profile)
Leeds strain (non p24)
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Figure 15: RAPD PCR gel showing that the five Truro strains which had











Truro strains which had identical RS profiles to p24
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Figure 16: RAPD PCR gel of Leeds community isolates, which had
identical p24 like RS profiles, to confirm their identity, (their
RAPD profile was confirmed as identical to that of strain p24 on
another gel) (by kind permission of Warren Fawley)
lane 9: 100 bp ladder
lanes 2,3,6,7,8,11,12,14,16: Leeds strains with p24 RAPD profile




4.1 THE SIGNIFICANCE OF CLOSTRIDIUM DIFFICILE INFECTION
Over the last two decades, the number of cases of CDI being reported have increased
sharply (see 1.5.3). Although greater awareness and reporting is likely to account for part of
this increase, CDI itself appears to be more common within hospitals and a genuine increase
in incidence seems to have occurred. Development of CDI has been shown to prolong
patients' hospital stay (Wilcox et al. 1996) and cause additional morbidity, so an increase in
the number of cases must be taken seriously. Amongst hospital patients, the elderly account
for the majority of CDI cases. Consequently, it is reasonable to concentrate on this group
when trying to find ways of reducing the risk of developing CDI. It is clearly important to
optimise the diagnosis of CDI as well as to find ways of reducing the risk of the infection.
Furthermore, an improved understanding of the epidemiology of the pathogen may enable
better strategies for managing CDI to be developed. In particular, a more comprehensive
understanding of how the infection is spread may allow appropriate preventive strategies to
be formulated.
4.2 AETIOLOGY OF CLOSTRIDIUM DIFFICILE INFECTION
Much is already known about the aetiology of CDI, and as previously outlined in
sections 1.5.3.1 and 1.5.3.3, elderly, hospitalised patients are at the highest risk. Antibiotics
are thought to be the most important factor that renders patients susceptible to CDI, with
clindamycin and 'third generation' cephalosporins likely to be the most incitory agents (see
1.3.2.3 and subsections). It was therefore decided to compare the incidence of CDI and C.
difficile colonisation in elderly patients who had received either cefotaxime (CTX) or
piperacillin-tazobactam (PT) for the treatment of serious infection.
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4.2.1 Findings of the clinical trial
The initial attempt at a randomised, double blind, prospective study was
unsuccessful, due to the difficulty in obtaining consent for trial entry. This was because
most of the patients suitable for study entry were confused and did not have relatives with
them who could give consent. This study was redesigned so that consent was no longer
required. However, this meant that no rectal swab could be taken at study entry and so the
carriage rate of C. difficile for patients at the time of admission could not be precisely
calculated. Instead, a stool sample was collected as soon as possible after hospital
admission. Inevitably this was sometimes several days after admission and when positive
results were then obtained it was no longer possible to determine when the organism had
been acquired. Asymptomatic carriage of C. difficile amongst elderly patients admitted to
our hospital has previously been shown to be approximately 12% (Settle et al. 1999). This
equates to an expected number of 6 patients in our study group being colonised with C.
difficile at the time of admission. As 29 patients (60%) were found to be colonised during
their hospital stay, it seems likely that most of them acquired the organism in hospital rather
than being colonised prior to admission. This theory is supported by the observation that the
proportion of environmental isolates found to be the endemic strain (93%) is higher than the
proportion of patient isolates shown to be the same strain in this study (76%). Nevertheless,
it should be noted that the median time until a first specimen was collected amongst patients
who were initially negative was the same as for those who were initially positive at 6 days.
Futhermore, in patients who were initially negative, the median period of time to C. difficile
acquisition was 13.5 days. This tends to suggest that patients whose first sample was
positive at 6 days might still have acquired the organism before admission to the study ward.
If this were the case, it would correspond to a rate of colonisation on admission of 39.6%
(19/48). This is far in excess of the 12% figure, previously generated from a larger number
of elderly admissions to this hospital. These patients were screened on admission, during the
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same time period. The possibility that such a large proportion of the patients in the study
may have been colonised on admission, might be accounted for if they had recently been
hospitalised before admission to the study ward. Alternatively, perhaps the relatively small
number ofpatients involved biases the figures.
In this hospital the great proportion of cases of CDI in elderly patients (>80%) are
caused by one 'endemic' strain, designated p24. The overall incidence of CDI in this
hospital has been high during the late 1990's, due to the organism being endemic on many
wards. The policy of using 'third generation' cephalosporins for the treatment of elderly
patients has done nothing to reduce this burden.
There was no significant difference between patient groups with respect to age, sex
distribution, diagnosis on study admission or quantity of antibiotics taken before study entry.
Although there was a difference between the types of antibiotics taken before study entry by
the patients of each group, PT patients may have been at greater risk ofCDI because of this.
Those receiving PT had received more cephradine prior to study entry, which may be
expected to be more likely to lead to CDI than the ciprofloxacin which CTX patients had
received more frequently (see 1.3.2.3.2 and 1.3.2.3.4). Ideally, patients would only have
been considered for study entry if they had received no antibiotic within the previous 10
weeks, however enforcing this condition would have ruled out most potential patients, so a
more realistic criterion had to be accepted. Consequently, the total amount of antibiotic
received by patients before study entry was noted along with a record ofwhich antibiotics
were taken. According to current understanding of susceptibility to CDI following receipt of
antibiotics (see 1.3.2.3 and subsections), if one group was at greater risk than the other of
developing CDI on study entry, it was the PT group. Use of cephalosporins other than CTX
was more prevalent overall in the CTX patients, primarily because of follow on therapy
(usually cephradine). However, analysing the receipt of non-study cephalosporins revealed
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no significant increase in the subsequent likelihood of developing CDI. This serves to
emphasize that the risk of CDI following cefotaxime is probably much greater than the risk
after cephradine, because although a relatively small number ofpatients was studied, there
was a highly significant effect following cefotaxime, whilst cephradine use did not correlate
with subsequent CDI.
The most interesting finding of the study is that patients who received CTX had a
significantly greater risk of subsequent C. difficile colonisation and CDI than did patients
who had received PT. The relative risk ofCDI in CTX treated patients was 7.4 (95% CI=
1.7-33) compared with those who received PT. The odds ratio (OR) for CDI in CTX treated
patients compared with those who received PT was 14.6 (CI= 1.7-124.7) and the number
needed to treat (NNT) to avoid one case of CDI was 2.18.
It is perhaps unexpected that PT is less likely to induce C. difficile colonisation or
CDI than CTX, given its broad-spectrum activity, particularly against anaerobes. This
observation may cast doubt on the theory that the anaerobic gut flora is a critical determinant
of'colonisation resistance' (see section 1.3.2.1). Alternatively, the relative C. difficile
sparing effect of PT may reflect the limited penetration ofthis antibiotic into the gut lumen
in some patients. Of 20 patients given PT, when sampled on one occasion during treatment,
six had detectable faecal concentrations ofpiperacillin, ofwhom four had measurable levels
of tazobactam, using a relatively insensitive antibiotic detection method. The effect on
anaerobic flora was noted to be minor, with anaerobic Gram-positive cocci and Bacteroides
sp. being unaffected (Nord et al. 1992). Alternatively, it may be because piperacillin and
tazobactam are secreted in bile at the incorrect relative proportions that PT is not as active as
would theoretically be expected. A report by Westphal et al. (1997), indicates that rather
than the 8:1 ratio present in serum, bile concentrations of piperacillin and tazobactam are on
average approximately 50:1. It should be noted that biliary levels of piperacillin and
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tazobactam in the 15 subjects studied did vary considerably (Westphal et al. 1997).
Conversely, as C. difficile is more susceptible to PT than CTX, it may be that the organism is
more likely to be killed in PT treated patients. Data on the gut levels of PT in patients
receiving the drug remain fairly limited. Preliminary in-vitro data using C. difficile
inoculated faeces spiked with either PT or CTX, or taken from antibiotic treated patients, do
not demonstrate a difference in the growth of C. difficile. (Freeman and Wilcox, 2000). One
possible explanation for the difference in rates of CDI following CTX or PT therapy is that
CTX is metabolised to an active compound, desacetylcefotaxime (Wise et al. 1980); (Jones
et al. 1982). This metabolite has also been shown to interact synergistically with cefotaxime
against many organisms, including enterobacteriacae and Bacteroides fragilis. These
findings are extensively reviewed by Jones, (1995). Not only is desacetylcefotaxime an
active metabolite with an antimicrobial activity and spectrum greater than the 'second
generation' cephalosporins, it has been shown to exceed cefotaxime concentrations in bile
(Novick, 1982). Consequently, it will be secreted into the bowel along with cefotaxime and
possibly interact in a synergistic fashion against bowel flora.
It is also of interest that patients who developed CDI did not have significantly
longer hospital stays, which is in contrast to some earlier findings (Wilcox et al. 1996).
However, the explanation for this could be that as patients in the PT group had longer in
hospital prior to study admission than their counterparts in the CTX group, they might have
been more severely ill. No formal assessment of severity of illness was made in this study
and such a factor should be controlled for if length of stay of patients in each group is to be
properly compared. That patients in the PT group were in hospital longer before study entry
than those in the CTX group would also be expected to leave them more susceptible to C.
difficile acquisition.
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One important factor, which has not been controlled for in earlier work (Anand et al.
1994); (de Lalla et al. 1989), is exposure to C. difficile spores in the environment. By
monitoring the environmental contamination of each ward on a monthly basis, it was
possible to determine whether increased ward contamination was leading to an increase in
cases of CDI or vice-versa. At the outset, the ward with the greater environmental load of C.
difficile was chosen for the PT group, so that these patients were not favoured in any way.
Despite this, and the other factors mentioned above, which might have resulted in the PT
group being at higher risk of developing CDI, it was the CTX group who demonstrated the
highest incidence of C. difficile colonisation and CDI in the first 10 months of the study.
Environmental contamination on the CTX ward increased significantly (p=<0.0001) but not
on the PT ward (p=0.17), subsequently falling after the cross-over from CTX to PT (p=0.03)
but not after the cross over from PT to CTX (p=1.00). If the incidence of CDI were purely to
reflect environmental contamination, then the rate ofCDI on ward A after changing from
CTX to PT should have remained high instead of falling significantly. Higher rates of CDI
in patients receiving CTX compared with PT, when patients are assumed to have had
equivalent exposure to C. difficile also indicates an effect of antibiotic rather than of
environment.
A further factor pointing to the role antibiotics in driving CDI, rather than
environmental contamination, is that during the study, the ward which used CTX always
started off as the cleaner of the two and became the most contaminated during the period of
CTX use. Conversely, the ward which used PT always commenced as the more
contaminated of the two and became the cleanest whilst using PT.
One alternative explanation for the greater degree of CDI on a ward when using
cefotaxime would be if the ward population (herd) were generally more susceptible to CDI
due to an overall greater use of antibiotics. It is noticeable that not as many patients received
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PT as did CTX over the study period. If this led to an increased 'herd' susceptibility, then
the number of cases of CDI on the ward using CTX (in patients not enrolled in the study)
should be greater than in the same group on the PT ward. Therefore the overall incidence
rate of CDI should be higher on ward with the poorest 'herd immunity'. In fact, the overall
incidence rate ofCDI was very similar on both wards, being slightly higher on ward A,
which used CTX for the 10 month period (9.2 versus 8.9 cases per 100 admissions). This is
in contrast to a slightly higher overall environmental contamination on ward B (34% versus
36% of sites over 22 months). Despite the overall incidence rate ofCDI being so similar on
both wards, CDI in those who had received PT was very uncommon. This suggests that it is
specifically the patients who received PT and not all patients on the ward who have a
reduced risk of developing CDI (which may explain the lower rate of CDI on ward B, in the
face of greater environmental contamination).
The decision to end the study was taken when the wards were due to be relocated,
because data analysis at this time showed a marked difference in C. difficile colonisation and
more importantly infection rates. It was therefore considered unethical to continue using
cefotaxime for treating elderly patients. Clinical response to treatment with CTX or PT was
similar, as might be expected in such patients, considering the spectra of the two antibiotics.
Although the study was neither blinded nor randomised, we are confident in the accuracy of
our findings given the absence of significant, identifiable confounding factors and the
objective measurements of C. difficile colonisation and infection used. Furthermore,
randomisation was found to be impractical because of the confused elderly patient cohort
under investigation.
The adoption of a block cross-over design rather than individual randomisation is a
weakness, as environmental factors such as 'herd immunity' and environmental
contamination with spores can differ between wards. Similar CDI incidence rates between
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wards coupled with environmental screening for spores serve to minimise the deficiencies of
the model used. Nevertheless, a more detailed statistical analysis of the data, using logistic
regression methods would perhaps have added further weight to the findings. Using such a
technique would have allowed the interrelationships between several risk factors to be
investigated and determine more accurately the contribution of factors such as environmental
contamination to the development of CDI.
Starr and colleagues recently speculated that the selective pressure resulting from
cephalosporin prescribing might increase the proportion of C. difficile susceptible patients in
a ward or unit (Starr et al. 1997). In this setting administration ofnarrow spectrum
antibiotics, with otherwise relatively low propensities to select for C. difficil,e may
subsequently induce symptomatic infection. Alternatives to cephalosporins, for example the
combinations ofpenicillin and either trimethoprim (McNulty et al. 1997) or ciprofloxacin
(Jones et al 1997) for the empirical antibiotic treatment of infection have been shown in
uncontrolled studies to be associated with a reduced incidence of CDI. Guidelines for the
treatment of community-acquired pneumonia, a common cause ofhospital admission in the
elderly, cite cephalosporins, including cefotaxime, as antibiotics of choice for severe as
opposed to mild-moderate infections (British Thoracic Society, 1993). These guidelines
were implicated in the increased incidence ofCDI in a department of medicine for the
elderly (Impallomeni et al. 1995). However, it should be noted that there was some evidence
that incidence of CDI was on the increase before the introduction of the BTS guidelines
(Wilcox, 2000).
In the light of current beliefs regarding the use 'third generation' cephalosporins and
risk of subsequent CDI, it may not have been justified to carry out the study based on the
null hypothesis that risk was equal for both antibiotics. If independent monitoring of the
study outcome had been performed, then any early indication of highly significant
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differences in risks between groups could have been obtained. This may have allowed an
earlier end to the study and reduction in any excess risk to patients.
PT may serve as a useful alternative antibacterial agent to 'third generation'
cephalosporins for the treatment of elderly patients. If the enormous apparent difference
between the incidence ofCDI following treatment with either CTX or PT is confirmed by
use on larger numbers ofpatients, analysis suggests that only 2-3 patients would require
treatment with PT rather than CTX to avoid a case ofCDI.
4.3 DIAGNOSIS OF CLOSTRIDIUM DIFFICILE INFECTION
Although the generally accepted gold standard test for C. difficile toxin B detection
is using CPE methodology, facilities do not always exist to perform this method and many
manufacturers have produced kits to allow more widespread availability of C. difficile toxin
B testing. Many of these tests are ELISA based (see section 1.4.3.3), and can give results in
2-4h, however attempts have been made to further simplify the testing procedure and reduce
the time taken to obtain a result. One recent test of this type is the Oxoid Toxin A test
(Unipath, Basingstoke, Hampshire, UK), the principle ofwhich is described in section 2.6.3.
This test is designed to be very straightforward to perform, with a minimum of additional
equipment required (centrifuge capable of 9800x g), and produces a result in around 30 min.
For small laboratories, with low numbers of specimens to be tested for C. difficile toxin, this
type of test represents a more practical solution than CPE or ELISA methods. Analysis of
the performance of such new tests is important to determine their role in the diagnosis of
CDI.
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4.3.1 Performance of the Oxoid toxin A detection kit
In this comparison of the the Oxoid Toxin A test (Unipath, Basingstoke, Hampshire,
UK) and CPE testing for toxin B using HEp-2 cells, the rapid test (sensitivity 72%,
specificity 94%) was similar in accuracy to the CPE method at 6h (sensitivity 67%,
specificity 94%). These figures are at odds with those published by Bentley et al. (1998),
which were used by Oxoid for their kit insert (83 .1% sensitivity and 96.9% specificity,
resolved to 91% and 98% respectively). In resolving the figures, cytotoxin positive but toxin
A negative faecal samples were reclassified as true negatives if culture for C. difficile was
negative. However, as the CPE testing was controlled with C. sordellii antitoxin, positive
results would indicate the presence of C. difficile or C. sordellii regardless of whether culture
was positive. It is extremely unlikely that 10% of positive results could occur due to C.
sordellii as this is not commonly isolated from faeces (presence of C. sordellii toxin in stool
specimens has not been descibed). Failure to grow C. difficile from the specimen should not
be grounds to reclassify the toxin A result as a true negative rather than a false negative and
doing so would serve to improve the sensitivity ofthe test in question. Detection oftoxin A
is not expected to be as sensitive as toxin B detection, due to the difference in sensitivity
between the two methods. Toxin B is extremely potent and can cause a cytopathic effect at
concentrations as low as a few pg/ml, whereas the threshold for toxin A detection kits is in
the ng/ml range (Lyerly et al. 1988).
Two other issues arising from the CPE testing methods in this study and in that of
Bentley et al. should be noted. Firstly, in the method used by the author, HEp-2 cell lines
were used for toxin B detection. This cell line has been reported to be inferior to others by
some researchers (Murray and Weber, 1983), although direct comparisons with Vero cells
are lacking. Vero cells have been shown to be the most sensitive for toxin B detection when
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compared with other cell lines (Maniar et al. 1987); (Torres et al. 1992), although there is
some evidence that human foreskin fibroblasts are also very sensitive (Tichota-Lee et al.
1987). Consequently, the results of the CPE testing in the author's study may have favoured
the Oxoid Toxin A test (Unipath, Basingstoke, Hampshire, UK) when compared to the
method used by Bentley et al. Secondly, the final dilution of stool filtrate in the author's
CPE method is 1 in 60, compared with 1 in 160 for Bentley et al. This could result in some
reduction in sensitivity for the CPE method, as used by Bentley et al., allowing a greater
chance of false negative results. Perhaps this may explain in part (along with their method of
resolving discrepant results) the poor sensitivity of the CPE method in their hands.
The overall performance of the Oxoid Toxin A test (Unipath, Basingstoke,
Hampshire, UK) in this study is not adequate for it to be recommended for the primary
diagnosis of CDI. If used for diagnostic purposes, then testing of repeat specimens would be
advisable in cases with negative results where the patient remains symptomatic. It should
also be emphasised that there are increasing numerous reports of toxin A negative, toxin B
positive (A-B+) clinical isolates of C. difficile, and these will not be detected by toxin A kits
(see 1.2.4.1.7). Brazier reported that C. difficile A-B+ isolates account for 3% of the total
number of strains received from laboratories (but 10% of the strains submitted from one
laboratory) in England and Wales by the Anaerobe Reference Laboratory (see section 1.5.4).
In Japan, 33% of isolates collected in one hospital were of this phenotype (Kato et al. 1997).
As A-B+ isolates of C. difficile have been recovered from symptomatic patients (Brazier et
al. 1999a); (Kato et al. 1997); (Sambol et al. 1998); (Sambol et al. 2000), previously held
beliefs that toxin A is the most important toxin in the pathogenesis of human antibiotic
associated diarrhoea must be called into question.
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4.3.2 Toxins A and B in stool specimens
The great majority of C. difficile strains are thought to produce equimolar quantities
of toxins A and B. The observation that one sample was toxin A test positive, but CPE test
negative is not likely to be due to differential toxin production, but possibly to unequal rates
of breakdown ofthe two toxins, as toxin B is known to be more labile than toxin A (see
section 1.2.4.1.1). The culture results indicate that it is possible for a toxigenic strain of C.
difficile to be present in a sample and yet toxins A and B remain undetectable. This may be
explained in several ways. Degradation of toxins in the faecal sample may occur prior to
testing due to proteolytic enzymes. Alternatively, toxins may not be produced if the patient
is being treated for CDI with either metronidazole or vancomycin, or in the presence of
inhibitory bowel flora. Theoretically, this effect could also be seen if the sample contained
only C. difficile spores in small numbers.
It is also of interest to consider whether the level of toxin B present in a sample
indicates the likelihood of detecting toxin A. Although not absolute, there does seem to be
some correlation between the level of toxin B in a sample and the likelihood of toxin A being
detected. As stated earlier, it is assumed that both toxins are produced in equimolar
quantities originally by the organism. The greater stability of toxin A to several
environmental factors (Borriello et al. 1992b); (Sullivan et al. 1982) may result in it
remaining at higher levels in a stool sample than toxin B. Consequently, although the
detection methods for toxin A are roughly 1000 times less sensitive than those for toxin B, it
is possible that toxin A could be detected at the same time as very low levels of toxin B.
Most of the time, however, this will not be the case and samples with low toxin B titres will
not have detectable levels of toxin A present. The author's findings do support this theory,
because no sample which had a toxin B titre of greater than 104 was toxin A negative.
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Correlation between levels of toxin B in stool samples and detection of toxin A by ELISA
have been demonstrated previously by some investigators (Lyerly et al. 1983), but others
have found no such link (Borriello et al. 1992).
The tendency of toxin B levels to fall in samples that are frozen and then thawed
(Lyerly et al. 1986b) is confirmed by the author's observations from this study. Toxin B in
stool filtrates appears to deteriorate more readily than when it is in stool specimens. The fact
that some samples had no detectable toxin but did contain toxigenic organisms suggests that
culture of toxigenic organisms alone from a sample may not automatically justify the
treatment of a patient for C. difficile infection.
4.4 EPIDEMIOLOGY OF CLOSTRIDIUM DIFFICILE INFECTION
C. difficile is known to be a ubiquitous environmental organism which is particularly
associated with the hospital environment. Despite widespread exposure to this organism, it
is not commonly found in the gastrointestinal tract ofnormal adults. However, at the
extremes of age, or after normal bowel microflora is compromised, C. difficile can readily
colonise the bowel and may lead to disease. Some strains of C. difficile are non-toxigenic
and not thought to cause disease, whilst other strains are frequently associated with CDI in
hospital patients. One clone in particular (PCR ribotype 1), accounts for the majority of
isolates from hospital patients (57%) sent to the PHLS Anaerobe Reference Unit, Cardiff
PHL (see section 1.5 .4). The next most frequently isolated strain (ribotype 15) accounts for
only 5% of isolates.
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In addition to allowing the detection of outbreaks ofCDI, epidemiological
investigation also detects trends in the particular C. difficile strams causing disease. When
strains such as ribotype 1 are identified, further research can proceed to determine what
enables them to cause disease so readily. Ribotype 1 (p24) displays several characteristics
which may distinguish it as more virulent than average. It is known to sporulate more
readily on exposure to detergents (Wilcox and Fawley, 2000) and has been found to be more
resistant to antibiotics than other strains tested (Freeman and Wilcox, 2001). These
properties may imbue upon it a survival advantage, both in the bowel and in the
environment. It is preferable to study the strains that cause most disease, comparing them
with those which do not, to try to determine what factors are most important in the
pathogenesis of CDI. Monitoring the level of environmental contamination in high-risk
hospital areas is also valuable as it can indicate when additional cleaning programmes may
be required.
A second epidemiological issue that is currently of increasing importance is the
prevalence of A-B+ strains. Increases in the number of such strains are of great interest
because of the potential for missing cases of CDI if tests that detect only toxin A are used for
diagnosis. Currently these tests detect the terminal repeat region of the toxin A molecule,
which is absent in the mutant strains. Redevelopment of toxin A only tests might be one
way of addressing the problem, but otherwise, methods which include toxin B detection
should be used for diagnosis of CDI. By monitoring the prevalence of these A-B+ strains, it
is possible to determine how safe current toxin A only tests are in a particular area.
Although CDI in hospitals accounts for most cases recorded at present, there is
currently increasing interest in the burden of disease in the community. This is not
particularly well described (see section 1.5.3.2), despite the large quantities of antibiotics
which are prescribed by General Practitioners. The level of undiagnosed CDI in UK
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community patients is not known and research into this area remains to be done. Another
interesting challenge is to discover whether CDI in the community is caused by the same C.
difficile strains that affect hospital patients. Furthermore, a comparison of community strains
that cause disease in different parts of the country could add an extra dimension to our
understanding of this pathogen in the UK.
4.4.1 Toxin gene determination of C. difficile from Leeds and Bradford
No A-B+ strains were detected out of the 269 that were tested (which included 5
community isolates). All toxigenic strains tested were noted to produce a PCR product
(Kato) and all non-toxigenic strains were found to produce no PCR product. As mentioned
in section 1.5.4, the reported incidence ofA-B+ in the UK is 3%, although from one hospital
10% of isolates typed were A-B+ strains. It would appear, therefore, that the level of A-B+
strains in Leeds and Bradford is below the national average. Based on results from SJUH, the
incidence ofnon-toxigenic strain isolation amongst C. difficile positive stools was 7 .8%.
Because little is published about such rates comparison is difficult. One non-toxigenic strain
was detected from a specimen that was toxin B positive and this was found to be due to a
mixture of two strains in the sample. As the sample had been initially found to be toxin B
positive when tested in the diagnostic laboratory, it seems unlikely that the toxigenic strain
was a later contaminant. Furthermore, the non-toxigenic strain was the more prevalent in the
sample and would also appear not to be a contaminant. Samples containing more than one
strain of C. difficile are not thought to be common (O'Neill et al. 1991) but have been
described (Sharp and Poxton, 1985).
One strain of C. difficile was found, in a reproducible fashion, to yield a PCR
product of-1400 bp rather than the expected 1200 bp. It produced toxin B when tested by
CPE and toxin A was detected using the Oxoid toxin A test. Consequently, the product is
likely to be genuine, because if the band seen was merely non-specific, a normal 1200 bp
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band should still be found representing the presence of the normal toxin A gene. PCR for
tcdA and tcdB as described by Cohen el al. (2000) demonstrated products of the expected
size for each gene. Further investigation of this strain is warranted, as the larger product
produced may indicate an insertion occurring in the terminal repeat region of the toxin A
gene.
4.4.2 Typing of community C. difficile isolates
Currently, research into the prevalence of CDI in community patients has only been
relatively limited (see section 1.5.3.2), although estimates of asymptomatic C. difficile
colonisation rates in community patients have been made by some UK researchers (Samore
et al. 1994); (Settle et al. 1999). Another large UK study suggested that there may be a large
number of community cases who never even present to their GP's (Wheeler et al. 1999).
One prospective Swedish study reported that 28% of CDI in hospitals was of community
origin (Karlstrom et al. 1998). Analysis ofwhether strains causing CDI in community
patients differ from those causing such illness in hospital patients forms another integral part
of epidemiological research. In addition to this, knowledge ofwhether the strains that cause
disease in the community differ depending on location is also of interest. The PHLS
Anaerobe Reference Unit, CardiffPHL has noted that amongst community strains they have
tested, the relative frequencies of strains found are different to those amongst hospital strains
(see section 1.5.4).
The comparison of C. difficile strains from community patients in Leeds, with strains
from similar patients in Truro, was intended to demonstrate whether similarities exist
between C. difficile isolates causing CDI in different communities. The opportunity to
compare isolates from an urban setting with those from a rural one was ideal and the findings
raise some interesting questions. The rate of colonisation with non-toxigenic strains of 15%
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is similar to rates previously reported in elderly patients (see section 1.5.2.2.1.3). Ofmore
interest, is the complete lack of strain p24 (described as ribotype 1 by Stubbs et al. 1999)
amongst the toxigenic isolates from Truro, whilst it represents 60% of those from Leeds (p=
<0.0001). Although the sample size of the Leeds cohort is small and therefore susceptible to
bias, it is consistent with the high level of p24 which is thought to cause disease in Leeds
hospitals (>80% of C. difficile isolates from patients with CDI on two care of the elderly
wards). Nevertheless, this is a different picture to that noted by Brazier, (1998b) amongst
390 community isolates when very few ribotype 1 isolates were detected. In order to be
more certain ofwhether the finding is genuine, a greater number of strains from Leeds
require testing. Ifthe finding is representative of the situation in Leeds, then it is perhaps
merely a reflection of the exceedingly high burden of strain p24 within Leeds hospitals,
which then disseminates out into the community. In one study, 82% ofpatients who were
noted to have C. difficile in hospital were still positive for the organism at discharge
(McFarland et al. 1989). Rather than having acquired it in the community, Leeds patients
may have only recently been discharged from hospital and still be carrying the organism in
their intestine. Ribotype 1 (p24) is also known to be the most common strain isolated from
patients with CDI in the UK (see section 1.5.4). The complete absence ofp24 amongst the
strains from Truro suggests that it is an uncommon strain there, ifpresent at all.
Nevertheless, a similar and possibly related strain does account for the greatest quantity of a
single strain found in Truro (13%, 5/39). This strain has the same RS-PCR pattern as p24,
but is recognised as being distinct from it by RAPD PCR. It is noticeable that amongst
Truro isolates there is no individual strain that predominates to the same degree that p24
does in Leeds. Perhaps the rural nature ofthe area has prevented the dissemination of this
otherwise widespread and prevalent clone.
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4.5 CONCLUSIONS AND FURTHER WORK
4.5.1 Aetiology of C. difficile infection
Antibiotics undoubtedly play an important contributory role in the development of
CDI. Some antibiotics would seem to be more hazardous in this respect than others and
'third generation' cephalosporins, along with clindamicin appear to pose the greatest risk.
As elderly patients are identified as one of the most susceptible patient populations for CDI,
it is reasonable to consider alternative antibiotic policies for the management of serious
infection, which minimise the use of such agents. More than one approach is valid in this
respect, but the use of PT in this setting can be considered as one option, given the findings
of this report. Despite greater expense, it is possible that a large reduction in the number of
patients developing CDI, with consequent reduction in length of stay would go a long way to
balancing this out. In addition, any reduction in morbidity and mortality would represent an
increase in the quality of care delivered to the patient.
Further work is required to try and confirm the findings of this report and this might
be accomplished by attempting to alter prescribing habits on elderly care units, whilst
monitoring C. difficile colonisation and CDI rates, along with environmental contamination
levels. Provided that the patient population being treated did not change over time and nor
did prescribing patterns of other drugs, then a reduction in CDI and C. difficile colonisation
with the new prescribing policy could confirm the findings of this study (see below). Levels
of environmental contamination should also be similar when comparing historical records
with the beginning of the new prescribing policy period. This would ensure that a lower
infection or colonisation rate was not due to lower levels of environmental contamination.
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If the environmental load of C. difficile was seen to fall after introduction of a new
antibiotic policy, then this might represent several possibilities:
1. The new policy resulted in patients being less susceptible to developing CDI or C.
difficile colonisation and so there was less environmental soiling due to fewer cases of
disease. The environmental load of C. difficile would then diminish after the reduction
in cases of disease.
2. The new policy resulted in lesser excretion of C. difficile in those individuals with
disease, although they were not any less susceptible to disease and the number of cases
was not lower. The reduction in the environmental burden would then be followed by a
decline in the number of cases of disease.
3. An outbreak was in progress before the change of policy that resolved at the same time
that the new policy was instituted.
One alternative way of testing whether the findings of this study are accurate would be
to repeat a similar type of study, with larger numbers ofpatients in each arm. However, this
type of study might be deemed unethical in the light of current beliefs regarding the
relationship of'third generation' cephalosporins with the development of CDI.
Consequently gaining ethical approval may prove impossible.
Ifpatients could be cared for in a standardised environment (probably a single room),
with the same initial level of environmental C. difficile, then likelihood of developing CDI
should only relate to the antibiotic received. Regular monitoring of the environmental
burden of C. difficile could be used to assess the degree of C. difficile excretion. This would
allow a direct comparison of environmental C. difficile levels when patients who were given
either PT or CTX developed CDI. It may also be necessary to measure antibody responses
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in patients , to try and get an indication of their ability to resist development of disease in the
presence of C. difficile toxins.
4.5.2 Diagnosis of C. difficile infection
New diagnostic tools are always being developed in medicine, to try and allow
easier and faster diagnosis of illness. It remains important for such new methods to be
independently evaluated, to ensure that they are appropriate for the use that they have been
designed for. The author's evaluation of the Oxoid toxin A test suggests that it is not
sufficiently sensitive to be used as a single test for the diagnosis of CDI. Nevertheless, due
to its relative ease of use and its self-contained design it may be useful in some laboratories
where cell tissue culture is not possible or where very low numbers of samples require to be
tested. However, if a negative result is obtained in a situation where clinical evidence
strongly suggests the diagnosis of CDI, then it would be wise to treat the patient as such and
retest a further specimen. If the local level ofA-B+ strains is known to be very low then a
further negative result would be highly suggestive of an alternative aetiology. If level of A-
B+ strains is high, or unknown, then it would be sensible to select a test which includes the
ability to detect toxin B as well as toxin A.
4.5.3 Epidemiology of C. difficile infection and colonisation
With the recent recognition of A-B+ strains of C. difficile, capable of causing
disease, it is important to know what the local level of such a pathogen is. This will allow an
informed decision about which tests should be used to diagnose CDI. In addition, screening
for such isolates may identify strains with other mutations in the toxin A and B gene region,
which could subsequently throw further light on the structure and function of these toxins.
This investigation has detected a strain that may have a mutation in the toxin gene region as
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it produced a product larger than expected by toxin gene PCR (Kato). Toxins A and B were
detected by traditional methods, and PCR for tcdA and tcdB, described by Cohen et al.,
demonstrated products of the correct size. Further evidence that the product is indeed
specific to the toxin gene region being tested for, could be obtained by using a probe of a
known section ofthe expected product to hybridise with it. The probe would be labelled to
allow its subsequent detection. If the PCR product was confirmed as being from the correct
region, then analysing its nucleotide sequence and comparing this with the corresponding
sequence from a type strain could clarify whether an insertion was present and what its
identity was.
The proportion of community p24 strains isolated from Leeds patients is interesting
and suggests recent hospitalisation or a high degree of environmental contamination with
this strain in the community. However, to be more certain that this observation is accurate,
larger numbers of isolates need to be tested. The marked difference in strain types from the
Truro community patients, with no highly prevalent single clone and p24 not represented at
all, may indicate the natural state in this country if contamination from patients who have
been hospitalised is avoided. In order to investigate this further it would be useful to use gel
documentation systems to better identify exactly how many distinct individual strains are
present, as it is not possible to test every strain against every other one manually. In addition
it may be useful to allow a reference facility such as the PHLS Anaerobe Reference Unit to
ribotype the strains to find out whether any are previously undocumented.
Obtaining strains from the local hospitals in the Truro area, both from the
environment and from patients, would also be very valuable in trying to determine the
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SUMMARY
Background: Rates of Clostridium difficile diarrhoea have
recently been rising, with the elderly being at highest
risk.
Aim: To compare the incidence of C. difficile colonization
and diarrhoea in elderly patients treated for presumed
infection with either empirical cefotaxime (CTX) or
piperacillin-tazobactam (PT).
Methods: A prospective, ward-based, crossover study was
carried out on two well-matched care of the elderly
wards at a UK tertiary care hospital, in patients requiring
empirical broad-spectrum antibiotic treatment.
Results: There was a highly significant increased
incidence of C. difficile colonization (26/34 vs. 3/14,
P = 0.001) and diarrhoea (18/34 vs. 1/14,
P = 0.006) in patients who received CTX as opposed
to PT. DNA fingerprinting suggested that most infec¬
tions arose from strains acquired from the hospital
environment.
Conclusions: Elderly patients are significantly less likely
to develop C. difficile diarrhoea after treatment with PT
than after CTX. The source of C. difficile appears to be
predominantly from the ward environment.
INTRODUCTION
Clostridium difficile has been recognized as the cause of
pseudomembranous colitis for 20 years, and is current¬
ly the principal infective cause of hospital-acquired
diarrhoea.1, 2 Laboratory reports of C. difficile continue
to increase, with a 32% increase in numbers in England
and Wales between 1996 and 1997.3 Infection usually
occurs following antibiotic therapy, particularly in
elderly patients.2 It is thought that broad-spectrum
antibiotics alter the balance of normal aerobic and
anaerobic intestinal flora, thereby reducing 'coloniza¬
tion resistance' and allowing C. difficile to proliferate.4
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In order to develop C. difficile diarrhoea (CDD), patients
need to be susceptible to infection, and also to be
colonized by or to acquire C. difficile. The source of
C. difficile in sporadic cases of infection is unclear, being
possibly patient (endogenous) strains, or exogenous
bacteria acquired either directly from the hospital
environment or via healthcare staff.3_/ In some hospital
settings 'endemic' strains of C. difficile exist, which
account for the great majority of both sporadic and
outbreak infections.8 These may occur due to differen¬
ces in the environmental distribution, transmissibility or
virulence of C. difficile strains.
Retrospective studies have shown that third-generation
cephalosporins such as cefotaxime (CTX) or ceftriaxone
are particularly associated with CDD.9-11 Some data
indicate that anti-pseudomonal penicillins, with or
without beta-Iactamase inhibitors such as clavulanic
9 1998 Blackwell Science Ltd 1217
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acid or tazobactam, may have a reduced propensity to
induce CDD compared with third-generation cephalo¬
sporins.9' 10, I2' '! However, to date there have been no
prospective studies, controlled for exposure to C. difficile,
which directly compare two broad-spectrum antibiotic
agents, in order to determine their influence on the risk
of developing CDD. A recent survey of UK hospitals
identified that the percentage of units which had ward
closures or a change of antibiotic policy due to C. difficile
infection increased by 3-fold and > 5-fold, respectively,
between 1993 and 1996.14 Preventative measures
which are proven to be effective are required to reverse
the increasing incidence of nosocomial C. difficile infec¬
tion. In the present study we compared colonization with
C. difficile or development of CDD in elderly patients
treated with either CTX or piperacillin-tazobactam (PT),
using a ward crossover design.
METHODS
The study took place between June 1996 and August
1997 on two care of the elderly wards at the General
Infirmary at Leeds. Ethics committee approval was
originally obtained for a randomized, double-blind pilot
study. As it was found that most eligible patients were
unable to give informed consent, recruitment was
extremely poor (one patient in 6 months). Therefore,
with ethics committee approval, the protocol was
changed to a ward crossover design without random¬
ization, so that individual patient consent would not be
required. Patients on one ward (A) received intravenous
(i.v.) CTX 1 g t.d.s. when broad-spectrum antibiotic
therapy was required, as had been normal practice
before the study. On the second ward (B). i.v. PT 4.5 g
t.d.s. was prescribed instead. No other changes were
made to antibiotic prescribing protocols. Patients who
had a history of penicillin allergy were given CTX
instead of PT. The two wards were of similar size (ward
A, 32 beds, ward B, 28 beds) and had comparable
admission policies and patient mix. Screening in the
8 months prior to the start of the study indicated that
ward B had twice the level of environmental C. difficile
contamination and that the incidence of CDD was 47%
greater than on ward A. Ward B was therefore selected
for initial PT use in order to minimize bias in favour of
PT. Study end-points were discharge or death. CDD was
defined as documented loose stools (once or more per
day for at least 2 days), which was not attributable to
another cause, in patients with concurrent C. difficile
cytotoxin-positive faeces. After 10 months, ward-based
antibiotic therapy crossed over so that PT was used on
ward A and CTX on ward B. After a further 4 months
the study wards were due to be re-sited as part of a
major hospital building development. We were unaware
that this move was to take place until late in the study.
At this point an analysis of the results was performed
and the study was terminated due to ethical consider¬
ations (see below).
A faecal specimen was obtained from each patient as
soon as possible after the prescription of the study
antibiotic, and then weekly during the patient's hospital
stay, where feasible. Records were kept of the patients'
maximum daily temperature and the nature and
frequency of stools, biochemistry, haematology and
microbiology results, and all drugs received. Culture oi
stool samples for C. difficile was performed by plating
onto cycloserine-cefoxitin-egg yolk (CCEY) agar (Lab M,
Bury, UK) and incubating anaerobically at 37 °C for
48 h. Suspect C. difficile colonies were identified by
characteristic colonial morphology and odour before
being tested for toxin B production by a microtitre tray
cytotoxin assay using HEp-2 cells with C. sordellii
antitoxin control wells. Suspect non-toxigenic isolates
were identified using the RapID ANAII identification kit
(Innovative Diagnostics Systems, Norcross, GA).
Environmental contamination with bacterial spores
was also monitored in order to assess the relative risk ol
C. difficile exposure of patients on each ward. This was
achieved by monthly, standardized swabbing of pre¬
selected sites, incubating the samples in Robertson's
cooked meat broth at 37 °C for 48 h, before sub-culture
to CCEY agar and re-incubation at 37 °C for 48 h. All
environmental and patient strains were fingerprinted
using PCR amplification of 16S-23S ribosomal spacer
DNA. Briefly, target DNA was extracted using lysozyme
and proteinase K.15 Oligonucleotide primers and reac¬
tion conditions were based on those reported by Jensen
et al.1 h Two-tailed Fisher's exact probability tests and
Mann-Whitney U-tests were used for statistical analyses.
RESULTS
Forty-eight patients were enrolled; 34 received CTX and
14 PT (Table 1). The two groups were well matched for
age (median 82 and 84.5 years for CTX and PT groups,
respectively) and primary diagnosis. The two mosl
frequent diagnoses in both groups were chest infection
and stroke. The number of females in each group was
© 1998 Blackwell Science Ltd. Aliment Pharmacol Ther 12, 1217-1223
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higher than the number of males, but did not differ
significantly between groups (23/34 vs. 13/14,
P = 0.13). The patients receiving CTX had a signifi¬
cantly shorter total hospital stay compared with the PT
patients (median 33 vs. 69 days, P = 0.04), but this
was mostly accounted for by the length of stay before
study entry (median 1 vs. 11 days, P = 0.07). Duration
of hospital stay after study entry was similar in each
group (median 27.5 vs. 34.5 days, P = 0.51). Total
antibiotic days before study admission did not differ
significantly [117 (n = 34) vs. 3 5 (n = 14).
P = 1.00], and days of antibiotics in the 72 h immedi¬
ately prior to study entry were also similar [20 (n = 34)
vs. 8 (n = 14), P = 0.93]. (When patients were treated
concurrently with more than one antibiotic, one day was
recorded for each complete day per antibiotic.) The
antibiotics most frequently administered in the CTX
group before study entry were ciprofloxacin, ampicillin
and erythromycin, compared with ampicillin, trimetho¬
prim and cephradine in the PT patients. Mortality rates in
the two groups did not differ significantly (11/34 CTX vs.
3/14 PT, P = 0.44). Response to therapy was also
similar (2/34 CTX vs. 1/14 PT had bacteriological failure
of therapy, P = 1.00).
Of 34 CTX patients. 26 were colonized with C. difficile,
of whom 18 developed CDD (Table 1). In the PT group,
three of 14 patients were colonized with C. difficile, and
one of these developed CDD. There was a significant
difference between the groups for development of CDD
(18/34 vs. 1/14, P = 0.006) and for C. difficile coloni¬
zation (26/34 vs. 3/14, P = 0.001). Of the 18 CTX
patients who developed CDD, 14 were treated, two died
of other causes (with diarrhoea), and two recovered
spontaneously. The patient who developed CDD after
receiving PT did not receive specific treatment and the
symptoms resolved after 2 days. Before the crossover,
77% (17/22) of study patients on ward A (CTX) were
colonized by C. difficile (of whom 11 developed CDD),
whilst on ward B (PT) 20% (2/10) were colonized by
C. difficile (of whom one patient developed CDD). This
represents a CDD incidence of 50% in patients who
received CTX vs. 10% in patients who received PT. After
crossover, on ward A (now PT), the incidence of CDD
remained high (75%) in the patients who still received
CTX (due to penicillin allergy), but was 0% in the
patients given PT. On ward B (now CTX), the C. difficile
colonization rate increased from 20% to 71% with a
CDD incidence of 43% in patients who received CTX
(Table 1). During the study there was greater consump¬
tion of oral cephalosporins (cephradine, 78 days and
cefaclor. 19 days) in the CTX group, usually as follow-
on therapy, compared with the PT patients (0 days).
However, of the 18 patients who developed CDD in the
CTX group, seven received one of these cephalosporins
while 11 did not (P = 0.76). Overall, comparing
patients who received another cephalosporin before or
during the study with those who did not, there was no
significant difference between the two groups in inci¬
dence of CDD (P = 0.91).
Environmental screening in the 8 months prior to the
start of the study showed that ward B was more heavily
contaminated with C. difficile (26% vs. 13% of sites
positive). In the first 10 months of the study, contam¬
ination rates increased on both wards, reaching 56% of
sites (from 13%) on ward A (CTX) and 40% of sites
(from 26%) on ward B (PT). In the last 4-month period
environmental C. difficile rates were 31% on ward A
(PT) and 38% on ward B (CTX). Despite the general
increase in environmental contamination on both
wards during the first study period, the difference was
highly significant on the ward using CTX (13% to 56%,
P < 0.0001, ward A) but not significant on the ward
using PT (26% to 40%, P = 0.17, ward B). Also,
there was a significant decrease in environmental
Table 1. C. difficile colonization and CDD before and after the crossover on each ward
Before crossover After crossover Totals
Ward* A B A B A +BA + B
Number of patients! 22 (CTX) 10 (PT) 1 (CTX) 4 (PT) 4 (CTX) 7 (CTX) 34 (CTX) 14 (PT)
C. difficile colonization! 17(77%) 2(20%) 1(100%) 1(25%) 3(75%) 5(71%) 26§ (76%) 3§ (21%)
CDD 11(50%) 1(10%) 1(100%) 0(0%) 3(75%) 3(43%) 181 (53%) 111(7%)
*Ward A used cefotaxime and ward B used piperacillin-tazobactam (PT) initially, and vice versa afterwards.
fCTX, cefotaxime; PT, piperacillin-tazobactam.
^Figures for C. difficile colonization include patients with CDD.
Using Fisher's exact probability test, §P = 0.001; IfP = 0.006.
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Table 2. Environmental contamination with C. difficile on the
two wards before and during the study
First study Second study
Before study period period
% colonized sites (8 months) (10 months) (4 months)
Ward A 13%" 56%*t 31%t
Ward B 2 6%J 40%t§ 38%§
Difference in P = 0.16 P = 0.08 P = 0.84
colonization rates
between wards
All probabilities in table calculated using two-tailed Fisher's exact
probability test.
"Change in colonization rate from before study to first study period.
P < 0.0001.
fChange in colonization rate from first to second study period.
P = 0.03.
JChange in colonization rate from before study to first study period,
P = 0.17.
§Change in colonization rate from first to second study period,
P = 1.00.
contamination on ward A after changing from CTX to
PT, from 56% (over 10 months) to 31% (over
4 months) of sites positive (P = 0.03). There was no
significant difference in environmental contamination
levels between the two wards either before (P = 0.16),
during the first 10 months (P = 0.08), or the last
4 months of the study (P = 0.84) (Table 2).
Of the strains isolated from the environments of wards
A and B, seven different DNA fingerprints were
identified, with an endemic strain accounting for 87%
of isolates (Figure 1). This strain accounts for most
sporadic cases of CDD at this hospital. C. difficile strains
with the endemic DNA fingerprint were isolated from
22/29 patients. In 10 patients, non-endemic strains
were recovered during the study, although in three
cases this was following previous isolation of the
endemic strain. In 34% (10/29) of the patients colo¬
nized with C. difficile, a culture- and toxin-negative
faecal sample had been obtained before any positive
sample, implying that the infecting strains were hospi¬
tal-acquired. Eight of these strains (80%) were the
endemic strain. For the remaining patients, molecular
typing methods showed that the strain isolated initially
was the endemic strain in 74% (14/19), and was a non-
endemic strain in 26% (5/19) of cases.
DISCUSSION
In the present study we observed a highly significant
difference in the rates of colonization with C. difficile and
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 1. Fingerprints of environmental and patient C. difficile
isolates obtained by PCR amplification of 16S-23S ribosomal
spacer DNA. Lanes 1-5: endemic C. difficile strain isolated from
CTX-treated patients: lanes 10, 11, 13-15: endemic C. difficile
strain isolated from ward environments; lane 6. 8: non-endemic
patient strains: lane 12: non-endemic environmental strain; lane
7: 100 base pairs DNA ladder; and lane 9: negative control.
development of CDD between the two antibiotic groups.
The relative risk of CDD in CTX-treated patients was 7.4
(95% CI: 1.7-33) compared with those who received
PT. Although CTX-treated patients received more non-
study cephalosporins, usually as oral follow-on therapy,
this factor was not associated with an increase in the
incidence of CDD. The patient groups were well matched
in all respects, except for the duration of hospital stay,
primarily before study entry, which was greater in the
PT group. This factor could be expected to make it more
likely for patients treated with PT to acquire C. difficile,
because of their prolonged exposure to the contaminat¬
ed hospital environment, which is at odds with our
findings. Therefore, our observation of a relative sparing
of CDD in PT-treated patients is strengthened. Secondly,
these patients may have been less well in general,
perhaps explaining the lack of difference in length of
hospital stay between the groups, despite fewer cases of
CDD in those receiving PT.
We attempted to determine the main source of the
C. difficile strains causing symptomatic infection. Rates
of colonization with C. difficile in elderly patients on
admission to hospital are =13% at our institution
(unpublished data). Recent work shows that asymp¬
tomatic, colonized patients are at lower risk of develop¬
ing CDD than non-colonized patients.' It therefore
seems unlikely that the C. difficile isolation rate (76%)
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in patients receiving CTX therapy can be accounted for
by endogenous strains. A more likely hypothesis is that
C. difficile is acquired from the ward environment either
directly or via healthcare professionals. This theory is
supported by the observation that the proportion of
environmental isolates found to be the endemic strain
(87%) is similar to the proportion of patient isolates
shown to be the same strain in this study (76%). In this
hospital the majority of cases of CDD in elderly patients
(> 80%) are caused by one 'endemic' strain. The overall
incidence of CDD in this hospital has been falling for the
last 2.5 years, in contrast with national experience,3
and the cases which we continue to experience are not
time clustered. We are confident therefore that patients
who developed CDD on the study wards represented
sporadic cases and were not part of an outbreak per se.
Although we measured significant changes in the
prevalence of environmental C. difficile at different
stages during the study, the differences in contamina¬
tion levels between the two wards during each phase did
not reach statistical significance. There is compelling
evidence that CTX use affects environmental contami¬
nation. In the first study period, which included winter,
there was a prominent increase in CDD cases and
ensuing environmental contamination by C. difficile on
ward A (CTX, P < 0.0001), but not on ward B (PT,
P = 0.17). In the second study period, which included
summer, the decrease in CDD cases and environmental
contamination was marked on ward A (PT, P = 0.03),
but not on ward B (CTX, P = 1.00). Higher rates of
CDD in patients receiving CTX compared with PT, when
patients are assumed to have had equivalent exposure
to C. difficile, also indicates an effect of antibiotic rather
than of environment. Although it is difficult to be
certain whether it is a highly contaminated ward which
leads to greater acquisition rates of C. difficile or vice
versa, our observations suggest the latter.
Antibiotics are accepted as the main causal factors for
CDD, with elderly patients being recognized as the most
susceptible. It is expected that PT is more likely than CTX
to induce C. difficile colonization or CDD, given its broad-
spectrum activity, particularly against anaerobes. This
observation may cast doubt on the theory that the
anaerobic gut flora are a critical determinant of 'coloni¬
zation resistance'.4 Alternatively, the relative C. difficile
sparing effect ofPT may reflect the limited penetration of
this antibiotic into the gut lumen in some patients. Of 20
patients given PT. when sampled on one occasion during
treatment, six had detectable faecal concentrations of
piperacillin, of whom four had measurable levels of
tazobactam, using a relatively insensitive antibiotic
detection method.1' Conversely, as C. difficile is more
susceptible to PT than CTX, it may be more likely to be
killed in PT-treated patients. Preliminary in vitro data
using C. difficile inoculated faeces either spiked with PT
or CTX, or taken from antibiotic-treated patients, do not
demonstrate a difference in the growth of C. difficile
(unpublished data). Further work is under way to
determine the effects of antibiotic exposure on spore
formation and toxin production by C. difficile.
The decision to end the study was taken because the
wards were due to be relocated, and because data
analysis at that time showed a marked difference in
C. difficile colonization and, more importantly, infection
rates. It was therefore considered to be unethical to
continue using cefotaxime in elderly patients. We were
anxious to exclude a confounding effect due to differences
in environmental exposure to C. difficile spores, and
therefore surveillance sampling was performed through¬
out the study. This factor has not previously been
addressed in studies investigating antibiotic causality of
C. difficile diarrhoea.9-11 The fact that this study did not
demonstrate a shorter hospital stay amongst patients
receiving PT, secondary to fewer cases of CDD, may be
due to differences in severity of illness in each group.
Controlling for length of hospital stay before study entry
is vital when comparing subsequent duration of admis¬
sion in different antibiotic groups. In studies where this
has been done, CDD patients stay significantly longer in
hospital than controls.18 Response to treatment with
CTX or PT was similar, as might be expected in such
patients, considering the spectra of the two antibiotics.
Although the study was neither blinded nor randomized,
we have confidence in the accuracy ofour findings, given
the absence of identifiable confounding factors and the
objective measurements of C. difficile colonization and
infection used. Furthermore, randomization was found to
be impractical because of the confused elderly patient
cohort under investigation.
Starr and colleagues recently speculated that the
selective pressure resulting from cephalosporin prescrib¬
ing may increase the proportion of C. difficile susceptible
patients in a ward or unit.19 In this setting administra¬
tion of narrow spectrum antibiotics with otherwise
relatively low propensities to select for C. difficile may
subsequently induce symptomatic infection. Alterna¬
tives to cephalosporins, for example the combinations of
penicillin and either trimethoprim20 or ciprofloxacin21
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for the empirical antibiotic treatment of infection have
been shown in uncontrolled studies to be associated
with a reduced incidence of C. difficile infection. Guide¬
lines for the treatment of community-acquired pneu¬
monia, a common cause of hospital admission in the
elderly, cite cephalosporins, including cefotaxime, as the
antibiotics of choice for severe, as opposed to mild to
moderate, infections.22 These guidelines were recently
implicated in the increased incidence of C. difficile
infection in a department of medicine for the elderly.11
We believe that if treatment of elderly patients with
broad-spectrum antibiotics is required, PT is a better
choice than CTX, due to lower morbidity secondary to
CDD. These findings are most pertinent to units with
endemic C. difficile infection, but although savings are
likely to be greater on units with higher rates of CDD,
the chance of developing CDD after CTX will probably be
higher than after PT on any unit (ward B had a low rate
of C. difficile colonization and disease before crossover to
CTX, after which the rates quadrupled). CDD has been
shown to be expensive to manage,18' 23 with additional
costs of up to £4000 per case.18 The extra savings
which could be expected if the 34 patients who received
CTX had been given PT would be approximately
£60 000, corresponding to 15.5 fewer cases of CDD.
The supplementary antibiotic costs would be approxi¬
mately £6000 (£40/day, PT vs. £15/day, CTX, per
patient, British National Formulary prices), or 10% of
the amount saved by the change. It remains unclear
why reports of C. difficile continue to increase so
markedly. Until such answers are forthcoming, judi¬
cious antibiotic prescribing and standard infection
control containment measures are the best approaches.
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ORIGINAL ARTICLE
Comparison of the Oxoid Clostridium difficile toxin A detection
kit with cytotoxin detection by a cytopathic effect method
examined at 4, 6, 24 and 48 h
Clin Microbiol Infect 1999; 5: 698—701
Christopher D. Settle and Mark H. Wilcox
Department of Microbiology, The General Infirmary at Leeds and The University of Leeds,
Old Medical School, Leeds, UK
Objective: To evaluate the Oxoid Toxin A test in comparison with a rapid cytotoxin method for the diagnosis of
Clostridium difficile diarrhea in a UK tertiary referral hospital.
Methods: One hundred previously tested samples were examined using a cytopathic effect (CPE) method and the Oxoid
Toxin A test. Culture and toxin B titer measurement of the samples were performed to evaluate discrepancies between
the tests.
Results: The sensitivity and specificity of the Oxoid Toxin A test were 72% and 94%, respectively. This was similar to
the CPE method read at 6 h: 67% and 94% in comparison. At 48 h, the sensitivity and specificity of the CPE method
reached 98% and 100%. Toxigenic strains of C. difficile were cultured from 58 of 100 samples, and toxin was detected
in 48 of 58. Following 4 weeks of storage at -20°C, seven of 47 previously toxin B-positive stool filtrates had no detectable
toxin.
Conclusions: The Oxoid Toxin A test does not demonstrate a high enough sensitivity and specificity to be used as a
primary test for C. difficile in hospitals where CPE testing is possible. Toxigenic strains of C. difficile can be cultured from
a significant number of samples where no toxins are detected. Toxin B titers in fecal samples and especially in stool
filtrates, stored at -20'C, diminish after thawing.
Key words: Clostridium difficile, toxin testing, diagnosis
INTRODUCTION
The growing recognition of Clostridium difficile as a
nosocomial pathogen [1—4] has led to a proliferation of
commercial kits for the detection of the bacterium or
its toxins. Antigen-detection kits for C. difficile toxin A
or toxins A and B obviate the need for cell-culture
facilities. The kits also aim to provide a more rapid
method for diagnosing C. difficile infection than the
standard cytopathic effect (CPE) tests using cell mono¬
layers, which conventionally require at least overnight
incubation. In theory, obtaining a same-day test result
may help in preventing the unnecessary use of specific
antibiotic treatment for patients with diarrhea, and may
reduce the spread of C. difficile by ensuring that infected
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patients are isolated. We aimed to determine the
accuracy of one of these new rapid methods compared
with a CPE method that was read at 4, 6, 24 and 48 h.
We then sought to determine the reasons for any
observed differences in results, using both C. difficile
culture and measurement of toxin B titers in stool
supernatants.
MATERIALS AND METHODS
We tested 100 stool samples that had been stored at
— 20°C since original CPE testing, immediately after
thawing. All samples were from patients with diarrheal
illness where no other infective cause was identified,
and 50 were previously cytotoxin positive while 50
were previously negative. C. difficile toxin detection was
performed using both a CPE method and the Oxoid
Toxin A test (Unipath, Basingstoke, UK). The prin¬
ciple of the test is that monoclonal toxin A antibody
labeled with blue latex particles binds'to any toxin A in
the specimen when it is added to the sample well. The
complex diffuses along the test strip and is bound to an
immobilized line of toxin A monoclonal antibody,
forming a blue line in a positive result. Immobilization
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of unbound latex particles occurs in a second window
to indicate that diffusion past the test window has
occurred. The 100 samples were randomly arranged so
that positives were indistinguishable from negatives.
They were then thawed in batches of 10, and roughly
0.5 g was suspended in the kit diluent or in 2 mL of
phosphate-buffered saline (for the CPE test) (to a
dilution of 1 in 5). The well-mixed suspensions were
then centrifuged for 10 min at 1200 g, before being
used for the kit test (according to the instructions), or
kept in a refrigerator at 4°C (for < 30 min) until the
CPE test was set up. If the supernatants were cloudy
following centrifugation, they were filtered through a
0.45 millipore filter (Nalge, Rochester, NY, USA).
C. difficile cytotoxin was detected by a modified 96-
well microtiter tray (Life Technologies, Glasgow, UK)
method [5], using HEp-2 cells with C. sordellii antitoxin
(Pro-Lab Diagnostics, Bromborough, UK) protected
controls, involving a further 1 in 10 dilution (20 p,L of
supernatant to 180 p.L of culture medium). Each batch
of tests was controlled using a known positive super¬
natant (with and without C. sordellii antitoxin), a well
without any additions and a well with antitoxin only.
The tests were incubated aerobically, in a wet box, at
37 C, conditions under which no problems with the
cell line have been encountered. Wells were examined
for CPE at 4, 6, 24 and 48 h independently by two
individuals. CPE consisted of a discernible, neutraliz-
able rounding-up of cells, often quite subtle at 4 h and
sometimes 6 h, but always affecting >10% of cells
initially and >50% of cells by 48 h.
The stool samples were prepared for the Oxoid
Toxin A test according to the manufacturer's instruc¬
tions. One hundred and twenty-five microliters of
supernatant was added to the sample window of the test
strip. This was left for 30 min before being examined
for any evidence of a blue line in the result window.
Tests where the control window had a blue line and
there was any sign of a blue line in the result window
were classified as positive.
All 100 specimens were cultured on cycloserine-
cefoxitin egg yolk (CCEY) agar (Lab M, Bury, UK) [6]
for 48 h in an anaerobic cabinet (Don Whitley
Scientific, Shipley, UK) in an atmosphere of 80% N2,
10% H2 and 10% CO2, before being examined for C.
difficile. Isolates were recognized by typical colony
appearance and characteristic odor. The toxigenicity of
isolates cultured from fecal samples that were toxin
negative by CPE was determined by CPE testing.
Toxin-negative strains were then identified using the
RapID ANAII kit (Innovative Diagnostics Systems,
Norcross, Ga, USA). The supernatants used for CPE
testing in this study were frozen at — 20°C immediately
after the cytotoxin test was set up. Cytotoxin titers were
determined in these samples after 4 weeks, due to time
constraints at the time of initial cytotoxin testing. They
were tested for CPE neat (1 in 50 dilution) and at seven
further 10-fold dilutions. The toxin titer was designated
as the highest dilution which caused a readily
discernible, classical CPE at 48 h (although in a few
cases, at the highest dilution, these changes did not
quite affect 50% of the total cells).
RESULTS
We found 53 samples to be CPE negative and 47 to be
CPE positive (Table 1). Sensitivities and specificities
are calculated using the CPE result at 48 h as the
standard (with the addition of a sample which was
Oxoid toxin A test positive, CPE negative, but culture
positive for toxigenic C. difficile as a true positive). By
comparison, the Oxoid Toxin A kit produced 13 false-
negative results (sensitivity 72%) and three false
positives (specificity 94%), although it did detect toxin
A in one specimen which was CPE test negative. A
strain of C. difficile was cultured from this specimen and
found to be cytotoxin positive (Table 1 and 2).
There was a high degree of correlation (100%
agreement at 48 h) between the two individuals who
read the CPE test. At 6 h, one investigator (the more
experienced of the two) identified three additional
positive specimens, one of which proved to be a false
positive.
Table 1 Sensitivity and specificity of CPE test for toxin B









4 21 5 54 90
6 15 3 67 94
24 3 0 92 100
48 1 0 98 100
Oxoid toxin
A test 13 3 72 94
Table 2 Concordance table for Oxoid Toxin A test and
Toxin B detection by cytopathic effect
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In this study, all 47 CPE-positive samples were C.
difficile culture positive, while 12 of the CPE-negative
feces were also culture positive. Of these 12 strains, all
but one was toxigenic by CPE testing. After storage of
fecal supernatants at — 20°C for 4 weeks, C. difficile
cytotoxin titers were found to range between 50 and at
least 5 X 108. In seven supernatants that were previously
CPE positive, no cytotoxin was detected at this time.
There were 11 samples with cytotoxin titers >103, and
all were toxin A kit-test positive. One toxin A kit
'positive sample had a titer of only 1. No toxin A kit-
negative samples had titers >103.
DISCUSSION
The study demonstrates that the rapid kit test studied
had a similar accuracy to our CPE method at 6 h, with
a sensitivity and specificity of 72% and 94% versus 67%
and 94%, respectively. These results differ from another
assessment of the Oxoid toxin A kit by Bentley et al in
1998 [7]. By 24 h, the sensitivity and specificity of the
CPE method reach 92% and 100% respectively. The
interesting observation that one sample was toxin A kit
test positive but CPE test negative could be due to
unequal rates of breakdown of the two toxins. The
great majority of C. difficile strains produce equimolar
quantities of toxins A and B [8]. The C. difficile culture
results indicate that it is possible for a toxigenic strain
of C. difficile to be present in a sample and yet for toxins
A and B to remain undetectable. This could be due to
proteolytic degradation of toxins in the fecal sample, or
lack of production of toxins in the bowel, possibly
secondary to antimicrobial therapy, or toxin inhibitory
effects of bowel flora. Theoretically, this effect could
also be seen if the sample contained only C. difficile
spores in small numbers.
Some toxin A-positive samples had low cytotoxin
titers, which may be because the greater stability of
toxin A [9,10] resulted in more of it remaining in the
sample than cytotoxin. There was an apparent correl¬
ation between cytotoxin titer and toxin A kit test
positivity, as previously described for an EL1SA
method [11]. Other workers have reported no
correlation between cytotoxin titer in samples and EIA
readings [12], The reliable threshold for toxin A
detection in the present study appeared to be a titer of
> 104. Cytotoxin in stool specimens and particularly in
stool filtrates may deteriorate when these are thawed,
after being stored at — 20°C, as previously noted [13],
The fact that some samples had no detectable toxin but
did contain toxigenic organisms suggests that culture
of toxigenic organisms alone from a sample may not
automatically justify the treatment of a patient for C.
difficile infection.
In this study, the sensitivity and specificity claimed
in the kit insert by the manufacturer were not achieved
(72% versus 90% and 94% versus 98%, respectively).
However, the manufacturer's sensitivity figures were
erroneously adjusted to classify cytotoxin-positive but
culture-negative fecal samples as true kit negatives. The
fact that detection of toxin A is not as sensitive as CPE
methods that detect toxin B (and toxin A) is not
surprising. Toxin B is extremely potent and can cause
a cytopathic effect at concentrations as low as a few
pg/mL, whereas the threshold of toxin A detection kits
is in the ng/mL range [7].
It should also be emphasized that there are
increasing reports of toxin A-negative, toxin B-positive
(A—B+) C. difficile clinical isolates [10,14], and these
will not be detected by toxin A kits [15—17]. Brazier
reported that C. difficile A-B+ isolates account for 3%
of the total number ofstrains received from laboratories
(but 10% of the strains submitted from one laboratory)
in England and Wales by the Anaerobe Reference
Laboratory [16]. While such strains appear to be
uncommon in the USA [15], 33% of isolates collected
in one hospital in Japan were of this phenotype [18].
As C. difficile A-B+ isolates have been recovered from
symptomatic patients [16,17], previously held beliefs
that toxin A is the most important toxin in the
pathogenesis of human antibiotic-associated diarrhea
must be called into question.
The CPE test is achievable by most large clinical
microbiology laboratories when several samples per day
require examination for C. difficile cytotoxin. Although
the CPE method at 6 h performs slightly less well than
the Oxoid kit, it is noticeably superior by 24 h. This
leaves the decision as to whether an immediate result is
preferable to a more accurate one after 24 h. While in
severe cases an immediate result may be argued to be
of value, in practice most of these patients will be
isolated and treated empirically. In addition, with the
use of a test with lower sensitivity and specificity, some
patients will be misidentified as being negative and
others will receive unnecessary therapy It should be
remembered that a significant number of patients with
C. difficile toxin-positive diarrhea will respond to
withdrawal of antibiotics alone [19], and reacting to a
very rapid test result may result in action before these
patients declare themselves. The sensitivity of the CPE
method may be improved ifVERO cell lines are used.
In our laboratory, testing around 5000 samples/year by
CPE, the cost per test (including technician time) is
around 25p. This compares to a list price of£4 per test
for the Oxoid toxin A test, excluding technician time.
Furthermore, an increased number of repeat tests
would be required if the Oxoid toxin A test was used.
The Oxoid toxin A kit does not appear to be accurate
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enough for use in primary diagnosis of C. difficile
disease. It is interesting to note that the sensitivity of
CPE testing for cytotoxin can reach 67% at 6 h. The
CPE method can also be employed to test the
toxigenicity of C. difficile isolates directly from the
culture plate. One or two colonies of C. difficile are
emulsified in 0.5 mL of phosphate-buffered saline,
which is then used in the same way as a stool filtrate in
the CPE test, with results typically being readable after
3-4 h of incubation (Settle and Wilcox, unpublished
data). Rapid kit tests are more suited to situations
where tests are infrequent, or cell-culture facilities are
not available (although a virology laboratory is not
essential for cell culture to be performed), but greater
sensitivity than that demonstrated by this kit is required.
In summary, the accuracy of the Oxoid toxin A test
is not high enough for routine use in practice. Reduced
sensitivity of the toxin A method may be due to
specimens with low toxin titers being present. Toxin A
levels may not decrease as quickly as toxin B levels,
and specimens may be C. difficile culture positive but yet
contain no detectable toxin A or B, even though the
strain is toxigenic. Cytotoxin levels fall in samples, and
particularly supernatants, that are frozen and thawed.
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